Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Inflammatory Bowel Diseases

  Free Subscription


Articles published in J Crohns Colitis

Retrieve available abstracts of 976 articles:
HTML format



Single Articles


    July 2021
  1. CHEE D, Nice R, Hamilton B, Jones E, et al
    Patient-led Remote IntraCapillary pharmacoKinetic Sampling (fingerPRICKS) for therapeutic drug monitoring in patients with inflammatory bowel disease.
    J Crohns Colitis. 2021 Jul 21. pii: 6325142. doi: 10.1093.
    PubMed     Abstract available


  2. DIEZ-OBRERO V, Moratalla-Navarro F, Ibanez-Sanz G, Guardiola J, et al
    Transcriptome-wide association study for inflammatory bowel disease reveals novel candidate susceptibility genes in specific colon subsites and tissue categories.
    J Crohns Colitis. 2021 Jul 21. pii: 6324884. doi: 10.1093.
    PubMed     Abstract available


  3. ZITTAN E, Steinhart AH, Aran H, Milgrom R, et al
    The Toronto Ibd Global Endoscopic Reporting (Tiger) Score: A Single, Easy To Use Endoscopic Score For Both Crohn's Disease And Ulcerative Colitis Patients.
    J Crohns Colitis. 2021 Jul 17. pii: 6323260. doi: 10.1093.
    PubMed     Abstract available


  4. DINALLO V, Di Fusco D, Di Grazia A, Laudisi F, et al
    The deubiquitinating enzyme OTUD5 sustains inflammatory cytokine response in inflammatory bowel disease.
    J Crohns Colitis. 2021 Jul 7. pii: 6316763. doi: 10.1093.
    PubMed     Abstract available


  5. CHOI WT, Salomao M, Zhao L, Alpert L, et al
    Hypermucinous, Goblet Cell Deficient, and Crypt Cell Dysplasias in Inflammatory Bowel Disease are Often Associated with Flat/Invisible Endoscopic Appearance and Advanced Neoplasia on Follow-Up.
    J Crohns Colitis. 2021 Jul 7. pii: 6316756. doi: 10.1093.
    PubMed     Abstract available


  6. DELISLE M, Wilkens R, Novak KL
    Keeping It Simple: Using Intestinal Ultrasound to Assess Ulcerative Colitis with a Novel UC-Ultrasound Index.
    J Crohns Colitis. 2021 Jul 5. pii: 6315708. doi: 10.1093.
    PubMed    


  7. RESTELLINI S, Lakatos PL
    Patient-Reported Outcomes in Inflammatory Bowel Diseases: Another Piece in the Puzzle.
    J Crohns Colitis. 2021;15:1085-1086.
    PubMed    


  8. GUPTA V, Mohsen W, Chapman TP, Satsangi J, et al
    Predicting Outcome in Acute Severe Colitis-Controversies in Clinical Practice in 2021.
    J Crohns Colitis. 2021;15:1211-1221.
    PubMed     Abstract available


  9. COX SR, Clarke H, O'Keeffe M, Dubois P, et al
    Nutrient, fibre and FODMAP intakes and food-related quality of life in patients with inflammatory bowel disease and their relationship with gastrointestinal symptoms of differing aetiologies.
    J Crohns Colitis. 2021 Jul 3. pii: 6314229. doi: 10.1093.
    PubMed     Abstract available


    June 2021
  10. WATANABE S, Hibiya S, Katsukura N, Kitagawa S, et al
    Importance of telomere shortening in the pathogenesis of ulcerative colitis: A new treatment from the aspect of telomeres in intestinal epithelial cells.
    J Crohns Colitis. 2021 Jun 28. pii: 6310549. doi: 10.1093.
    PubMed     Abstract available


  11. GUBATAN J, Rubin SJS, Bai L, Haileselassie Y, et al
    Vitamin D is Associated with alpha4beta7+ Immunophenotypes and Predicts Vedolizumab Therapy Failure in Patients with Inflammatory Bowel Disease.
    J Crohns Colitis. 2021 Jun 28. pii: 6310486. doi: 10.1093.
    PubMed     Abstract available


  12. KUENZIG ME, Bitton A, Carroll MW, Kaplan GG, et al
    Inflammatory bowel disease increases the risk of venous thromboembolism in children: a population-based matched cohort study.
    J Crohns Colitis. 2021 Jun 27. pii: 6310166. doi: 10.1093.
    PubMed     Abstract available


  13. KIM PH, Yoon HM, Jung AY, Lee JS, et al
    Diagnostic Performance of Diffusion-weighted Imaging for Evaluation of Bowel Inflammation in Pediatric Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
    J Crohns Colitis. 2021 Jun 22. pii: 6308099. doi: 10.1093.
    PubMed     Abstract available


  14. GILMORE R, Hilley P, Srinivasan A, Choy M, et al
    Sequential use of high-dose tofacitinib after infliximab salvage therapy in acute severe ulcerative colitis.
    J Crohns Colitis. 2021 Jun 22. pii: 6308093. doi: 10.1093.
    PubMed     Abstract available


  15. ABAKKOUY Y, Cleynen I
    The Promise of Polygenic Risk Scores as a Research Tool to Analyse the Genetics Underlying IBD Phenotypes.
    J Crohns Colitis. 2021;15:877-878.
    PubMed    


  16. ATTAUABI M, Seidelin JB, Burisch J
    Authors' Reply to: 'COVID-19 in the IBD Population: The Need for Correct Nomenclature'.
    J Crohns Colitis. 2021;15:1080.
    PubMed    


  17. GIANOTTI RJ, Cheifetz AS
    Cannabis and Inflammatory Bowel Disease: All Smoke and Mirrors?
    J Crohns Colitis. 2021 Jun 17. pii: 6301791. doi: 10.1093.
    PubMed    


  18. JOHNSON AM, Harmsen WS, Aniwan S, Tremaine WJ, et al
    Prevalence and Impact of Obesity on Disease-Specific Outcomes in a Population-Based Cohort of Patients with Ulcerative Colitis.
    J Crohns Colitis. 2021 Jun 12. pii: 6297429. doi: 10.1093.
    PubMed     Abstract available


  19. PORTER RJ, Arends MJ, Churchhouse AMD, Din S, et al
    Inflammatory bowel disease-associated colorectal cancer: translational risks from mechanisms to medicines.
    J Crohns Colitis. 2021 Jun 10. pii: 6295922. doi: 10.1093.
    PubMed     Abstract available


  20. GHOSH S, Sanchez Gonzalez Y, Zhou W, Clark R, et al
    Upadacitinib Treatment Improves Symptoms of Bowel Urgency and Abdominal Pain, and Correlates With Quality of Life Improvements in Patients With Moderate to Severe Ulcerative Colitis.
    J Crohns Colitis. 2021 Jun 9. pii: 6295522. doi: 10.1093.
    PubMed     Abstract available


  21. HERNANDEZ-ROCHA C, Borowski K, Turpin W, Filice M, et al
    Integrative analysis of colonic biopsies from inflammatory bowel disease patients identifies an interaction between microbial bile-acid inducible gene abundance and human Angiopoietin-like 4 gene expression.
    J Crohns Colitis. 2021 Jun 2. pii: 6291049. doi: 10.1093.
    PubMed     Abstract available


    May 2021
  22. FUMERY M, Chatelain D
    Histological Scores in Inflammatory Bowel Disease: A New Kid in the Block.
    J Crohns Colitis. 2021 May 27. pii: 6286012. doi: 10.1093.
    PubMed    


  23. DHERI AK, Kuenzig ME, Mack DR, Murthy SK, et al
    Shifting health care use from hospitalizations and surgeries to outpatient visits in children with inflammatory bowel disease: a population-based cohort study from Ontario, Canada.
    J Crohns Colitis. 2021 May 21. pii: 6279878. doi: 10.1093.
    PubMed     Abstract available


  24. WEISSMAN S, Patel K, Kolli S, Lipcsey M, et al
    Obesity in Inflammatory Bowel Disease is Associated with Early Readmissions characterized by an Increased Systems and Patient-level Burden.
    J Crohns Colitis. 2021 May 17. pii: 6276891. doi: 10.1093.
    PubMed     Abstract available


  25. REZAZADEH ARDABILI A, Creemers RH, van Bodegraven AA
    COVID-19 in the IBD Population: The Need for Correct Nomenclature.
    J Crohns Colitis. 2021;15:872-873.
    PubMed    


  26. BERTE' R, Mazza S, Stefanucci MR, Noviello D, et al
    Seroprevalence of SARS-CoV2 in IBD Patients Treated with Biologic Therapy.
    J Crohns Colitis. 2021;15:864-868.
    PubMed     Abstract available


    April 2021
  27. VAN ERP LW, van Gerven J, Bloem S, Groenen MJM, et al
    Acceptance and perceived control are independently associated with quality of life in inflammatory bowel disease: Introduction of a new segmentation model.
    J Crohns Colitis. 2021 Apr 28. pii: 6257076. doi: 10.1093.
    PubMed     Abstract available


  28. STRAATMIJER T, Biemans VBC, Hoentjen F, de Boer NKH, et al
    Ustekinumab for Crohn's Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study.
    J Crohns Colitis. 2021 Apr 28. pii: 6256992. doi: 10.1093.
    PubMed     Abstract available


  29. OUAHED J, Kelsen JR, Spessott WA, Kooshesh K, et al
    Variants in STXBP3 Are Associated With Very Early Onset Inflammatory Bowel Disease, Bilateral Sensorineural Hearing Loss and Immune Dysregulation.
    J Crohns Colitis. 2021 Apr 23. pii: 6247960. doi: 10.1093.
    PubMed     Abstract available


  30. SLEIMAN J, Hitawala AA, Cohen B, Falloon K, et al
    Systematic review: Sweet syndrome associated with inflammatory bowel disease.
    J Crohns Colitis. 2021 Apr 23. pii: 6247949. doi: 10.1093.
    PubMed     Abstract available


  31. UNTERWEGER AL, Jensen MO, Giordanetto F, Jogini V, et al
    Suppressing Kv1.3 Ion Channel Activity with a Novel Small Molecule Inhibitor Ameliorates Inflammation in a Humanized Mouse Model of Ulcerative Colitis.
    J Crohns Colitis. 2021 Apr 23. pii: 6247959. doi: 10.1093.
    PubMed     Abstract available


  32. PANES J, Vermeire S, Dubinsky MC, Loftus EV, et al
    Efficacy and Safety of Tofacitinib Retreatment for Ulcerative Colitis After Treatment Interruption: Results From the OCTAVE Clinical Trials.
    J Crohns Colitis. 2021 Apr 22. pii: 6245086. doi: 10.1093.
    PubMed     Abstract available


  33. CHAPARRO M, Garre A, Iborra M, Sierra M, et al
    Effectiveness and safety of ustekinumab in ulcerative colitis: Real-world evidence from the ENEIDA registry.
    J Crohns Colitis. 2021 Apr 16. pii: 6228235. doi: 10.1093.
    PubMed     Abstract available


  34. JUNG S, Ye BD, Lee HS, Baek J, et al
    Identification of three novel susceptibility loci for inflammatory bowel disease in Koreans in an extended genome-wide association study.
    J Crohns Colitis. 2021 Apr 14. pii: 6225940. doi: 10.1093.
    PubMed     Abstract available


  35. FUMERY M, Yzet C, Chatelain D, Yzet T, et al
    Colonic strictures in inflammatory bowel disease: epidemiology, complications, and management.
    J Crohns Colitis. 2021 Apr 12. pii: 6222697. doi: 10.1093.
    PubMed     Abstract available


  36. D'AMICO F, Guillo L, Baumann C, Danese S, et al
    Histological disease activity measured by the Nancy index is associated with long-term outcomes in patients with ulcerative colitis.
    J Crohns Colitis. 2021 Apr 5. pii: 6211061. doi: 10.1093.
    PubMed     Abstract available


  37. NG A
    Clinical efficacy of tofacitinib in moderate to severe ulcerative colitis.
    J Crohns Colitis. 2021 Apr 5. pii: 6211060. doi: 10.1093.
    PubMed    


    March 2021
  38. BRESSLER B, Yarur A, Silverberg MS, Bassel M, et al
    Vedolizumab and Anti-TNFalpha Real-World Outcomes in Biologic-Naive Inflammatory Bowel Disease Patients: Results from the EVOLVE Study.
    J Crohns Colitis. 2021 Mar 31. pii: 6205394. doi: 10.1093.
    PubMed     Abstract available


  39. LANG-SCHWARZ C, Angeloni M, Agaimy A, Atreya R, et al
    Validation of the "Inflammatory Bowel Disease - Distribution, Chronicity, Activity (IBD-DCA) Score" for Ulcerative Colitis and Crohn s disease.
    J Crohns Colitis. 2021 Mar 27. pii: 6196021. doi: 10.1093.
    PubMed     Abstract available


  40. PALMIERI C, Muller G, Kroesen AJ, Galata C, et al
    Perianal fistula-associated carcinoma in Crohn s disease: a multicenter retrospective case control study.
    J Crohns Colitis. 2021 Mar 27. pii: 6189787. doi: 10.1093.
    PubMed     Abstract available


  41. NORSA L, Berni Canani R, Duclaux-Loras R, Bequet E, et al
    Inflammatory bowel disease in patients with congenital chloride diarrhoea.
    J Crohns Colitis. 2021 Mar 26. pii: 6189668. doi: 10.1093.
    PubMed     Abstract available


  42. RUDDY J, Taft T, Keszthelyi D
    Gut-Brain Interactions in patients with Inflammatory Bowel Disease (IBD) and the role of Hypnotherapy in Managing Symptoms.
    J Crohns Colitis. 2021 Mar 18. pii: 6175701. doi: 10.1093.
    PubMed    


  43. TORRES J, Halfvarson J, Rodriguez-Lago I, Hedin CRH, et al
    Results of the Seventh Scientific Workshop of ECCO: Precision medicine in IBD- prediction and prevention of inflammatory bowel disease.
    J Crohns Colitis. 2021 Mar 17. pii: 6175312. doi: 10.1093.
    PubMed     Abstract available


  44. KUCHARZIK T, Ellul P, Greuter T, Rahier JF, et al
    ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease.
    J Crohns Colitis. 2021 Mar 17. pii: 6175313. doi: 10.1093.
    PubMed    


  45. PIOVANI D, Pansieri C, Kotha SRR, Piazza AC, et al
    Ethnic Differences in the Smoking-Related Risk of Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
    J Crohns Colitis. 2021 Mar 15. pii: 6171987. doi: 10.1093.
    PubMed     Abstract available


  46. VERSTOCKT B, Verstockt S, Abdu Rahiman S, Ke BJ, et al
    Intestinal Receptor of SARS-CoV-2 in Inflamed IBD Tissue Seems Downregulated by HNF4A in Ileum and Upregulated by Interferon Regulating Factors in Colon.
    J Crohns Colitis. 2021;15:485-498.
    PubMed     Abstract available


  47. FOURIE S, Norton C, Jackson D, Czuber-Dochan W, et al
    'These discussions aren't happening'. Experiences of people living with inflammatory bowel disease talking about sexual well-being with healthcare professionals.
    J Crohns Colitis. 2021 Mar 4. pii: 6158978. doi: 10.1093.
    PubMed     Abstract available


  48. PAI RK, Hartman DJ, Leighton JA, Shabana PF, et al
    Validated Indices for Histopathologic Activity Predict Development of Colorectal Neoplasia in Ulcerative Colitis.
    J Crohns Colitis. 2021 Mar 4. pii: 6158975. doi: 10.1093.
    PubMed     Abstract available


  49. ATREYA R, Neurath MF
    Can Serum Proteomic Profiling Annunciate Individual Disease Progression in Newly Diagnosed Inflammatory Bowel Disease Patients?
    J Crohns Colitis. 2021 Mar 2. pii: 6156783. doi: 10.1093.
    PubMed    


    February 2021
  50. LUDVIGSSON JF, Olen O, Larsson H, Halfvarson J, et al
    Association between inflammatory bowel disease and psychiatric morbidity and suicide: A Swedish nationwide population-based cohort study with sibling comparisons.
    J Crohns Colitis. 2021 Feb 26. pii: 6153473. doi: 10.1093.
    PubMed     Abstract available


  51. GUILLO L, Peyrin-Biroulet L, Louis E
    Tofacitinib De-escalation Strategy in Ulcerative Colitis: Is It the End of the Story?
    J Crohns Colitis. 2021 Feb 23. pii: 6146725. doi: 10.1093.
    PubMed    


  52. ALLIN KH, Jacobsen RK, Ungaro RC, Colombel JF, et al
    Bariatric surgery and risk of new-onset inflammatory bowel disease: A nationwide cohort study.
    J Crohns Colitis. 2021 Feb 20. pii: 6145790. doi: 10.1093.
    PubMed     Abstract available


  53. GOETGEBUER RL, Kreijne JE, Aitken CA, Dijkstra G, et al
    Increased risk of high-grade cervical neoplasia in women with inflammatory bowel disease: a case-controlled cohort study.
    J Crohns Colitis. 2021 Feb 20. pii: 6145789. doi: 10.1093.
    PubMed     Abstract available


  54. REINISCH W, Sandborn WJ, Danese S, Hebuterne X, et al
    Long-term safety and efficacy of the anti-MAdCAM-1 monoclonal antibody ontamalimab (SHP647) for the treatment of ulcerative colitis: the open-label study TURANDOT II.
    J Crohns Colitis. 2021 Feb 18. pii: 6144575. doi: 10.1093.
    PubMed     Abstract available


  55. ARAKI T, Mitsuyama K, Yamasaki H, Morita M, et al
    Therapeutic Potential of a Self-Assembling Peptide Hydrogel to Treat Colonic Injuries Associated with Inflammatory Bowel Disease.
    J Crohns Colitis. 2021 Feb 17. pii: 6141509. doi: 10.1093.
    PubMed     Abstract available


  56. ACKERMANN M, Mucci A, McCabe A, Frei S, et al
    Restored macrophage function ameliorates disease pathophysiology in a mouse model for IL10 receptor deficient very early onset inflammatory bowel disease.
    J Crohns Colitis. 2021 Feb 17. pii: 6141466. doi: 10.1093.
    PubMed     Abstract available


  57. WATANABE S, Nishimura R, Shirasaki T, Katsukura N, et al
    Schlafen 11 is a novel target for mucosal regeneration in Ulcerative Colitis.
    J Crohns Colitis. 2021 Feb 17. pii: 6141476. doi: 10.1093.
    PubMed     Abstract available


  58. ZHAO M, Gonczi L, Lakatos PL, Burisch J, et al
    The burden of inflammatory bowel disease in Europe in 2020.
    J Crohns Colitis. 2021 Feb 14. pii: 6134782. doi: 10.1093.
    PubMed     Abstract available


  59. BARNES EL, Holubar SD, Herfarth HH
    Systematic Review and Meta-Analysis of Outcomes after Ileal Pouch-Anal Anastomosis in Primary Sclerosing Cholangitis-Ulcerative Colitis.
    J Crohns Colitis. 2021 Feb 5. pii: 6129144. doi: 10.1093.
    PubMed     Abstract available


  60. GHOSH S, Iacucci M
    Measuring Patient Experience in Inflammatory Bowel Disease Care: A Key Component of Continuous Quality Improvement.
    J Crohns Colitis. 2021 Feb 5. pii: 6129099. doi: 10.1093.
    PubMed    


    January 2021
  61. RUIGROK RAAA, Collij V, Sureda P, Klaassen MAY, et al
    The composition and metabolic potential of the human small intestinal microbiota within the context of inflammatory bowel disease.
    J Crohns Colitis. 2021 Jan 30. pii: 6123997. doi: 10.1093.
    PubMed     Abstract available


  62. GRIM C, Noble R, Uribe G, Khanipov K, et al
    Impairment of tissue resident mesenchymal stem cells in chronic ulcerative colitis and Crohn's disease.
    J Crohns Colitis. 2021 Jan 28. pii: 6121690. doi: 10.1093.
    PubMed     Abstract available


  63. ALLOCCA M, Bonovas S, Danese S
    Letter to the Editor Intestinal Ultrasound to Assess Disease Activity in Ulcerative Colitis: Development of a novel UC-Ultrasound index.
    J Crohns Colitis. 2021 Jan 25. pii: 6119566. doi: 10.1093.
    PubMed    


  64. LOVE BL, Finney CJ, Gaidos JKJ
    Effectiveness of Conjugate and Polysaccharide Pneumococcal Vaccines for Prevention of Severe Pneumococcal Disease Among Inflammatory Bowel Disease Patients.
    J Crohns Colitis. 2021 Jan 25. pii: 6118663. doi: 10.1093.
    PubMed     Abstract available


  65. VERMEIRE S, Chiorean M, Panes J, Peyrin-Biroulet L, et al
    Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study.
    J Crohns Colitis. 2021 Jan 21. pii: 6105062. doi: 10.1093.
    PubMed     Abstract available


  66. ZAIATZ BITTENCOURT V, Jones F, Tosetto M, Doherty GA, et al
    Dysregulation of metabolic pathways in circulating natural killer cells isolated from inflammatory bowel disease patients.
    J Crohns Colitis. 2021 Jan 18. pii: 6103919. doi: 10.1093.
    PubMed     Abstract available


  67. SANDBORN WJ, Feagan BG, Hanauer S, Vermeire S, et al
    Long-Term Efficacy And Safety Of Ozanimod In Moderate-To-Severe Ulcerative Colitis: Results From The Open-Label Extension Of The Randomized, Phase 2 Touchstone Study.
    J Crohns Colitis. 2021 Jan 13. pii: 6092404. doi: 10.1093.
    PubMed     Abstract available


  68. BARBERIO B, Segal JP, Quraishi MN, Black CJ, et al
    Efficacy of Oral, Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Network Meta-Analysis.
    J Crohns Colitis. 2021 Jan 12. pii: 6089122. doi: 10.1093.
    PubMed     Abstract available


  69. DE VOOGD F, Wilkens R, Gecse K, Allocca M, et al
    A reliability study - strong inter-observer agreement of an expert panel for intestinal ultrasound in ulcerative colitis.
    J Crohns Colitis. 2021 Jan 9. pii: 6073674. doi: 10.1093.
    PubMed     Abstract available


  70. BOTS S, Nylund K, Lowenberg M, Gecse K, et al
    Intestinal Ultrasound to Assess Disease Activity in Ulcerative Colitis: Development of a novel UC-Ultrasound index.
    J Crohns Colitis. 2021 Jan 7. pii: 6067606. doi: 10.1093.
    PubMed     Abstract available


    December 2020
  71. VAN DER SLOOT KWJ, Voskuil MD, Blokzijl T, Dinkla A, et al
    Isotype specific antibody responses to Mycobacterium Avium subspecies Paratuberculosis antigens are associated with the use of biological therapy in Inflammatory Bowel Disease.
    J Crohns Colitis. 2020 Dec 30. pii: 6055607. doi: 10.1093.
    PubMed     Abstract available


  72. GUILLO L, D'Amico F, Danese S, Peyrin-Biroulet L, et al
    Ustekinumab for extra-intestinal manifestations of inflammatory bowel disease: a systematic literature review.
    J Crohns Colitis. 2020 Dec 24. pii: 6046385. doi: 10.1093.
    PubMed     Abstract available


  73. CROUWEL F, Waaijenberg-Warmenhoven P, Buiter HJC, de Boer NK, et al
    Recurrent COVID-19 in a patient with ulcerative colitis on vedolizumab therapy.
    J Crohns Colitis. 2020 Dec 22. pii: 6044002. doi: 10.1093.
    PubMed    


  74. RAHMI G, Coron E, Perrod G, Levy M, et al
    Probe-based confocal laser endomicroscopy for in vivo assessment of histological healing in ulcerative colitis: development and validation of the ENHANCE index.
    J Crohns Colitis. 2020 Dec 18. pii: 6041240. doi: 10.1093.
    PubMed     Abstract available


  75. BANCIL AS, Sandall AM, Rossi M, Chassaing B, et al
    Food additive emulsifiers and their impact on gut microbiome, permeability and inflammation: mechanistic insights in inflammatory bowel disease.
    J Crohns Colitis. 2020 Dec 18. pii: 6041235. doi: 10.1093.
    PubMed     Abstract available


  76. VENTIN-HOLMBERG R, Eberl A, Saqib S, Korpela K, et al
    Bacterial and fungal profiles as markers of infliximab drug response in inflammatory bowel disease.
    J Crohns Colitis. 2020 Dec 10. pii: 6029424. doi: 10.1093.
    PubMed     Abstract available


  77. VERMEIRE S, Su C, Lawendy N, Kobayashi T, et al
    Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomized RIVETING Trial.
    J Crohns Colitis. 2020 Dec 8. pii: 6027842. doi: 10.1093.
    PubMed     Abstract available


  78. MONSTAD IL, Solberg IC, Cvancarova M, Hovde O, et al
    Outcome of Ulcerative Colitis 20 Years after Diagnosis in a Prospective Population-based Inception Cohort from South-Eastern Norway, the IBSEN Study.
    J Crohns Colitis. 2020 Dec 2. pii: 6015889. doi: 10.1093.
    PubMed     Abstract available


    November 2020
  79. JOHNSON LE, Lee MJ, Turner-Moore T, Grinsted Tate LR, et al
    Systematic review of factors affecting transition readiness skills in patients with inflammatory bowel disease.
    J Crohns Colitis. 2020 Nov 30. pii: 6012510. doi: 10.1093.
    PubMed     Abstract available


  80. HAMAMA-RAZ Y, Nativ S, Hamama L
    Posttraumatic Growth in Inflammatory Bowel Disease Patients: The Role of Illness Cognitions and Physical Quality in Life.
    J Crohns Colitis. 2020 Nov 30. pii: 6012764. doi: 10.1093.
    PubMed     Abstract available


  81. TADBIRI S, Nachury M, Bouhnik Y, Serrero M, et al
    The IBD-disk is a reliable tool to assess the daily-life burden of patients with inflammatory bowel disease.
    J Crohns Colitis. 2020 Nov 27. pii: 6007776. doi: 10.1093.
    PubMed     Abstract available


  82. WINTHROP KL, Loftus EV Jr, Baumgart DC, Reinisch W, et al
    Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme.
    J Crohns Colitis. 2020 Nov 27. pii: 6007683. doi: 10.1093.
    PubMed     Abstract available


  83. VAN DEN BERGHE N, Verstockt B, Gils A, Sabino J, et al
    Tissue exposure does not explain non-response in ulcerative colitis patients with adequate serum vedolizumab concentrations.
    J Crohns Colitis. 2020 Nov 27. pii: 6007493. doi: 10.1093.
    PubMed     Abstract available


  84. EVERHOV AH, Bruze G, Soderling J, Askling J, et al
    Women's earnings are more affected by inflammatory bowel disease than men's: a register-based Swedish cohort study.
    J Crohns Colitis. 2020 Nov 27. pii: 6007494. doi: 10.1093.
    PubMed     Abstract available


  85. HOEKMAN DR, Vlieger AM, Stokkers PC, Mahhmod N, et al
    Hypnotherapy for irritable bowel syndrome-type symptoms in patients with quiescent inflammatory bowel disease: a randomized, controlled trial.
    J Crohns Colitis. 2020 Nov 27. pii: 6007495. doi: 10.1093.
    PubMed     Abstract available


  86. AGRAWAL M, Brenner EJ, Zhang X, Colombel JF, et al
    Physician practice patterns on holding inflammatory bowel disease medications due to COVID-19 in the SECURE-IBD registry.
    J Crohns Colitis. 2020 Nov 24. pii: 6000079. doi: 10.1093.
    PubMed     Abstract available


  87. TRAN-MINH ML, Gornet JM, Maillet M, Houze P, et al
    Safety of hydrocortisone premedication discontinuation in patients with inflammatory bowel disease on maintenance therapy with Infliximab: a prospective clinical and pharmacological study.
    J Crohns Colitis. 2020 Nov 18. pii: 5986749. doi: 10.1093.
    PubMed     Abstract available


  88. KALLA R, Adams AT, Bergemalm D, Vatn S, et al
    Serum proteomic profiling at diagnosis predicts clinical course, and need for intensification of treatment in inflammatory bowel disease.
    J Crohns Colitis. 2020 Nov 17. pii: 5985635. doi: 10.1093.
    PubMed     Abstract available


  89. GALLAGHER K, Catesson A, Griffin JL, Holmes E, et al
    Metabolomic Analysis in Inflammatory Bowel Disease: A Systematic Review.
    J Crohns Colitis. 2020 Nov 11. pii: 5974408. doi: 10.1093.
    PubMed     Abstract available


  90. KIM MA, Kim YH, Chun J, Lee HS, et al
    The influence of disease activity on pregnancy outcomes in women with inflammatory bowel disease: A systematic review and meta-analysis.
    J Crohns Colitis. 2020 Nov 11. pii: 5974276. doi: 10.1093.
    PubMed     Abstract available


  91. BARBERIO B, Black CJ, Savarino EV, Ford AC, et al
    Ciclosporin or Infliximab as Rescue Therapy in Acute Glucorticosteroid-refractory Ulcerative Colitis: Systematic Review and Network Meta-Analysis.
    J Crohns Colitis. 2020 Nov 11. pii: 5974124. doi: 10.1093.
    PubMed     Abstract available


  92. SEBASTIAN S, Gonzalez HA, Peyrin-Biroulet L
    Safety of Drugs During Previous and Current Coronavirus Pandemics: Lessons for Inflammatory Bowel Disease.
    J Crohns Colitis. 2020;14:1632-1643.
    PubMed     Abstract available


  93. TURSI A, Papa A
    Impact of Anti-TNFalpha Antibodies on the Risk of Covid-19 and its Severity in Patients with Inflammatory Bowel Diseases.
    J Crohns Colitis. 2020;14:1646-1647.
    PubMed    


  94. VOSKUIL MD, Spekhorst LM, van der Sloot KWJ, Jansen BH, et al
    Genetic risk scores identify genetic aetiology of inflammatory bowel disease phenotypes.
    J Crohns Colitis. 2020 Nov 6. pii: 5957220. doi: 10.1093.
    PubMed     Abstract available


  95. YOKOYAMA Y, Sawada K, Aoyama N, Yoshimura N, et al
    Erratum to: Efficacy of Granulocyte and Monocyte Adsorptive Apheresis in Patients With Inflammatory Bowel Disease Showing Lost Response to Infliximab.
    J Crohns Colitis. 2020 Nov 6. pii: 5958727. doi: 10.1093.
    PubMed    


    October 2020
  96. MAHMOUD R, van Lieshout C, Frederix GWJ, Jharap B, et al
    Continuation of anti-TNF in patients with Ulcerative Colitis in Remission is not Cost-effective compared to Treatment Withdrawal: a Markov Model.
    J Crohns Colitis. 2020 Oct 30. pii: 5944009. doi: 10.1093.
    PubMed     Abstract available


  97. SIEGEL CA, Christensen B, Kornbluth A, Rosh JR, et al
    Guidance for Restarting Inflammatory Bowel Disease Therapy in Patients Who Withheld Immunosuppressant Medications During COVID-19.
    J Crohns Colitis. 2020;14.
    PubMed     Abstract available


  98. LEWIN S, Lees C, Regueiro M, Hart A, et al
    International Organization for the Study of Inflammatory Bowel Disease: Global Strategies for Telemedicine and Inflammatory Bowel Diseases.
    J Crohns Colitis. 2020;14.
    PubMed     Abstract available


  99. DE LIMA-KARAGIANNIS A, Juillerat P, Sebastian S, Pedersen N, et al
    Management of Pregnant Inflammatory Bowel Disease Patients During the COVID-19 Pandemic.
    J Crohns Colitis. 2020;14.
    PubMed     Abstract available


  100. ABREU MT, Peyrin-Biroulet L
    Providing Guidance During a Global Viral Pandemic for the Care of Patients With Inflammatory Bowel Disease.
    J Crohns Colitis. 2020;14.
    PubMed    


  101. NG SC, Mak JWY, Hitz L, Chowers Y, et al
    COVID-19 Pandemic: Which IBD Patients Need to Be Scoped-Who Gets Scoped Now, Who Can Wait, and how to Resume to Normal.
    J Crohns Colitis. 2020;14.
    PubMed     Abstract available


  102. DOTAN I, Panaccione R, Kaplan GG, O'Morain C, et al
    Best Practice Guidance for Adult Infusion Centres during the COVID-19 Pandemic: Report from the COVID-19 International Organization for the Study of IBD [IOIBD] Task Force.
    J Crohns Colitis. 2020;14.
    PubMed     Abstract available


  103. ALLEZ M, Fleshner P, Gearry R, Lakatos PL, et al
    Care of the Patient With IBD Requiring Hospitalisation During the COVID-19 Pandemic.
    J Crohns Colitis. 2020;14.
    PubMed     Abstract available


  104. QURAISHI MN, Iqbal TH, Hart AL
    Precision Medicine with FMT for Ulcerative Colitis: Are We There Yet?
    J Crohns Colitis. 2020 Oct 20. pii: 5932516. doi: 10.1093.
    PubMed    


  105. DERIKX LAAP, Lantinga MA, de Jong DJ, van Dop WA, et al
    Clinical Outcomes of Covid-19 in Patients with Inflammatory Bowel Disease: A Nationwide Cohort Study.
    J Crohns Colitis. 2020 Oct 20. pii: 5932316. doi: 10.1093.
    PubMed     Abstract available


  106. BOSSUYT P, Bisschops R, Vermeire S, De Hertogh G, et al
    Variability in the distribution of histological disease activity in the colon of patients with ulcerative colitis.
    J Crohns Colitis. 2020 Oct 14. pii: 5923369. doi: 10.1093.
    PubMed     Abstract available


  107. ATTAUABI M, Poulsen A, Theede K, Pedersen N, et al
    Prevalence and outcomes of COVID-19 among patients with inflammatory bowel disease - A Danish prospective population-based cohort study.
    J Crohns Colitis. 2020 Oct 9. pii: 5920382. doi: 10.1093.
    PubMed     Abstract available


  108. ALOI M, Bramuzzo M, Norsa L, Arrigo S, et al
    Disease activity patterns in the first 5 years after diagnosis in children with ulcerative colitis: a population-based study.
    J Crohns Colitis. 2020 Oct 6. pii: 5918427. doi: 10.1093.
    PubMed     Abstract available


    September 2020
  109. MEREDITH J, Khedim CA, Henderson P, Wilson DC, et al
    Paediatric Inflammatory Multisystem Syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in a patient receiving Infliximab therapy for Inflammatory Bowel Disease.
    J Crohns Colitis. 2020 Sep 30. pii: 5913452. doi: 10.1093.
    PubMed     Abstract available


  110. ARHI C, Askari A, Nachiappan S, Bottle A, et al
    Stage at diagnosis and survival of colorectal cancer with or without underlying inflammatory bowel disease: a population-based study.
    J Crohns Colitis. 2020 Sep 29. pii: 5912977. doi: 10.1093.
    PubMed     Abstract available


  111. CHAPARRO M, Garre A, Mesonero F, Rodriguez C, et al
    Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry.
    J Crohns Colitis. 2020 Sep 24. pii: 5910901. doi: 10.1093.
    PubMed     Abstract available


  112. MULLER M, Broseus J, Feugier P, Thieblemont C, et al
    Characteristics Of Lymphoma In Patients With Inflammatory Bowel Disease: A Systematic Review.
    J Crohns Colitis. 2020 Sep 19. pii: 5908884. doi: 10.1093.
    PubMed     Abstract available


  113. DRUVEFORS E, Landerholm K, Hammar U, Myrelid P, et al
    Impaired fertility in Women with Inflammatory Bowel Disease: A National Cohort Study from Sweden.
    J Crohns Colitis. 2020 Sep 19. pii: 5908862. doi: 10.1093.
    PubMed     Abstract available


  114. VENY M, Garrido-Trigo A, Corraliza AM, Masamunt MC, et al
    Dissecting common and unique effects of anti-alpha4beta7 and anti-tumor necrosis factor treatment in ulcerative colitis.
    J Crohns Colitis. 2020 Sep 14. pii: 5905252. doi: 10.1093.
    PubMed     Abstract available


  115. MERLI AM, Vieujean S, Massot C, Bletard N, et al
    Solute carrier family 12 member 2 as a proteomic and histological biomarker of dysplasia and neoplasia in ulcerative colitis.
    J Crohns Colitis. 2020 Sep 13. pii: 5905032. doi: 10.1093.
    PubMed     Abstract available


  116. CONLEY TE, Probert C, Subramanian S
    Prevalence of COVID-19 Symptoms among Inflammatory Bowel Disease Patients Treated with Biological Agents.
    J Crohns Colitis. 2020 Sep 11. pii: 5904432. doi: 10.1093.
    PubMed    


  117. JANGI S, Holmer AK, Dulai PS, Boland BS, et al
    Risk of Relapse in Patients with Ulcerative Colitis with Persistent Endoscopic Healing: A Durable Treatment Endpoint.
    J Crohns Colitis. 2020 Sep 10. pii: 5903914. doi: 10.1093.
    PubMed     Abstract available


  118. MAK JWY, Ho CLT, Wong K, Cheng TY, et al
    Epidemiology and Natural History of Elderly-onset inflammatory bowel disease: Results from a territory-wide Hong Kong IBD registry.
    J Crohns Colitis. 2020 Sep 10. pii: 5903917. doi: 10.1093.
    PubMed     Abstract available


  119. VALTER M, Verstockt S, Finalet Ferreiro JA, Cleynen I, et al
    Extracellular vesicles in inflammatory bowel disease: small particles, big players.
    J Crohns Colitis. 2020 Sep 9. pii: 5903363. doi: 10.1093.
    PubMed     Abstract available


  120. WASMANN KA, van der Does de Willebois EM, Koens L, Duijvestein M, et al
    The Impact of Rectal Stump Inflammation After Subtotal Colectomy on Pouch Outcomes in Ulcerative Colitis Patients.
    J Crohns Colitis. 2020 Sep 9. pii: 5903251. doi: 10.1093.
    PubMed     Abstract available


  121. MAGRO F, Estevinho MM, Dias CC, Correia L, et al
    Clinical, endoscopic and histological outcomes in induction of moderate-to-severe ulcerative colitis: a systematic review with meta-analysis.
    J Crohns Colitis. 2020 Sep 8. pii: 5902904. doi: 10.1093.
    PubMed     Abstract available


  122. MAGRO F, Estevinho MM
    Newborn Congenital Abnormalities and Inflammatory Bowel Disease: Unveiling an Unexplored Relationship.
    J Crohns Colitis. 2020;14:1033-1034.
    PubMed    


    August 2020
  123. CAMILLERI M
    Ten Reasons to Think about Bile Acids in Managing Inflammatory Bowel Disease.
    J Crohns Colitis. 2020 Aug 31. pii: 5899784. doi: 10.1093.
    PubMed    


  124. MATSUOKA K, Igarashi A, Sato N, Isono Y, et al
    Trends in corticosteroid prescriptions for ulcerative colitis and factors associated with long-term corticosteroid use: analysis using Japanese claims data from 2006 to 2016.
    J Crohns Colitis. 2020 Aug 26. pii: 5897347. doi: 10.1093.
    PubMed     Abstract available


  125. OLESEN SW, Gerardin Y
    Re-evaluating the evidence for fecal microbiota transplantation "super-donors" in inflammatory bowel disease.
    J Crohns Colitis. 2020 Aug 18. pii: 5893677. doi: 10.1093.
    PubMed     Abstract available


  126. SOOD A, Singh A, Mahajan R, Midha V, et al
    Clinical Predictors of response to Faecal Microbiota Transplantation in patients with active ulcerative colitis.
    J Crohns Colitis. 2020 Aug 9. pii: 5890140. doi: 10.1093.
    PubMed     Abstract available


  127. REINISCH W, Danese S, Peyrin-Biroulet L, Loftus EV, et al
    Clinical Trials for Inflammatory Bowel Disease: Global Guidance During the COVID-19 Pandemic.
    J Crohns Colitis. 2020 Aug 7. pii: 5885159. doi: 10.1093.
    PubMed    


    July 2020
  128. GHOSH S, Sensky T, Casellas F, Rioux LC, et al
    A Global, Prospective, Observational Study Measuring Disease Burden and Suffering in Patients with Ulcerative Colitis Using the Pictorial Representation of Illness and Self-Measure Tool.
    J Crohns Colitis. 2020 Jul 29. pii: 5877457. doi: 10.1093.
    PubMed     Abstract available


  129. MAGRO F, Rahier JF, Abeu C, MacMahon E, et al
    Inflammatory bowel disease management during the COVID-19 outbreak: The 10 do's and don'ts from the ECCO-COVID Taskforce.
    J Crohns Colitis. 2020 Jul 29. pii: 5877458. doi: 10.1093.
    PubMed     Abstract available


  130. MANTA R, Zullo A, Telesca A, Castellani D, et al
    Endoscopic Submucosal Dissection for visible dysplasia treatment in ulcerative colitis patients: cases series and systematic review of literature.
    J Crohns Colitis. 2020 Jul 25. pii: 5876412. doi: 10.1093.
    PubMed     Abstract available


  131. FUMERY M, Matias C, Brochot E
    Seroconversion of immunoglobulins to SARS-CoV2 in patients with inflammatory bowel disease patients treated by biologics.
    J Crohns Colitis. 2020 Jul 22. pii: 5875101. doi: 10.1093.
    PubMed    


  132. PRIVITERA G, Onali S, Pugliese D, Renna S, et al
    Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease.
    J Crohns Colitis. 2020 Jul 17. pii: 5872608. doi: 10.1093.
    PubMed     Abstract available


  133. ALLOCCA M, Furfaro F, Fiorino G, Peyrin-Biroulet L, et al
    Point-of-care ultrasound in Inflammatory Bowel Disease.
    J Crohns Colitis. 2020 Jul 17. pii: 5872609. doi: 10.1093.
    PubMed     Abstract available


  134. BLACKWELL J, Saxena S, Jayasooriya N, Bottle A, et al
    Prevalence and duration of gastrointestinal symptoms before diagnosis of Inflammatory Bowel Disease and predictors of timely specialist review: a population-based study.
    J Crohns Colitis. 2020 Jul 15. pii: 5871943. doi: 10.1093.
    PubMed     Abstract available


  135. CROUWEL F, Buiter HJC, de Boer NK
    Gut microbiota-driven drug metabolism in inflammatory bowel disease.
    J Crohns Colitis. 2020 Jul 11. pii: 5870328. doi: 10.1093.
    PubMed     Abstract available


  136. TARGOWNIK LE, Benchimol EI, Bernstein CN, Singh H, et al
    Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications.
    J Crohns Colitis. 2020 Jul 10. pii: 5869652. doi: 10.1093.
    PubMed     Abstract available


  137. MARGALIT-YEHUDA R, Ben-Horin S
    Bottom-up: Can Trans-anal Rectal Resection Improve Outcomes in Ulcerative Colitis Patients Undergoing Proctocolectomy and Ileo-anal Pouch Anastomosis?
    J Crohns Colitis. 2020;14:724-725.
    PubMed    


  138. PARRA RS, Feitosa MR, Feres O
    Segmental Colectomy: An Alternative for Ulcerative Colitis in Endoscopic Remission?
    J Crohns Colitis. 2020 Jul 6. pii: 5868033. doi: 10.1093.
    PubMed    


  139. GOODSALL TM, Nguyen TM, Parker CE, Ma C, et al
    Systematic review: Gastrointestinal ultrasound scoring indices for inflammatory bowel disease.
    J Crohns Colitis. 2020 Jul 2. pii: 5866421. doi: 10.1093.
    PubMed     Abstract available


  140. SULTAN K, Swaminath A
    From Bad to Worse: The Relationship Between Opioid Use and Inflammatory Bowel Disease.
    J Crohns Colitis. 2020 Jul 2. pii: 5866377. doi: 10.1093.
    PubMed    


    June 2020
  141. TSENG CH
    Metformin use is associated with a lower risk of inflammatory bowel disease in patients with type 2 diabetes mellitus.
    J Crohns Colitis. 2020 Jun 30. pii: 5865444. doi: 10.1093.
    PubMed     Abstract available


  142. GOODSALL TM, Costello SP, Bryant RV
    Histological Healing in Ulcerative Colitis: Near Enough Is Not Good Enough.
    J Crohns Colitis. 2020 Jun 30. pii: 5865087. doi: 10.1093.
    PubMed    


  143. ZHOU M, He J, Shi Y, Liu X, et al
    ABIN3 negatively regulates necroptosis-induced intestinal inflammation through recruiting A20 and restricting the ubiquitination of RIPK3 in inflammatory bowel disease.
    J Crohns Colitis. 2020 Jun 30. pii: 5864883. doi: 10.1093.
    PubMed     Abstract available


  144. KALLA R, Adams AT, Ventham NT, Kennedy NA, et al
    Whole blood profiling of T-cell derived miRNA allows the development of prognostic models in inflammatory bowel disease.
    J Crohns Colitis. 2020 Jun 29. pii: 5864785. doi: 10.1093.
    PubMed     Abstract available


  145. SCHREINER P, Mueller NJ, Fehr J, Maillard MH, et al
    Varicella zoster virus in inflammatory bowel disease patients: what every gastroenterologist should know.
    J Crohns Colitis. 2020 Jun 27. pii: 5864104. doi: 10.1093.
    PubMed     Abstract available


  146. LIGHTNER AL, Vogler S, McMichael J, Jia X, et al
    Dysplastic Progression to Adenocarcinoma is Equivalent in Ulcerative Colitis and Crohn's disease.
    J Crohns Colitis. 2020 Jun 27. pii: 5864008. doi: 10.1093.
    PubMed     Abstract available


  147. SCHREIBER S, Dignass A, Rogge A, Rubin DT, et al
    Stopping Clinical Trials in Inflammatory Bowel Disease During the COVID-19 Pandemic is not a Responsible Act.
    J Crohns Colitis. 2020 Jun 25. pii: 5862397. doi: 10.1093.
    PubMed     Abstract available


  148. D'AMICO F, Peyrin-Biroulet L, Danese S
    JAK or GUT Selectivity: Tipping the Balance for Efficacy and Safety in Ulcerative Colitis.
    J Crohns Colitis. 2020 Jun 24. pii: 5862030. doi: 10.1093.
    PubMed    


  149. MUKHERJEE S, Beresford B, Atkin K, Sebastian S, et al
    The need for culturally competent care within gastroenterology services: Evidence from research with adults of South Asian origin living with inflammatory bowel disease.
    J Crohns Colitis. 2020 Jun 23. pii: 5861668. doi: 10.1093.
    PubMed     Abstract available


  150. VAN DER SLOOT KWJ, Weersma RK, Alizadeh BZ, Dijkstra G, et al
    Identification of environmental risk factors associated with the development of Inflammatory Bowel Disease.
    J Crohns Colitis. 2020 Jun 23. pii: 5861037. doi: 10.1093.
    PubMed     Abstract available


  151. GRUNERT PC, Reuken PA, Stallhofer J, Teich N, et al
    Inflammatory Bowel Disease in the COVID-19 Pandemic - the Patients' Perspective.
    J Crohns Colitis. 2020 Jun 20. pii: 5860461. doi: 10.1093.
    PubMed     Abstract available


  152. D'AMICO F, Baumann C, Rousseau H, Danese S, et al
    Phase I, II and III Trials in Inflammatory Bowel Diseases: A Practical Guide for the Non-specialist.
    J Crohns Colitis. 2020;14:710-718.
    PubMed     Abstract available


  153. SOMERS M, Bossuyt P, Ferrante M, Peeters H, et al
    Belgian IBD Research Group [BIRD] Position Statement 2019 on the Use of Adalimumab Biosimilars in Inflammatory Bowel Diseases.
    J Crohns Colitis. 2020;14:680-685.
    PubMed     Abstract available


  154. VON MARTELS JZH, Bourgonje AR, Klaassen MAY, Alkhalifah HAA, et al
    Riboflavin Supplementation in Patients with Crohn's Disease [the RISE-UP study].
    J Crohns Colitis. 2020;14:595-607.
    PubMed     Abstract available


  155. FAUNY M, D'Amico F, Bonovas S, Netter P, et al
    Faecal Calprotectin for the Diagnosis of Bowel Inflammation in Patients With Rheumatological Diseases: A Systematic Review.
    J Crohns Colitis. 2020;14:688-693.
    PubMed     Abstract available


  156. ZHOU C, Wu XR, Liu HS, Liu XH, et al
    Immunomodulatory Effect of Urine-derived Stem Cells on Inflammatory Bowel Diseases via Downregulating Th1/Th17 Immune Responses in a PGE2-dependent Manner.
    J Crohns Colitis. 2020;14:654-668.
    PubMed     Abstract available


  157. VALE RODRIGUES R, Sladek M, Katsanos K, van der Woude CJ, et al
    Diagnosis and Outcome of Oesophageal Crohn's Disease.
    J Crohns Colitis. 2020;14:624-629.
    PubMed     Abstract available


  158. AL NABHANI Z, Berrebi D, Martinez-Vinson C, Montcuquet N, et al
    Nod2 Protects the Gut From Experimental Colitis Spreading to Small Intestine.
    J Crohns Colitis. 2020;14:669-679.
    PubMed     Abstract available


  159. ZHAO M, Burisch J
    The Sooner the Better? Cost-effectiveness of Early Biological Therapy in Patients With Crohn's Disease.
    J Crohns Colitis. 2020;14:573-574.
    PubMed    


  160. EDER P, Dobrowolska A, Rydzewska G
    Historical Upheavals and Eponyms in Crohn's Disease-Is There Any Relation?
    J Crohns Colitis. 2020;14:719.
    PubMed    


  161. WEISSMAN S, Goldowsky A, Mehta TI, Sciarra MA, et al
    Are Quality Metrics in Inflammatory Bowel Disease Rooted on Substantial Quality Evidence? A Systematic Review.
    J Crohns Colitis. 2020 Jun 16. pii: 5858213. doi: 10.1093.
    PubMed     Abstract available


  162. REINISCH W, Danese S, Peyrin-Biroulet L, Loftus EV, et al
    Clinical trials for inflammatory bowel disease: a global guidance during COVID-19 pandemic.
    J Crohns Colitis. 2020 Jun 10. pii: 5855532. doi: 10.1093.
    PubMed     Abstract available


  163. MAGRO F, Doherty G, Peyrin-Biroulet L, Svrcek M, et al
    ECCO Position Paper: Harmonisation of the approach to Ulcerative Colitis Histopathology.
    J Crohns Colitis. 2020 Jun 6. pii: 5854301. doi: 10.1093.
    PubMed     Abstract available


  164. FRONTALI A, Cohen L, Bridoux V, Myrelid P, et al
    Segmental colectomy for ulcerative colitis: is there a place in selected patients without active colitis ? An international multicentric retrospective study in 72 patients.
    J Crohns Colitis. 2020 Jun 4. pii: 5851522. doi: 10.1093.
    PubMed     Abstract available


  165. FRIEDMAN S, Nielsen J, Jolving LR, Nohr EA, et al
    Long-term motor and cognitive function in the children of women with inflammatory bowel disease.
    J Crohns Colitis. 2020 Jun 4. pii: 5851419. doi: 10.1093.
    PubMed     Abstract available


    May 2020
  166. NEHRA AK, Sheedy SP, Wells ML, VanBuren WM, et al
    Imaging Findings of Ileal Inflammation at Computed Tomography and Magnetic Resonance Enterography: What do They Mean When Ileoscopy and Biopsy are Negative?
    J Crohns Colitis. 2020;14:455-464.
    PubMed     Abstract available


  167. DANIELOU M, Sarter H, Pariente B, Fumery M, et al
    Natural History of Perianal Fistulising Lesions in Patients With Elderly-onset Crohn's Disease: A Population-based Study.
    J Crohns Colitis. 2020;14:501-507.
    PubMed     Abstract available


  168. PILLAI N, Lupatsch JE, Dusheiko M, Schwenkglenks M, et al
    Evaluating the Cost-Effectiveness of Early Compared with Late or No Biologic Treatment to Manage Crohn's Disease using Real-World Data.
    J Crohns Colitis. 2020;14:490-500.
    PubMed     Abstract available


  169. CONDAMINA M, Diaz E, Jamart C, Loget J, et al
    Severe Attack of Henoch-Schonlein Purpura With Neurological Involvement During Adalimumab Treatment for Crohn's Disease.
    J Crohns Colitis. 2020;14:538-542.
    PubMed     Abstract available


  170. SPARROW MP, Papamichael K, Ward MG, Riviere P, et al
    Therapeutic Drug Monitoring of Biologics During Induction to Prevent Primary Non-Response.
    J Crohns Colitis. 2020;14:542-556.
    PubMed     Abstract available


  171. RODRIGUEZ-LAGO I, Gisbert JP
    The Role of Immunomodulators and Biologics in the Medical Management of Stricturing Crohn's Disease.
    J Crohns Colitis. 2020;14:557-566.
    PubMed     Abstract available


  172. DHALIWAL J, Walters TD, Mack DR, Huynh HQ, et al
    Phenotypic Variation in Paediatric Inflammatory Bowel Disease by Age: A Multicentre Prospective Inception Cohort Study of the Canadian Children IBD Network.
    J Crohns Colitis. 2020;14:445-454.
    PubMed     Abstract available


  173. MADARAME A, Kimura H, Kunisaki R
    Successful Treatment With Ustekinumab for Enterocutaneous Fistulas in Crohn's Disease.
    J Crohns Colitis. 2020;14:569-570.
    PubMed    


  174. CHATEAU T, Angioi K, Peyrin-Biroulet L
    Two Cases of Successful Ustekinumab Treatment for Non-infectious Uveitis Associated With Crohn's Disease.
    J Crohns Colitis. 2020;14:571.
    PubMed    


  175. PARK SH, Kim HJ, Lee CK, Song EM, et al
    Safety and optimal timing of BCG vaccination in infants born to mothers receiving anti-TNF therapy for inflammatory bowel disease.
    J Crohns Colitis. 2020 May 17. pii: 5838422. doi: 10.1093.
    PubMed     Abstract available


  176. VARIOLA A, Zanolin E, Cipriano G, Macchioni P, et al
    The IBIS-Q (IBd Identification of Spondyloarthrytis Questionnaire): a novel tool to detect both Axial and Peripheral Arthritis in Inflammatory Bowel Disease patients.
    J Crohns Colitis. 2020 May 15. pii: 5837772. doi: 10.1093.
    PubMed     Abstract available


  177. LIANG G, Conrad MA, Kelsen JR, Kessler LR, et al
    The dynamics of the stool virome in very early onset inflammatory bowel disease.
    J Crohns Colitis. 2020 May 14. pii: 5837025. doi: 10.1093.
    PubMed     Abstract available


  178. CHAPMAN S, Sibelli A, St-Clair Jones A, Forbes A, et al
    Personalised Adherence Support for Maintenance Treatment of Inflammatory Bowel Disease: A Tailored Digital Intervention to Change Adherence-related Beliefs and Barriers.
    J Crohns Colitis. 2020 May 7. pii: 5831700. doi: 10.1093.
    PubMed     Abstract available


  179. HORIO Y, Uchino M, Bando T, Sasaki H, et al
    Incidence, Risk Factors, and Outcomes of Cancer of the Anal Transitional Zone with Ulcerative Colitis..
    J Crohns Colitis. 2020 May 4. pii: 5828994. doi: 10.1093.
    PubMed     Abstract available


    April 2020
  180. BOIVINEAU L, Le Mehaute A, Roblin X
    Prospective evaluation of cytomegalovirus time-course kinetics in colonic biopsies from patients with moderate-to-severe ulcerative colitis following infliximab treatment: a prospective study.
    J Crohns Colitis. 2020 Apr 28. pii: 5826392. doi: 10.1093.
    PubMed    


  181. FLANAGAN E, Wright EK, Begun J, Bryant RV, et al
    Monitoring Inflammatory Bowel Disease in Pregnancy using Gastrointestinal Ultrasonography.
    J Crohns Colitis. 2020 Apr 28. pii: 5826347. doi: 10.1093.
    PubMed     Abstract available


  182. ZHANG B, Gulati A, Alipour O, Shao L, et al
    Relapse from deep remission after therapeutic de-escalation in inflammatory bowel disease: a systematic review and meta-analysis.
    J Crohns Colitis. 2020 Apr 26. pii: 5825450. doi: 10.1093.
    PubMed     Abstract available


  183. PHILLIPS FM, Verstockt B, Sebastian S, Ribaldone DG, et al
    Inflammatory cutaneous lesions in inflammatory bowel disease treated with Vedolizumab or Ustekinumab: an ECCO CONFER multicentre case series.
    J Crohns Colitis. 2020 Apr 22. pii: 5823596. doi: 10.1093.
    PubMed     Abstract available


  184. PEYRIN-BIROULET C, D'Amico F, Peyrin-Biroulet L
    Will COVID-19 infection be less severe in ulcerative colitis than in Crohn's patients due to a lower rate of smokers?
    J Crohns Colitis. 2020 Apr 18. pii: 5821493. doi: 10.1093.
    PubMed    


  185. HONAP S, Chee D, Chapman TP, Patel M, et al
    Real-World Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multi-Centre UK Experience.
    J Crohns Colitis. 2020 Apr 13. pii: 5819381. doi: 10.1093.
    PubMed     Abstract available


  186. CARDINALE CJ, March ME, Lin X, Liu Y, et al
    Regulation of Janus Kinase 2 by an Inflammatory Bowel Disease Causal Non-coding Single Nucleotide Polymorphism.
    J Crohns Colitis. 2020 Apr 9. pii: 5818372. doi: 10.1093.
    PubMed     Abstract available


  187. CHRISTENSEN B, Hanauer SB, Gibson PR, Turner JR, et al
    Segmental Histologic Normalisation Occurs in Ulcerative Colitis but does not Improve Clinical Outcomes.
    J Crohns Colitis. 2020 Apr 8. pii: 5817864. doi: 10.1093.
    PubMed     Abstract available


    March 2020
  188. BAI X, Yang H, Qian J
    COVID-19 outbreak and inflammatory bowel disease management: a questionnaire survey from realistic practice.
    J Crohns Colitis. 2020 Mar 28. pii: 5812999. doi: 10.1093.
    PubMed    


  189. MONTELEONE G, Ardizzone S
    Are patients with inflammatory bowel disease at increased risk for Covid-19 infection?
    J Crohns Colitis. 2020 Mar 26. pii: 5811674. doi: 10.1093.
    PubMed     Abstract available


  190. VAN ANDEL EM, Koopmann BDM, Crouwel F, Noomen CG, et al
    Systematic review of development and content validity of patient-reported outcome measures in Inflammatory Bowel Disease: do we measure what we measure?
    J Crohns Colitis. 2020 Mar 25. pii: 5811405. doi: 10.1093.
    PubMed     Abstract available


  191. FIORINO G, Allocca M, Furfaro F, Gilardi D, et al
    Inflammatory bowel disease care in the COVID-19 pandemic era: the Humanitas, Milan experience.
    J Crohns Colitis. 2020 Mar 24. pii: 5811431. doi: 10.1093.
    PubMed     Abstract available


  192. CALAFAT M, Manosa M, Mesonero F, Guardiola J, et al
    Switching to a second thiopurine in adult and elderly patients with inflammatory bowel disease: a nationwide study from the ENEIDA registry.
    J Crohns Colitis. 2020 Mar 23. pii: 5810964. doi: 10.1093.
    PubMed     Abstract available


  193. IACUCCI M, Cannatelli R, Gui XS, Zardo D, et al
    Assessment of endoscopic healing by using advanced technologies reflects histologic healing in ulcerative colitis.
    J Crohns Colitis. 2020 Mar 23. pii: 5810912. doi: 10.1093.
    PubMed     Abstract available


  194. SCHREIBER S, Hanauer SB, Sandborn WJ, Barrett K, et al
    Time to Symptom Resolution in Ulcerative Colitis With Multimatrix Mesalazine Treatment: A Pooled Analysis.
    J Crohns Colitis. 2020 Mar 17. pii: 5807996. doi: 10.1093.
    PubMed     Abstract available


  195. SLEVIN SM, Garner LC, Lahiff C, Tan M, et al
    Lymphocyte activation gene (LAG)-3 is associated with mucosal inflammation and disease activity in ulcerative colitis.
    J Crohns Colitis. 2020 Mar 16. pii: 5807948. doi: 10.1093.
    PubMed     Abstract available


  196. DORRINGTON AM, Selinger CP, Parkes GC, Smith M, et al
    The historical role and contemporary use of corticosteroids in inflammatory bowel disease.
    J Crohns Colitis. 2020 Mar 14. pii: 5805149. doi: 10.1093.
    PubMed     Abstract available


  197. BARTKO J, Reichardt B, Kocijan R, Klaushofer K, et al
    Inflammatory Bowel Disease: A Nationwide Study of Hip Fracture and Mortality Risk after Hip Fracture.
    J Crohns Colitis. 2020 Mar 14. pii: 5805150. doi: 10.1093.
    PubMed     Abstract available



  198. Retraction: An interim analysis of real-world safety data from an ongoing, non-interventional, observational study of patients with inflammatory bowel disease treated with CT-P13, an infliximab biosimilar, in the context of usual care with reference i
    J Crohns Colitis. 2020;14:428.
    PubMed    


  199. YOKOYAMA Y, Sawada K, Aoyama N, Yoshimura N, et al
    Efficacy of Granulocyte and Monocyte Adsorptive Apheresis in Patients with Inflammatory Bowel Disease Showing Lost Response to Infliximab.
    J Crohns Colitis. 2020 Mar 13. pii: 5804700. doi: 10.1093.
    PubMed     Abstract available


  200. ANNESE V
    Small Bowel Adenocarcinoma in Crohn's Disease: An Underestimated Risk?
    J Crohns Colitis. 2020;14:285-286.
    PubMed    


  201. CARBONNEL F, Svrcek M
    Progress in the Molecular and Histological Dissection of Crohn's Disease-associated Small Bowel Adenocarcinomas.
    J Crohns Colitis. 2020;14:283-284.
    PubMed    


  202. DELATTRE C, Lewis A, Kirchgesner J, Nion-Larmurier I, et al
    Impact of Aphthous Colitis at Diagnosis on Crohn's Disease Outcomes.
    J Crohns Colitis. 2020;14:342-350.
    PubMed     Abstract available


  203. FELWICK RK, Dingley GJR, Martinez-Nunez R, Sanchez-Elsner T, et al
    MicroRNA23a Overexpression in Crohn's Disease Targets Tumour Necrosis Factor Alpha Inhibitor Protein 3, Increasing Sensitivity to TNF and Modifying the Epithelial Barrier.
    J Crohns Colitis. 2020;14:381-392.
    PubMed     Abstract available


  204. FIELDS AC, Hu FY, Lu P, Irani J, et al
    Small Bowel Adenocarcinoma: Is There a Difference in Survival for Crohn's Versus Sporadic Cases?
    J Crohns Colitis. 2020;14:303-308.
    PubMed     Abstract available


  205. BORREN NZ, Tan W, Colizzo FP, Luther J, et al
    Longitudinal Trajectory of Fatigue With Initiation of Biologic Therapy in Inflammatory Bowel Diseases: A Prospective Cohort Study.
    J Crohns Colitis. 2020;14:309-315.
    PubMed     Abstract available


  206. PIOVANI D, Danese S, Peyrin-Biroulet L, Bonovas S, et al
    Environmental, Nutritional, and Socioeconomic Determinants of IBD Incidence: A Global Ecological Study.
    J Crohns Colitis. 2020;14:323-331.
    PubMed     Abstract available


  207. FRANZE E, Monteleone I, Laudisi F, Rizzo A, et al
    Cadherin-11 Is a Regulator of Intestinal Fibrosis.
    J Crohns Colitis. 2020;14:406-417.
    PubMed     Abstract available


  208. VERSTOCKT B, Mertens E, Dreesen E, Outtier A, et al
    Influence of Drug Exposure on Vedolizumab-Induced Endoscopic Remission in Anti-Tumour Necrosis Factor [TNF] Naive and Anti-TNF Exposed IBD Patients.
    J Crohns Colitis. 2020;14:332-341.
    PubMed     Abstract available


  209. POREDSKA K, Kunovsky L, Marek F, Kala Z, et al
    The Influence of Microscopic Inflammation at Resection Margins on Early Postoperative Endoscopic Recurrence After Ileocaecal Resection for Crohn's Disease.
    J Crohns Colitis. 2020;14:361-368.
    PubMed     Abstract available


  210. ARPA G, Grillo F, Giuffrida P, Nesi G, et al
    Separation of Low- Versus High-grade Crohn's Disease-associated Small Bowel Carcinomas is Improved by Invasive Front Prognostic Marker Analysis.
    J Crohns Colitis. 2020;14:295-302.
    PubMed     Abstract available


  211. PELLINO G, Vinci D, Signoriello G, Kontovounisios C, et al
    Long-Term Bowel Function and Fate of the Ileal Pouch After Restorative Proctocolectomy in Patients With Crohn's Disease: A Systematic Review With Meta-Analysis and Metaregression.
    J Crohns Colitis. 2020;14:418-427.
    PubMed     Abstract available


  212. LIAO X, Li G, McBride R, Houldsworth J, et al
    Clinicopathological and Molecular Characterisation of Crohn's Disease-associated Small Bowel Adenocarcinomas.
    J Crohns Colitis. 2020;14:287-294.
    PubMed     Abstract available


  213. SANDBORN WJ, Nguyen DD, Beattie DT, Brassil P, et al
    Development of gut-selective pan-Janus kinase inhibitor TD-1473 for ulcerative colitis: A translational medicine program.
    J Crohns Colitis. 2020 Mar 11. pii: 5803305. doi: 10.1093.
    PubMed     Abstract available


  214. SEVERYNS T, Kirchgesner J, Lambert J, Thieblemont C, et al
    Prognosis of lymphoma in patients with known Inflammatory Bowel Disease: a French multicentre cohort study.
    J Crohns Colitis. 2020 Mar 11. pii: 5803309. doi: 10.1093.
    PubMed     Abstract available


  215. BARNHOORN MC, Hakuno SK, Bruckner RS, Rogler G, et al
    Stromal Cells in the Pathogenesis of Inflammatory Bowel Disease.
    J Crohns Colitis. 2020 Mar 11. pii: 5803221. doi: 10.1093.
    PubMed     Abstract available


  216. LEFEVRE PLC, Vande Casteele N
    Clinical Pharmacology of Janus Kinase Inhibitors in Inflammatory Bowel Disease.
    J Crohns Colitis. 2020 Mar 11. pii: 5803222. doi: 10.1093.
    PubMed     Abstract available


  217. LAUBE R, Yau Y, Selinger CP, Seow CH, et al
    Knowledge and attitudes towards pregnancy in females with Inflammatory Bowel Disease - an international, multi-centre study.
    J Crohns Colitis. 2020 Mar 11. pii: 5803333. doi: 10.1093.
    PubMed     Abstract available


  218. SHAH SC, Itzkowitz SH
    Reappraising risk factors for inflammatory bowel disease-associated neoplasia: Implications for colonoscopic surveillance in IBD.
    J Crohns Colitis. 2020 Mar 9. pii: 5801093. doi: 10.1093.
    PubMed     Abstract available


    February 2020
  219. ROBERTS SE, Thorne K, Thapar N, Broekaert I, et al
    A systematic review and meta analysis of paediatric inflammatory bowel disease incidence and prevalence across Europe.
    J Crohns Colitis. 2020 Feb 28. pii: 5770946. doi: 10.1093.
    PubMed     Abstract available


  220. NOHR EA, Nielsen J, Norgard BM, Friedman S, et al
    Sexual health in women with inflammatory bowel disease in the Danish National Birth Cohort.
    J Crohns Colitis. 2020 Feb 27. pii: 5760869. doi: 10.1093.
    PubMed     Abstract available


  221. MOURAD FH, Hashash JG, Kariyawasam VC, Leong RW, et al
    Ulcerative Colitis and Cytomegalovirus Infection: From A to Z.
    J Crohns Colitis. 2020 Feb 27. pii: 5760718. doi: 10.1093.
    PubMed     Abstract available


  222. SOLA TAPIAS N, Vergnolle N, Denadai-Souza A, Barreau F, et al
    The interplay between genetic risk factors and proteolytic dysregulation in the pathophysiology of inflammatory bowel disease.
    J Crohns Colitis. 2020 Feb 22. pii: 5748295. doi: 10.1093.
    PubMed     Abstract available


  223. MEUNIER L, Clerc C, Meszaros M
    Use of Tofacitinib for ulcerative colitis in a liver transplant patient.
    J Crohns Colitis. 2020 Feb 19. pii: 5740228. doi: 10.1093.
    PubMed    


  224. SHAH R, Hoffman GR, El-Dallal M, Goldowsky AM, et al
    Is Therapeutic Drug Monitoring for Anti-Tumor Necrosis Factor Agents in Adults with Inflammatory Bowel Disease Ready for Standard of Care?: A Systematic Review and Meta-analysis.
    J Crohns Colitis. 2020 Feb 17. pii: 5736596. doi: 10.1093.
    PubMed     Abstract available


  225. VERMEIRE S, Lukas M, Magro F, Adsul S, et al
    Vedolizumab Efficacy, Safety, and Pharmacokinetics with Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients with Crohn's Disease or Ulcerative Colitis.
    J Crohns Colitis. 2020 Feb 15. pii: 5736390. doi: 10.1093.
    PubMed     Abstract available


  226. ZADRO V, Santus P, Maconi G
    Ulcerative Colitis: not only gut.
    J Crohns Colitis. 2020 Feb 14. pii: 5735761. doi: 10.1093.
    PubMed    


  227. SCHREIBER S
    Lack of Efficacy in Crohn's Disease Prompts Unplanned Interim Analysis and Termination of Study in Ulcerative Colitis.
    J Crohns Colitis. 2020;14:282.
    PubMed    


  228. SIEGMUND B
    Are Serum-Based Markers Going to Replace Faecal Neutrophil Markers in Ulcerative Colitis?
    J Crohns Colitis. 2020;14:151-152.
    PubMed    


  229. ADAMINA M, Bonovas S, Raine T, Spinelli A, et al
    ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment.
    J Crohns Colitis. 2020;14:155-168.
    PubMed     Abstract available


  230. MAGRO F, Lopes J, Borralho P, Lopes S, et al
    Comparing the Continuous Geboes Score With the Robarts Histopathology Index: Definitions of Histological Remission and Response and their Relation to Faecal Calprotectin Levels.
    J Crohns Colitis. 2020;14:169-175.
    PubMed     Abstract available


  231. WASMANN KA
    Complications While Waiting for IBD Surgery-Short Report.
    J Crohns Colitis. 2020;14:277-280.
    PubMed     Abstract available


  232. KEITA AV, Alkaissi LY, Holm EB, Heil SDS, et al
    Enhanced E. coli LF82 Translocation through the Follicle-associated Epithelium in Crohn's Disease is Dependent on Long Polar Fimbriae and CEACAM6 expression, and Increases Paracellular Permeability.
    J Crohns Colitis. 2020;14:216-229.
    PubMed     Abstract available


  233. AGRAWAL M, Burisch J, Colombel JF, C Shah S, et al
    Viewpoint: Inflammatory Bowel Diseases Among Immigrants From Low- to High-Incidence Countries: Opportunities and Considerations.
    J Crohns Colitis. 2020;14:267-273.
    PubMed     Abstract available


  234. PIERRE N, Salee C, Massot C, Bletard N, et al
    Proteomics Highlights Common and Distinct Pathophysiological Processes Associated with Ileal and Colonic Ulcers in Crohn's Disease.
    J Crohns Colitis. 2020;14:205-215.
    PubMed     Abstract available


  235. COSTA-MOREIRA P, Lopes S, Santos AL, Pedrosa AF, et al
    Leukocytoclastic Vasculitis Related to Ustekinumab in a Crohn's Disease Patient: First Case Report and Literature Review.
    J Crohns Colitis. 2020;14:274-276.
    PubMed     Abstract available


  236. KOTWANI P, Terdiman J, Lewin S
    Tofacitinib for rescue therapy in acute severe ulcerative colitis: a real-world experience.
    J Crohns Colitis. 2020 Feb 5. pii: 5727212. doi: 10.1093.
    PubMed     Abstract available


  237. OSTVIK AE, Svendsen TD, Granlund AVB, Doseth B, et al
    Intestinal epithelial cells express immunomodulatory ISG15 during active ulcerative colitis and Crohn's disease.
    J Crohns Colitis. 2020 Feb 5. pii: 5727513. doi: 10.1093.
    PubMed     Abstract available


  238. LO B, Holm JP, Vester-Andersen MK, Bendtsen F, et al
    Incidence, risk factors and evaluation of osteoporosis in patients with inflammatory bowel disease - a Danish population-based inception cohort with 10 years of follow-up.
    J Crohns Colitis. 2020 Feb 4. pii: 5722012. doi: 10.1093.
    PubMed     Abstract available


  239. QURAISHI MN, Acharjee A, Beggs AD, Horniblow R, et al
    A pilot integrative analysis of colonic gene expression, gut microbiota and immune infiltration in primary sclerosing cholangitis-inflammatory bowel disease: association of disease with bile acid pathways.
    J Crohns Colitis. 2020 Feb 4. pii: 5722016. doi: 10.1093.
    PubMed     Abstract available


  240. AGRAWAL M, Kim ES, Colombel JF
    JAK inhibitors safety in ulcerative colitis: practical implications.
    J Crohns Colitis. 2020 Feb 1. pii: 5719575. doi: 10.1093.
    PubMed     Abstract available


    January 2020
  241. DE JONG ME, Smits LJT, van Ruijven B, den Broeder N, et al
    Increased discontinuation rates of anti-TNF therapy in elderly inflammatory bowel disease patients.
    J Crohns Colitis. 2020 Jan 24. pii: 5715073. doi: 10.1093.
    PubMed     Abstract available


  242. MAGRO F, Lopes J, Borralho P, Dias CC, et al
    Comparison of the Nancy index with continuous Geboes score: histological remission and response in ulcerative colitis.
    J Crohns Colitis. 2020 Jan 22. pii: 5713474. doi: 10.1093.
    PubMed     Abstract available


  243. MARTIN A, Nachury M, Peyrin-Biroulet L, Bouhnik Y, et al
    Maintenance of remission among patients with inflammatory bowel disease after vedolizumab discontinuation: a multicentre cohort study.
    J Crohns Colitis. 2020 Jan 13. pii: 5701423. doi: 10.1093.
    PubMed     Abstract available


  244. NICOLAIDES S, Vasudevan A, Van Langenberg D
    Medical Management of Infliximab Failure in Acute Severe Ulcerative Colitis.
    J Crohns Colitis. 2020 Jan 13. pii: 5701450. doi: 10.1093.
    PubMed    


  245. AUGER N, Cote-Daigneault J, Bilodeau-Bertrand M, Arbour L, et al
    Inflammatory bowel disease and risk of birth defects in offspring.
    J Crohns Colitis. 2020 Jan 7. pii: 5697329. doi: 10.1093.
    PubMed     Abstract available


  246. LUKAS M, Malickova K, Kolar M, Bortlik M, et al
    Switching from originator adalimumab to the biosimilar SB5 in patients with inflammatory bowel disease: Short-term experience from a single tertiary clinical center.
    J Crohns Colitis. 2020 Jan 6. pii: 5697282. doi: 10.1093.
    PubMed     Abstract available


  247. SCOTT FI, Luo M, Shah Y, Lasch K, et al
    Identification of the most cost effective position of vedolizumab among the available biologic drugs for the treatment of ulcerative colitis.
    J Crohns Colitis. 2020 Jan 4. pii: 5696657. doi: 10.1093.
    PubMed     Abstract available


  248. HOMMEL C, Pillet S, Rahier JF
    Comment on: 'Resolution of CMV Infection in the Bowel on Vedolizumab Therapy'.
    J Crohns Colitis. 2020;14:148-149.
    PubMed    


  249. BIEMANS VBC, van der Meulen-de Jong AE, van der Woude CJ, Lowenberg M, et al
    Ustekinumab for Crohn's Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study.
    J Crohns Colitis. 2020;14:33-45.
    PubMed     Abstract available


  250. VERDIER J, Breunig IR, Ohse MC, Roubrocks S, et al
    Faecal Micro-RNAs in Inflammatory Bowel Diseases.
    J Crohns Colitis. 2020;14:110-117.
    PubMed     Abstract available


  251. BARNHOORN MC, Wasser MNJM, Roelofs H, Maljaars PWJ, et al
    Long-term Evaluation of Allogeneic Bone Marrow-derived Mesenchymal Stromal Cell Therapy for Crohn's Disease Perianal Fistulas.
    J Crohns Colitis. 2020;14:64-70.
    PubMed     Abstract available


  252. LEVINE A, Chanchlani N, Hussey S, Ziv-Baran T, et al
    Complicated Disease and Response to Initial Therapy Predicts Early Surgery in Paediatric Crohn's Disease: Results From the Porto Group GROWTH Study.
    J Crohns Colitis. 2020;14:71-78.
    PubMed     Abstract available


  253. BRAGA-NETO MB, Gaballa JM, Bamidele AO, Sarmento OF, et al
    Deregulation of Long Intergenic Non-coding RNAs in CD4+ T Cells of Lamina Propria in Crohn's Disease Through Transcriptome Profiling.
    J Crohns Colitis. 2020;14:96-109.
    PubMed     Abstract available


  254. HANAUER SB, Sandborn WJ, Feagan BG, Gasink C, et al
    IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease.
    J Crohns Colitis. 2020;14:23-32.
    PubMed     Abstract available


  255. TORRES J, Bonovas S, Doherty G, Kucharzik T, et al
    ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment.
    J Crohns Colitis. 2020;14:4-22.
    PubMed    


  256. TRAVIS S
    IM-UNITI at Three Years: Stellar Stelara(R) or Stardust? The Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease.
    J Crohns Colitis. 2020;14:1-3.
    PubMed    


    December 2019
  257. HARRIS RE, Curtis L, Hegde V, Garrick V, et al
    A decade of Varicella screening within a paediatric inflammatory bowel disease population.
    J Crohns Colitis. 2019 Dec 31. pii: 5691246. doi: 10.1093.
    PubMed     Abstract available


  258. FERRANTE M, Sabino J
    Efficacy of anti-JAK inhibitors in ulcerative colitis.
    J Crohns Colitis. 2019 Dec 27. pii: 5687770. doi: 10.1093.
    PubMed     Abstract available


  259. KOBAYASHI T, Uda A, Udagawa E, Hibi T, et al
    Lack of Increased Risk of Lymphoma by Thiopurines or Biologics in Japanese Patients with Inflammatory Bowel Disease: A Large-Scale Administrative Database Analysis.
    J Crohns Colitis. 2019 Dec 23. pii: 5684917. doi: 10.1093.
    PubMed     Abstract available


  260. FLEMING C, Mohan H, Coffey JC
    Should we Resect the Mesentery in Ileocolic Crohn's Disease?-A Response to 'A Warning About the Role of Extended Mesenteric Resection in Crohn's Disease Recurrence'.
    J Crohns Colitis. 2019;13:1584.
    PubMed    


  261. MARK-CHRISTENSEN A, Erichsen R, Veres K, Laurberg S, et al
    Extracolonic cancer risk after total colectomy for inflammatory bowel disease: A population-based cohort study.
    J Crohns Colitis. 2019 Dec 7. pii: 5666210. doi: 10.1093.
    PubMed     Abstract available


  262. CHARILAOU P, Mohapatra S, Joshi T, Devani K, et al
    Opioid Use Disorder Increases 30-Day Readmission Risk in Inflammatory Bowel Disease Hospitalizations: a Nationwide Matched Analysis.
    J Crohns Colitis. 2019 Dec 5. pii: 5658684. doi: 10.1093.
    PubMed     Abstract available


  263. REES WD, Stahl M, Jacobson K, Bressler B, et al
    Enteroids derived from inflammatory bowel disease patients display dysregulated endoplasmic reticulum stress pathways, leading to differential inflammatory responses and dendritic cell maturation.
    J Crohns Colitis. 2019 Dec 4. pii: 5651304. doi: 10.1093.
    PubMed     Abstract available


    November 2019
  264. GISBERT JP, Chaparro M
    Predictors of primary response to biologic treatment (anti-TNF, vedolizumab and ustekinumab) in patients with inflammatory bowel disease: from basic science to clinical practice.
    J Crohns Colitis. 2019 Nov 28. pii: 5645127. doi: 10.1093.
    PubMed     Abstract available


  265. SHARMA U, Olson RK, Erhart FN, Zhang L, et al
    Prescription opioid induce gut dysbiosis and exacerbate colitis in a murine model of Inflammatory Bowel Disease.
    J Crohns Colitis. 2019 Nov 27. pii: 5644048. doi: 10.1093.
    PubMed     Abstract available


  266. PAPAMICHAEL K, Cheifetz AS
    Proactive adalimumab monitoring in inflammatory bowel disease: current data and future perspectives.
    J Crohns Colitis. 2019 Nov 25. pii: 5639767. doi: 10.1093.
    PubMed    


  267. KING D, Rees J, Mytton J, Harvey P, et al
    The Outcomes of Emergency Admissions with Ulcerative Colitis between 2007 and 2017 in England.
    J Crohns Colitis. 2019 Nov 12. pii: 5623020. doi: 10.1093.
    PubMed     Abstract available


    October 2019
  268. AKSAN A, Wohlrath M, Iqbal TH, Dignass A, et al
    Inflammation, but Not the Underlying Disease or Its Location, Predicts Oral Iron Absorption Capacity in Patients With Inflammatory Bowel Disease.
    J Crohns Colitis. 2019 Oct 28. pii: 5608095. doi: 10.1093.
    PubMed     Abstract available


  269. VAVRICKA SR, Greuter T
    Simple and Simply the Best? Dublin in the European Spotlight.
    J Crohns Colitis. 2019;13:1363-1364.
    PubMed    


  270. PEPPELENBOSCH MP, Parikh K, Fuhler G
    Cannabinoid Signal Transduction Explains Disconnect of Cannabis Effects in Experimental and Clinical Colitis.
    J Crohns Colitis. 2019;13:1479.
    PubMed    


  271. SMEETS FGM, Liedorp PR, van der Poel M, Miclea RL, et al
    Anaplastic Large Cell T Cell Lymphoma in a Patient With Severe Therapy-refractory Crohn's Disease on Long-standing Immunosuppressive Medication During Ustekinumab Treatment: A Case Report and Review of the Literature.
    J Crohns Colitis. 2019;13:1470-1473.
    PubMed     Abstract available


  272. KLAASSEN MAY, Imhann F, Collij V, Fu J, et al
    Anti-inflammatory Gut Microbial Pathways Are Decreased During Crohn's Disease Exacerbations.
    J Crohns Colitis. 2019;13:1439-1449.
    PubMed     Abstract available


  273. MOHAMMADI A, Kelly OB, Smith MI, Kabakchiev B, et al
    Differential miRNA Expression in Ileal and Colonic Tissues Reveals an Altered Immunoregulatory Molecular Profile in Individuals With Crohn's Disease versus Healthy Subjects.
    J Crohns Colitis. 2019;13:1459-1469.
    PubMed     Abstract available


  274. LIEFFERINCKX C, Verstockt B, Gils A, Noman M, et al
    Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort Study.
    J Crohns Colitis. 2019;13:1401-1409.
    PubMed     Abstract available


  275. NOBLE A, Durant L, Hoyles L, McCartney AL, et al
    Deficient Resident Memory T-Cell and Cd8 T-Cell Response to Commensals in Inflammatory Bowel Disease.
    J Crohns Colitis. 2019 Oct 26. pii: 5607395. doi: 10.1093.
    PubMed     Abstract available


  276. ADLER J
    Can we Improve the Prognostic Value of Phenotype at Inflammatory Bowel Disease Diagnosis?
    J Crohns Colitis. 2019 Oct 22. pii: 5602619. doi: 10.1093.
    PubMed    


  277. CHANDRASINGHE P, Carvello M, Wasmann K, Foppa C, et al
    Transanal ileal pouch-anal anastomosis for ulcerative colitis has comparable long-term functional outcomes to transabdominal approach: a multicentre comparative study.
    J Crohns Colitis. 2019 Oct 22. pii: 5602131. doi: 10.1093.
    PubMed     Abstract available


  278. SCHMITT H, Ulmschneider J, Billmeier U, Vieth M, et al
    The TLR9 agonist cobitolimod induces IL10 producing wound healing macrophages and regulatory T cells in ulcerative colitis.
    J Crohns Colitis. 2019 Oct 20. pii: 5601212. doi: 10.1093.
    PubMed     Abstract available


  279. DE BRUYN M, Ringold R, Martens E, Ferrante M, et al
    The Ulcerative Colitis Response Index for Detection of Mucosal Healing in Patients Treated With Anti-tumour Necrosis Factor.
    J Crohns Colitis. 2019 Oct 19. pii: 5601149. doi: 10.1093.
    PubMed     Abstract available


  280. ELIADOU E, Moleiro J, Ribaldone DG, Astegiano M, et al
    Interstitial and Granulomatous lung disease in inflammatory bowel disease patients.
    J Crohns Colitis. 2019 Oct 11. pii: 5585570. doi: 10.1093.
    PubMed     Abstract available


    September 2019
  281. SMITH RL, Taylor KM, Friedman AB, Gibson RN, et al
    Systematic review: Clinical utility of gastrointestinal ultrasound in the diagnosis, assessment and management of patients with ulcerative colitis.
    J Crohns Colitis. 2019 Sep 28. pii: 5575710. doi: 10.1093.
    PubMed     Abstract available


  282. SCHOEPFER A, Santos J, Fournier N, Schibli S, et al
    Systematic Analysis of the Impact of Diagnostic Delay on Bowel Damage in Paediatric Versus Adult Onset Crohn's Disease.
    J Crohns Colitis. 2019;13:1334-1342.
    PubMed     Abstract available


  283. SINGH K, Al Khoury A, Kurti Z, Gonczi L, et al
    High Adherence to Surveillance Guidelines in Inflammatory Bowel Disease Patients Results in Low Colorectal Cancer and Dysplasia Rates, While Rates of Dysplasia are Low Before the Suggested Onset of Surveillance.
    J Crohns Colitis. 2019;13:1343-1350.
    PubMed     Abstract available


  284. BOLIN K, Hertervig E, Louis E
    The Cost-effectiveness of Biological Therapy Cycles in the Management of Crohn's Disease.
    J Crohns Colitis. 2019;13:1323-1333.
    PubMed     Abstract available


  285. JERUC J, Drobne D, Zidar N
    Diffuse Colitis Cystica Profunda in Crohn's Disease: A Potential Diagnostic Pitfall.
    J Crohns Colitis. 2019;13:1362.
    PubMed    


  286. FREI R, Fournier N, Zeitz J, Scharl M, et al
    Early Initiation of Anti-TNF is Associated with Favourable Long-term Outcome in Crohn's Disease: 10-Year-Follow-up Data from the Swiss IBD Cohort Study.
    J Crohns Colitis. 2019;13:1292-1301.
    PubMed     Abstract available


  287. PACHLER FR, Toft G, Bisgaard T, Laurberg S, et al
    Use and Success of In Vitro Fertilisation Following Restorative Proctocolectomy and Ileal Pouch-anal Anastomosis. A Nationwide 17-year Cohort Study.
    J Crohns Colitis. 2019;13:1283-1286.
    PubMed     Abstract available


  288. GODNY L, Maharshak N, Reshef L, Goren I, et al
    Fruit Consumption is Associated with Alterations in Microbial Composition and Lower Rates of Pouchitis.
    J Crohns Colitis. 2019;13:1265-1272.
    PubMed     Abstract available


  289. VANDE CASTEELE N, Baert F, Bian S, Dreesen E, et al
    Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn's Disease: A Prospective Multicentre Study.
    J Crohns Colitis. 2019;13:1248-1256.
    PubMed     Abstract available


  290. GALAZZO G, Tedjo DI, Wintjens DSJ, Savelkoul PHM, et al
    Faecal Microbiota Dynamics and their Relation to Disease Course in Crohn's Disease.
    J Crohns Colitis. 2019;13:1273-1282.
    PubMed     Abstract available


  291. ADAMINA M, Gerasimidis K, Sigall-Boneh R, Zmora O, et al
    Perioperative dietary therapy in inflammatory bowel disease.
    J Crohns Colitis. 2019 Sep 24. pii: 5573284. doi: 10.1093.
    PubMed     Abstract available


  292. CHAPUY L, Bsat M, Rubio M, Harvey F, et al
    Transcriptomic analysis and High dimensional phenotypic mapping of mononuclear phagocytes in mesenteric lymph nodes reveal differences between ulcerative colitis and Crohn's disease.
    J Crohns Colitis. 2019 Sep 21. pii: 5572419. doi: 10.1093.
    PubMed     Abstract available


  293. RASELLI T, Wyss A, Gonzalez Alvarado MN, Weder B, et al
    The Oxysterol Synthesising Enzyme CH25H Contributes to the Development of Intestinal Fibrosis.
    J Crohns Colitis. 2019;13:1186-1200.
    PubMed     Abstract available


  294. GLICK LR, Sossenheimer PH, Ollech JE, Cohen RD, et al
    Low-Dose Metronidazole is Associated With a Decreased Rate of Endoscopic Recurrence of Crohn's Disease After Ileal Resection: A Retrospective Cohort Study.
    J Crohns Colitis. 2019;13:1158-1162.
    PubMed     Abstract available


  295. GONCZI L, Kurti Z, Verdon C, Reinglas J, et al
    Perceived Quality of Care is Associated with Disease Activity, Quality of Life, Work Productivity, and Gender, but not Disease Phenotype: A Prospective Study in a High-volume IBD Centre.
    J Crohns Colitis. 2019;13:1138-1147.
    PubMed     Abstract available


  296. BRIOT C, Faure P, Parmentier AL, Nachury M, et al
    Efficacy, Tolerability, and Safety of Low-Volume Bowel Preparations for Patients with Inflammatory Bowel Diseases: The French Multicentre CLEAN Study.
    J Crohns Colitis. 2019;13:1121-1130.
    PubMed     Abstract available


  297. KHOURY T, Daher S, Massarwa M, Hakimian D, et al
    A Validated Score Assessing the Risk of an Intra-Abdominal Abscess in Patients with Crohn's Disease Presenting at the Emergency Department.
    J Crohns Colitis. 2019;13:1131-1137.
    PubMed     Abstract available


  298. HISAMATSU T, Matsumoto T, Watanabe K, Nakase H, et al
    Concerns and Side Effects of Azathioprine During Adalimumab Induction and Maintenance Therapy for Japanese Patients With Crohn's Disease: A Subanalysis of a Prospective Randomised Clinical Trial [DIAMOND Study].
    J Crohns Colitis. 2019;13:1097-1104.
    PubMed     Abstract available


  299. WEISSHOF R, Ollech JE, El Jurdi K, Yvellez OV, et al
    Ciclosporin Therapy After Infliximab Failure in Hospitalized Patients With Acute Severe Colitis is Effective and Safe.
    J Crohns Colitis. 2019;13:1105-1110.
    PubMed     Abstract available


  300. RAWA-GOLEBIEWSKA A, Lenarcik M, Zagorowicz E
    Resolution of CMV Infection in the Bowel on Vedolizumab Therapy.
    J Crohns Colitis. 2019;13:1234-1235.
    PubMed    


  301. ROJO E, Chaparro M, Garcia-Buey L
    Efficacy and Safety of Glecaprevir/pibrentasvir in a Patient With HCV-Induced Porphyria Cutanea Tarda Receiving Vedolizumab for Crohn s Disease.
    J Crohns Colitis. 2019 Sep 17. pii: 5570723. doi: 10.1093.
    PubMed    


  302. BUTERA A, Di Paola M, Vitali F, De Nitto D, et al
    IL-13 mRNA tissue content identifies two subsets of adult ulcerative colitis patients with different clinical and mucosa-associated microbiota profiles.
    J Crohns Colitis. 2019 Sep 10. pii: 5566583. doi: 10.1093.
    PubMed     Abstract available


  303. RAKNES G, Simonsen P, Smabrekke L
    Corrigendum: The Effect of Low-Dose Naltrexone on Medication in Inflammatory Bowel Disease: A Quasi Experimental Before-and-After Prescription Database Study.
    J Crohns Colitis. 2019 Sep 9. pii: 5566443. doi: 10.1093.
    PubMed    


    August 2019
  304. ALINAGHI F, Tekin HG, Burisch J, Wu JJ, et al
    Global prevalence and bidirectional association between psoriasis and inflammatory bowel disease - A systematic review and meta-analysis.
    J Crohns Colitis. 2019 Aug 30. pii: 5556860. doi: 10.1093.
    PubMed     Abstract available


  305. LEE C, Hong SN, Paik NY, Kim TJ, et al
    CD1d Modulates Colonic Inflammation in NOD2-/- Mice by Altering the Intestinal Microbial Composition Comprising Acetatifactor muris.
    J Crohns Colitis. 2019;13:1081-1091.
    PubMed     Abstract available


  306. KANSAL S, Catto-Smith AG, Boniface K, Thomas S, et al
    The Microbiome in Paediatric Crohn's Disease-A Longitudinal, Prospective, Single-Centre Study.
    J Crohns Colitis. 2019;13:1044-1054.
    PubMed     Abstract available


  307. BORREN NZ, Luther J, Colizzo FP, Garber JG, et al
    Low-dose Methotrexate has Similar Outcomes to High-dose Methotrexate in Combination with Anti-TNF Therapy in Inflammatory Bowel Diseases.
    J Crohns Colitis. 2019;13:990-995.
    PubMed     Abstract available


  308. POTDAR AA, Li D, Haritunians T, VanDussen KL, et al
    Ileal Gene Expression Data from Crohn's Disease Small Bowel Resections Indicate Distinct Clinical Subgroups.
    J Crohns Colitis. 2019;13:1055-1066.
    PubMed     Abstract available


  309. BUISSON A, Mak WY, Andersen MJ, Lei D, et al
    Faecal Calprotectin Is a Very Reliable Tool to Predict and Monitor the Risk of Relapse After Therapeutic De-escalation in Patients With Inflammatory Bowel Diseases.
    J Crohns Colitis. 2019;13:1012-1024.
    PubMed     Abstract available


  310. COHEN RD, Bhayat F, Blake A, Travis S, et al
    The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-Marketing Data.
    J Crohns Colitis. 2019 Aug 13. pii: 5549489. doi: 10.1093.
    PubMed     Abstract available


  311. COLOMBEL JF, D'haens G, Lee WJ, Petersson J, et al
    Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review.
    J Crohns Colitis. 2019 Aug 12. pii: 5548492. doi: 10.1093.
    PubMed     Abstract available


  312. NICOLAIDES S, Vasudevan A, Van Langenberg D
    Inflammatory Bowel Disease Helpline Reduces Subsequent Inpatient Admission Rates.
    J Crohns Colitis. 2019 Aug 2. pii: 5543172. doi: 10.1093.
    PubMed    


    July 2019
  313. ORTIZ-MASIA D, Salvador P, Macias-Ceja DC, Gisbert-Ferrandiz L, et al
    WNT2b activates epithelial-mesenchymal transition through FZD4: relevance in penetrating Crohn s disease.
    J Crohns Colitis. 2019 Jul 30. pii: 5540685. doi: 10.1093.
    PubMed     Abstract available


  314. NEARY PM, Aiello AC, Stocchi L, Shawki S, et al
    High-Risk Ileocolic Anastomoses for Crohn's Disease: When Is Diversion Indicated?
    J Crohns Colitis. 2019;13:856-863.
    PubMed     Abstract available


  315. DEUTSCHMANN C, Sowa M, Murugaiyan J, Roesler U, et al
    Identification of Chitinase-3-Like Protein 1 as a Novel Neutrophil Antigenic Target in Crohn's Disease.
    J Crohns Colitis. 2019;13:894-904.
    PubMed     Abstract available


  316. PEKOW J, Hernandez K, Meckel K, Deng Z, et al
    IBD-associated Colon Cancers Differ in DNA Methylation and Gene Expression Profiles Compared With Sporadic Colon Cancers.
    J Crohns Colitis. 2019;13:884-893.
    PubMed     Abstract available


  317. BISHU S, El Zaatari M, Hayashi A, Hou G, et al
    CD4+ Tissue-resident Memory T Cells Expand and Are a Major Source of Mucosal Tumour Necrosis Factor alpha in Active Crohn's Disease.
    J Crohns Colitis. 2019;13:905-915.
    PubMed     Abstract available


  318. VERSTOCKT B, Dreesen E, Noman M, Outtier A, et al
    Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates.
    J Crohns Colitis. 2019;13:864-872.
    PubMed     Abstract available


  319. VERSTOCKT S, De Hertogh G, Van der Goten J, Verstockt B, et al
    Gene and Mirna Regulatory Networks During Different Stages of Crohn's Disease.
    J Crohns Colitis. 2019;13:916-930.
    PubMed     Abstract available


  320. PIGNEUR B, Lepage P, Mondot S, Schmitz J, et al
    Mucosal Healing and Bacterial Composition in Response to Enteral Nutrition Vs Steroid-based Induction Therapy-A Randomised Prospective Clinical Trial in Children With Crohn's Disease.
    J Crohns Colitis. 2019;13:846-855.
    PubMed     Abstract available


  321. YZET C, Brazier F, Fumery M
    Post-operative Entero-cutaneous Fistula Closure by Over-the-Scope Clip in Crohn's Disease.
    J Crohns Colitis. 2019;13:954-955.
    PubMed    


  322. KEEFER L
    The Time Has Come to Integrate Behavioural Health Services Into IBD Centres.
    J Crohns Colitis. 2019;13:817-818.
    PubMed    


  323. LAMB CA, Mansfield JC, Kirby JA, Keir ME, et al
    The Importance of Molecular Immune Investigation in Therapeutic Clinical Development for Biomarker Assessment.
    J Crohns Colitis. 2019;13:956-957.
    PubMed    


  324. LI T, Wang C, Liu Y, Li B, et al
    Neutrophil Extracellular Traps Induce Intestinal Damage and Thrombotic Tendency in Inflammatory Bowel Disease.
    J Crohns Colitis. 2019 Jul 20. pii: 5536603. doi: 10.1093.
    PubMed     Abstract available


  325. NOVELLO M, Stocchi L, Steele SR, Holubar SD, et al
    Case-matched comparison of postoperative outcomes following surgery for inflammatory bowel disease after exposure to vedolizumab vs. other biologics.
    J Crohns Colitis. 2019 Jul 20. pii: 5536704. doi: 10.1093.
    PubMed     Abstract available


  326. LOWENBERG M, Van Der Vlugt M
    Risk of Progression of Low-Grade Dysplasia to Advanced Neoplasia in Inflammatory Bowel Disease.
    J Crohns Colitis. 2019 Jul 17. pii: 5533430. doi: 10.1093.
    PubMed    


    June 2019
  327. KIERNAN MG, Coffey JC, Sahebally SM, Tibbitts P, et al
    Systemic molecular mediators of inflammation differentiate between Crohn's disease and ulcerative colitis, implicating threshold levels of IL-10 and relative ratios of pro-inflammatory cytokines in therapy.
    J Crohns Colitis. 2019 Jun 26. pii: 5523600. doi: 10.1093.
    PubMed     Abstract available


  328. CHAPUY L, Bsat M, Rubio M, Sarkizova S, et al
    IL-12 and mucosal CD14+ monocyte-like cells induce IL-8 in colonic memory CD4+ T cells of patients with Ulcerative colitis but not Crohn's disease.
    J Crohns Colitis. 2019 Jun 15. pii: 5519696. doi: 10.1093.
    PubMed     Abstract available


  329. SHINZAKI S, Matsuoka K, Iijima H, Mizuno S, et al
    Erratum: Leucine-rich Alpha-2 Glycoprotein is a Serum Biomarker of Mucosal Healing in Ulcerative Colitis.
    J Crohns Colitis. 2019 Jun 13. pii: 5514465. doi: 10.1093.
    PubMed    


  330. HART L, Chavannes M, Kherad O, Maedler C, et al
    Faecal Calprotectin Predicts Endoscopic and Histological Activity in Clinically Quiescent Ulcerative Colitis.
    J Crohns Colitis. 2019 Jun 10. pii: 5513281. doi: 10.1093.
    PubMed     Abstract available


  331. DE JONG ME, van Tilburg SB, Nissen LHC, Kievit W, et al
    Long-term risk of advanced neoplasia after colonic low-grade dysplasia in patients with inflammatory bowel disease: a nationwide cohort study.
    J Crohns Colitis. 2019 Jun 7. pii: 5513020. doi: 10.1093.
    PubMed     Abstract available


  332. BOLTON C, Burch N, Morgan J, Harrison B, et al
    Remission of inflammatory bowel disease in Glucose-6-Phosphatase 3 deficiency by allogeneic haematopoietic stem cell transplantation.
    J Crohns Colitis. 2019 Jun 3. pii: 5510347. doi: 10.1093.
    PubMed     Abstract available


    May 2019
  333. ALRUBAIY L, Cheung WY, Dodds P, Hutchings HA, et al
    Corrigendum: Development of a Short Questionnaire to Assess the Quality of Life in Crohn's Disease and Ulcerative Colitis.
    J Crohns Colitis. 2019 May 29. pii: 5505359. doi: 10.1093.
    PubMed    


  334. PANACCIONE R, Lofberg R, Rutgeerts P, Sandborn WJ, et al
    Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn's Disease Studies.
    J Crohns Colitis. 2019;13:725-734.
    PubMed     Abstract available


  335. BURR NE, Hall B, Hamlin PJ, Selinger CP, et al
    Systematic Review and Network Meta-Analysis of Medical Therapies to Prevent Recurrence of Post-Operative Crohn's Disease.
    J Crohns Colitis. 2019;13:693-701.
    PubMed     Abstract available


  336. BARNHOORN MC, Van Halteren AGS, Van Pel M, Molendijk I, et al
    Lymphoproliferative Disease in the Rectum 4 Years After Local Mesenchymal Stromal Cell Therapy for Refractory Perianal Crohn's Fistulas: A Case Report.
    J Crohns Colitis. 2019;13:807-811.
    PubMed     Abstract available


  337. VLEUGELS JLA, Rutter MD, Ragunath K, Rees CJ, et al
    Diagnostic Accuracy of Endoscopic Trimodal Imaging and Chromoendoscopy for Lesion Characterization in Ulcerative Colitis.
    J Crohns Colitis. 2019 May 24. pii: 5498236. doi: 10.1093.
    PubMed    


  338. LITTLE RD, Chu IE, van der Zanden EP, Flanagan E, et al
    Comparison of adalimumab serum drug levels when delivered by pen versus syringe in patients with inflammatory bowel disease. An international, multicentre cohort analysis.
    J Crohns Colitis. 2019 May 15. pii: 5490060. doi: 10.1093.
    PubMed     Abstract available


  339. CHATEAU T, Bonovas S, Le Berre C, Mathieu N, et al
    Vedolizumab Treatment in Extra-Intestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review.
    J Crohns Colitis. 2019 May 10. pii: 5488014. doi: 10.1093.
    PubMed     Abstract available


  340. LO B, Vind I, Vester-Andersen MK, Bendtsen F, et al
    Direct and Indirect Costs of Inflammatory Bowel Disease: Ten Years of Follow Up in a Danish Population-Based Inception Cohort.
    J Crohns Colitis. 2019 May 10. pii: 5488021. doi: 10.1093.
    PubMed     Abstract available


  341. GUERRA I, Bujanda L, Castro J, Merino O, et al
    Clinical characteristics, associated malignancies and management of primary sclerosing cholangitis in inflammatory bowel disease patients: A multicenter retrospective cohort study.
    J Crohns Colitis. 2019 May 7. pii: 5486538. doi: 10.1093.
    PubMed     Abstract available


  342. CARON B, Peyrin-Biroulet L, Pariente B, Bouhnik Y, et al
    Vedolizumab therapy is ineffective for primary sclerosing cholangitis in patients with inflammatory bowel disease: A GETAID multicentre cohort study.
    J Crohns Colitis. 2019 May 6. pii: 5485858. doi: 10.1093.
    PubMed     Abstract available


  343. SCHARDEY J, Globig AM, Janssen C, Hofmann M, et al
    Vitamin D inhibits pro-inflammatory T cell function in patients with inflammatory bowel disease.
    J Crohns Colitis. 2019 May 4. pii: 5485498. doi: 10.1093.
    PubMed     Abstract available


  344. MA C, Panaccione NR, Nguyen TM, Guizzetti L, et al
    Adverse Events and Nocebo Effects in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    J Crohns Colitis. 2019 May 3. pii: 5492672. doi: 10.1093.
    PubMed     Abstract available


    April 2019
  345. MAO R, Chen YJ, Chen BL, Xie XH, et al
    Intra-Cavitary Contrast-Enhanced Ultrasound: A Novel Radiation-Free Method for Detecting Abscess-Associated Penetrating Disease in Crohn's Disease.
    J Crohns Colitis. 2019;13:593-599.
    PubMed     Abstract available


  346. CHAVANNES M, Martinez-Vinson C, Hart L, Kaniki N, et al
    Management of Paediatric Patients With Medically Refractory Crohn's Disease Using Ustekinumab: A Multi-Centred Cohort Study.
    J Crohns Colitis. 2019;13:578-584.
    PubMed     Abstract available


  347. OSTROWSKI J, Dabrowska M, Lazowska I, Paziewska A, et al
    Redefining the Practical Utility of Blood Transcriptome Biomarkers in Inflammatory Bowel Diseases.
    J Crohns Colitis. 2019;13:626-633.
    PubMed     Abstract available


  348. RIPOLLES T, Martinez-Perez MJ, Paredes JM, Vizuete J, et al
    The Role of Intravenous Contrast Agent in the Sonographic Assessment of Crohn's Disease Activity: Is Contrast Agent Injection Necessary?
    J Crohns Colitis. 2019;13:585-592.
    PubMed     Abstract available


  349. CORRALIZA AM, Ricart E, Lopez-Garcia A, Carme Masamunt M, et al
    Differences in Peripheral and Tissue Immune Cell Populations Following Haematopoietic Stem Cell Transplantation in Crohn's Disease Patients.
    J Crohns Colitis. 2019;13:634-647.
    PubMed     Abstract available


  350. KAKUTA Y, Kawai Y, Naito T, Hirano A, et al
    A Genome-wide Association Study Identifying RAP1A as a Novel Susceptibility Gene for Crohn's Disease in Japanese Individuals.
    J Crohns Colitis. 2019;13:648-658.
    PubMed     Abstract available


  351. HAIN E, Maggiori L, Orville M, Treton X, et al
    Diverting Stoma for Refractory Ano-perineal Crohn's Disease: Is It Really Useful in the Anti-TNF Era? A Multivariate Analysis in 74 Consecutive Patients.
    J Crohns Colitis. 2019;13:572-577.
    PubMed     Abstract available


  352. HEDIN CRH, Vavricka SR, Stagg AJ, Schoepfer A, et al
    The Pathogenesis of Extraintestinal Manifestations: Implications for IBD Research, Diagnosis, and Therapy.
    J Crohns Colitis. 2019;13:541-554.
    PubMed     Abstract available


  353. ROOSENBOOM B, van Lochem EG, Horjus Talabur Horje CS
    AlphaE Expression in Inflammatory Bowel Disease: a Biomarker for the use of Etrolizumab?
    J Crohns Colitis. 2019;13:671.
    PubMed    


  354. SIFUENTES-DOMINGUEZ L, Starokadomskyy P, Welch J, Gurram B, et al
    Mosaic Tetrasomy 9p Associated With Inflammatory Bowel Disease.
    J Crohns Colitis. 2019 Apr 25. pii: 5479520. doi: 10.1093.
    PubMed     Abstract available


  355. NGUYEN GC, Du L, Chong RY, Jackson TD, et al
    Hypoalbuminaemia and Postoperative Outcomes in Inflammatory Bowel Disease: the NSQIP Surgical Cohort.
    J Crohns Colitis. 2019 Apr 23. pii: 5477382. doi: 10.1093.
    PubMed     Abstract available


  356. ASSCHER VER, Lee-Kong FVY, Kort ED, van Deudekom FJ, et al
    Systematic review: components of a comprehensive geriatric assessment in inflammatory bowel disease - a potentially promising but often neglected risk stratification.
    J Crohns Colitis. 2019 Apr 19. pii: 5475282. doi: 10.1093.
    PubMed     Abstract available


  357. AL-KANDARI A, Thayalasekaran S, Bhandari M, Przybysz A, et al
    Endoscopic Resections in Inflammatory Bowel Disease: A Multicentre European Outcomes Study.
    J Crohns Colitis. 2019 Apr 17. pii: 5474921. doi: 10.1093.
    PubMed     Abstract available


  358. MAGRO F, Lopes S, Silva M, Coelho R, et al
    Low Golimumab Trough Levels at Week 6 are Associated with Poor Clinical, Endoscopic and Histological Outcomes in Ulcerative Colitis Patients: Pharmacokinetic and Pharmacodynamic Sub-analysis of the Evolution Study.
    J Crohns Colitis. 2019 Apr 16. pii: 5466449. doi: 10.1093.
    PubMed     Abstract available


  359. PARK SH, Kim YJ, Rhee KH, Kim YH, et al
    A 30-year trend analysis in the epidemiology of inflammatory bowel disease in the Songpa-Kangdong District of Seoul, Korea in 1986-2015.
    J Crohns Colitis. 2019 Apr 16. pii: 5467272. doi: 10.1093.
    PubMed     Abstract available


  360. STEUBE A, Vital M, Grunert P, Pieper DH, et al
    Long-term Multidonor Fecal Microbiota Transfer (FMT) by Oral Capsules for Active Ulcerative Colitis.
    J Crohns Colitis. 2019 Apr 15. pii: 5458563. doi: 10.1093.
    PubMed    


  361. CHAPARRO M, Garre A, Guerra Veloz MF, Vazquez JM, et al
    Effectiveness and safety of the switch from Remicade to CT-P13 in patients with inflammatory bowel disease.
    J Crohns Colitis. 2019 Apr 12. pii: 5446199. doi: 10.1093.
    PubMed     Abstract available


  362. DOMENECH E, Panes J, Hinojosa J, Annese V, et al
    Corrigendum: Addition of Granulocyte/Monocyte Apheresis to Oral Prednisone for Steroid-dependent Ulcerative Colitis: A Randomized Multicentre Clinical Trial.
    J Crohns Colitis. 2019 Apr 5. pii: 5429525. doi: 10.1093.
    PubMed    


  363. ELLUL P, Zammit SC, Katsanos KH, Cesarini M, et al
    Corrigendum: Perception of Reproductive Health in Women with Inflammatory Bowel Disease.
    J Crohns Colitis. 2019 Apr 5. pii: 5429524. doi: 10.1093.
    PubMed    


  364. MAVROUDIS G, Magnusson MK, Isaksson S, Sundin J, et al
    Mucosal and systemic immune profiles differ during early and late phase of the disease in patients with active ulcerative colitis.
    J Crohns Colitis. 2019 Apr 4. pii: 5427807. doi: 10.1093.
    PubMed     Abstract available


  365. CREMER A, Ku J, Amininejad L, Bouvry MR, et al
    Variability of Faecal Calprotectin in Inflammatory Bowel Disease patients: an Observational Case-Control Study.
    J Crohns Colitis. 2019 Apr 4. pii: 5427075. doi: 10.1093.
    PubMed     Abstract available


    March 2019
  366. JONES GR, Fasci-Spurio F, Kennedy NA, Plevris N, et al
    Faecal Calprotectin and Magnetic Resonance Enterography in Ileal Crohn's Disease: Correlations Between Disease Activity and Long-Term Follow-Up.
    J Crohns Colitis. 2019;13:442-450.
    PubMed     Abstract available


  367. MENG X, Dunsmore G, Koleva P, Elloumi Y, et al
    The Profile of Human Milk Metabolome, Cytokines, and Antibodies in Inflammatory Bowel Diseases Versus Healthy Mothers, and Potential Impact on the Newborn.
    J Crohns Colitis. 2019;13:431-441.
    PubMed     Abstract available


  368. MA C, Wu W, Lin R, Ge Y, et al
    Critical Role of CD6highCD4+ T Cells in Driving Th1/Th17 Cell Immune Responses and Mucosal Inflammation in IBD.
    J Crohns Colitis. 2019;13:510-524.
    PubMed     Abstract available


  369. KAWAMOTO A, Nagata S, Anzai S, Takahashi J, et al
    Ubiquitin D is Upregulated by Synergy of Notch Signalling and TNF-alpha in the Inflamed Intestinal Epithelia of IBD Patients.
    J Crohns Colitis. 2019;13:495-509.
    PubMed     Abstract available


  370. VANCAMELBEKE M, Laeremans T, Vanhove W, Arnauts K, et al
    Butyrate does not protect against inflammation-induced loss of epithelial barrier function and cytokine production in primary cell monolayers from patients with ulcerative colitis.
    J Crohns Colitis. 2019 Mar 28. pii: 5421326. doi: 10.1093.
    PubMed     Abstract available


  371. PILLAI N, Dusheiko M, Maillard MH, Rogler G, et al
    The Evolution of Health Care Utilisation and Costs for Inflammatory Bowel Disease Over Ten Years.
    J Crohns Colitis. 2019 Mar 27. pii: 5420756. doi: 10.1093.
    PubMed     Abstract available


  372. ROWAN CR, Cullen G, Mulcahy HE, Sheridan J, et al
    DUBLIN (Degree of Ulcerative colitis Burden of Luminal INflammation) score, a simple method to quantify inflammatory burden in Ulcerative Colitis.
    J Crohns Colitis. 2019 Mar 26. pii: 5419817. doi: 10.1093.
    PubMed     Abstract available


  373. DIERCKX T, Verstockt B, Vermeire S, van Weyenbergh J, et al
    GlycA, a Nuclear Magnetic Resonance Spectroscopy Measure for Protein Glycosylation, is a Viable Biomarker for Disease Activity in IBD.
    J Crohns Colitis. 2019;13:389-394.
    PubMed     Abstract available


  374. BAR YEHUDA S, Axlerod R, Toker O, Zigman N, et al
    The Association of Inflammatory Bowel Diseases with Autoimmune Disorders: A Report from the epi-IIRN.
    J Crohns Colitis. 2019;13:324-329.
    PubMed     Abstract available


  375. D'HOORE A
    Persistent Mesorectal Inflammatory Activity is Associated With Complications After Proctectomy in Crohn's Disease: Immediate Surgical Implications!
    J Crohns Colitis. 2019;13:271-272.
    PubMed    


  376. DE GROOF EJ, van der Meer JHM, Tanis PJ, de Bruyn JR, et al
    Persistent Mesorectal Inflammatory Activity is Associated With Complications After Proctectomy in Crohn's Disease.
    J Crohns Colitis. 2019;13:285-293.
    PubMed     Abstract available


  377. DUMAY A, Gergaud O, Roy M, Hugot JP, et al
    Is Crohn Disease the price to pay today for having survived to the Black Death?
    J Crohns Colitis. 2019 Mar 20. pii: 5409350. doi: 10.1093.
    PubMed     Abstract available


  378. ZHOU H, Xi L, Ziemek D, O'Neil S, et al
    Molecular Profiling of Ulcerative Colitis Subjects from the TURANDOT Trial Reveals Novel Pharmacodynamic/Efficacy Biomarkers.
    J Crohns Colitis. 2019 Mar 19. pii: 5393625. doi: 10.1093.
    PubMed     Abstract available


  379. LOO SY, Vutcovici M, Bitton A, Lakatos PL, et al
    Risk of malignant cancers in inflammatory bowel disease.
    J Crohns Colitis. 2019 Mar 15. pii: 5381147. doi: 10.1093.
    PubMed     Abstract available


  380. KRUIS W, Nguyen P, Morgenstern J, Ramlow W, et al
    Novel Leucocyte/Thrombocyte Apheresis for Induction of Steroid-Free Remission in Ulcerative Colitis: A Controlled Randomized Pilot Study.
    J Crohns Colitis. 2019 Mar 13. pii: 5376679. doi: 10.1093.
    PubMed     Abstract available


  381. SOOD A, Mahajan R, Singh A, Midha V, et al
    Role of Fecal Microbiota Transplantation for Maintenance of Remission in Patients with Ulcerative Colitis: A Pilot Study.
    J Crohns Colitis. 2019 Mar 11. pii: 5381070. doi: 10.1093.
    PubMed     Abstract available


  382. AZIMIRAD M, Yadegar A, Asadzadeh Aghdaei H, Kelly CR, et al
    Enterotoxigenic Clostridium perfringens Infection as an Adverse Event After Faecal Microbiota Transplantation in Two Patients With Ulcerative Colitis and Recurrent Clostridium difficile Infection: A Neglected Agent in Donor Screening.
    J Crohns Colitis. 2019 Mar 10. pii: 5372934. doi: 10.1093.
    PubMed    


  383. PHILIP G, Cornillie F, Adedokun JO, Melsheimer R, et al
    Early dose optimization of golimumab in nonresponders to induction treatment for ulcerative colitis is effective and supported by pharmacokinetic data.
    J Crohns Colitis. 2019 Mar 7. pii: 5371269. doi: 10.1093.
    PubMed     Abstract available


  384. MORAN-LEV H, Galai T, Yerushalmy-Feler A, Weisman Y, et al
    Vitamin D Decreases Hepcidin and Inflammatory Markers in Newly Diagnosed Inflammatory Bowel Disease Pediatric Patients- A Prospective Study.
    J Crohns Colitis. 2019 Mar 6. pii: 5370430. doi: 10.1093.
    PubMed     Abstract available


  385. TORRES J, Ellul P, Langhorst J, Mikocka-Walus A, et al
    European Crohn's and Colitis Organisation Topical Review on Complementary Medicine and Psychotherapy in Inflammatory Bowel Disease.
    J Crohns Colitis. 2019 Mar 1. pii: 5367297. doi: 10.1093.
    PubMed     Abstract available


    February 2019
  386. PANES J, Lindsay JO, Teich N, Lindgren S, et al
    Five-year Safety Data From OPUS, A European Observational Safety Registry For Adults With Ulcerative Colitis Treated With Originator Infliximab [Remicade(R)] Or Conventional Therapy.
    J Crohns Colitis. 2019 Feb 27. pii: 5365571. doi: 10.1093.
    PubMed     Abstract available


  387. PLEVRIS N, Chuah CS, Allen RM, Arnott ID, et al
    Real-world effectiveness and safety of Vedolizumab for the treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort.
    J Crohns Colitis. 2019 Feb 14. pii: 5320521. doi: 10.1093.
    PubMed     Abstract available


  388. BRINK GVD, Gaalen MACV, de Ridder L, van der Woude CJ, et al
    Health Care Transition Outcomes in Inflammatory Bowel Disease: a Multinational Delphi Study.
    J Crohns Colitis. 2019 Feb 14. pii: 5320372. doi: 10.1093.
    PubMed     Abstract available


  389. SANDS BE, Cheifetz AS, Nduaka CI, Quirk D, et al
    The Impact of Raising the Bar for Clinical Trials in Ulcerative Colitis.
    J Crohns Colitis. 2019 Feb 14. pii: 5320037. doi: 10.1093.
    PubMed     Abstract available


  390. UNGARO RC, Yarur A, Jossen J, Phan BL, et al
    Higher Trough Vedolizumab Concentrations During Maintenance Therapy are Associated With Corticosteroid-Free Remission in Inflammatory Bowel Disease.
    J Crohns Colitis. 2019 Feb 13. pii: 5319184. doi: 10.1093.
    PubMed     Abstract available


  391. DAI C, Jiang M, Yu JH
    Long-term outcomes of Proactive therapeutic drug monitoring of adalimumab and standard of care in patients with inflammatory bowel disease.
    J Crohns Colitis. 2019 Feb 7. pii: 5308914. doi: 10.1093.
    PubMed    


  392. HANAUER S, Sandborn WJ, Colombel JF, Vermeire S, et al
    Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in 2 Clinical Trials.
    J Crohns Colitis. 2019 Feb 6. pii: 5308120. doi: 10.1093.
    PubMed     Abstract available


  393. CHEN S, Zuo S, Zhu J, Yue T, et al
    Decreased expression of cystathionine beta-synthase exacerbates intestinal barrier injury in ulcerative colitis.
    J Crohns Colitis. 2019 Feb 5. pii: 5307110. doi: 10.1093.
    PubMed     Abstract available


  394. BROOKS AJ, Norman P, Peach EJ, Ryder AH, et al
    Prospective Study of Psychological Morbidity and Illness Perceptions in Young People with Inflammatory Bowel Disease.
    J Crohns Colitis. 2019 Feb 5. pii: 5306964. doi: 10.1093.
    PubMed     Abstract available


  395. LORES T, Goess C, Mikocka-Walus A, Collins KL, et al
    Integrated psychological care is needed, welcomed and effective in ambulatory Inflammatory Bowel Disease management: Evaluation of a new initiative.
    J Crohns Colitis. 2019 Feb 5. pii: 5307105. doi: 10.1093.
    PubMed     Abstract available


  396. CHAVARRIA C, Casanova MJ, Chaparro M, Barreiro-de Acosta M, et al
    Prevalence and Factors Associated with Fatigue in Patients with Inflammatory Bowel Disease: A Multicenter Study.
    J Crohns Colitis. 2019 Feb 5. pii: 5306517. doi: 10.1093.
    PubMed     Abstract available


  397. LI K, Strauss R, Marano C, Greenbaum LE, et al
    A simplified definition of histologic improvement in ulcerative colitis and its association with disease outcomes up to 30 weeks from initiation of therapy: Post-hoc analysis of three clinical trials.
    J Crohns Colitis. 2019 Feb 4. pii: 5306493. doi: 10.1093.
    PubMed     Abstract available


  398. DINALLO V, Marafini I, Di Fusco D, Laudisi F, et al
    Neutrophil Extracellular Traps Sustain Inflammatory Signals in Ulcerative Colitis.
    J Crohns Colitis. 2019 Feb 3. pii: 5306154. doi: 10.1093.
    PubMed     Abstract available


  399. KANG B, Choi SY, Choi YO, Lee SY, et al
    Infliximab Trough Levels Are Associated With Mucosal Healing During Maintenance Treatment With Infliximab in Paediatric Crohn's Disease.
    J Crohns Colitis. 2019;13:189-197.
    PubMed     Abstract available


  400. KLENSKE E, Osaba L, Nagore D, Rath T, et al
    Drug Levels in the Maternal Serum, Cord Blood and Breast Milk of a Ustekinumab-Treated Patient with Crohn's Disease.
    J Crohns Colitis. 2019;13:267-269.
    PubMed     Abstract available


  401. GUILLEMOT-LEGRIS O, Mutemberezi V, Buisseret B, Paquot A, et al
    Colitis Alters Oxysterol Metabolism and is Affected by 4beta-Hydroxycholesterol Administration.
    J Crohns Colitis. 2019;13:218-229.
    PubMed     Abstract available


  402. GREGORY MH, McKinnon A, Stwalley D, Hippensteel KJ, et al
    Anti-Tumour Necrosis Factor Therapy for Inflammatory Bowel Diseases Do Not Impact Serious Infections after Arthroplasty.
    J Crohns Colitis. 2019;13:182-188.
    PubMed     Abstract available


  403. MAASER C
    New ECCO Guidelines Generation.
    J Crohns Colitis. 2019;13:141.
    PubMed    


  404. SZVARCA D, Borum ML
    Don't Be Late on Latent TB: Inconsistent Tuberculosis Screening in IBD Patients on Biologics.
    J Crohns Colitis. 2019;13:270.
    PubMed    


    January 2019
  405. SLUITER RL, van Marrewijk C, de Jong D, Scheffer H, et al
    Genotype-guided thiopurine dosing does not lead to additional costs in patients with inflammatory bowel disease.
    J Crohns Colitis. 2019 Jan 30. pii: 5304472. doi: 10.1093.
    PubMed     Abstract available


  406. BRITTO S, Kellermayer R
    Carbohydrate Monotony as Protection and Treatment for Inflammatory Bowel Disease.
    J Crohns Colitis. 2019 Jan 30. pii: 5304571. doi: 10.1093.
    PubMed     Abstract available


  407. POUILLON L, Rousseau H, Busby-Venner H, De Carvalho Bittencourt M, et al
    Vedolizumab Trough Levels and Histological Healing During Maintenance Therapy in Ulcerative Colitis.
    J Crohns Colitis. 2019 Jan 29. pii: 5304135. doi: 10.1093.
    PubMed     Abstract available


  408. CHURCH PC, Ho S, Sharma A, Tomalty D, et al
    Intensified infliximab induction is associated with improved response and decreased colectomy in steroid-refractory paediatric ulcerative colitis.
    J Crohns Colitis. 2019 Jan 23. pii: 5306100. doi: 10.1093.
    PubMed     Abstract available


  409. LO PRESTI E, Di Mitri R, Mocciaro F, Di Stefano AB, et al
    Characterization of gammadelta T cells in intestinal mucosa from patients with early onset or long standing inflammatory bowel disease and their correlation with clinical status.
    J Crohns Colitis. 2019 Jan 21. pii: 5298961. doi: 10.1093.
    PubMed     Abstract available


  410. PAPAMICHAEL K, Juncadella A, Wong D, Rakowsky S, et al
    Proactive therapeutic drug monitoring of adalimumab is associated with better long-term outcomes compared to standard of care in patients with inflammatory bowel disease.
    J Crohns Colitis. 2019 Jan 21. pii: 5298979. doi: 10.1093.
    PubMed     Abstract available


  411. WANG MH, Friton JJ, Raffals LE, Leighton JA, et al
    Novel Genetic Risk Variants Can Predict Anti-TNF Agent Response in Patients With Inflammatory Bowel Disease.
    J Crohns Colitis. 2019 Jan 21. pii: 5299128. doi: 10.1093.
    PubMed     Abstract available


  412. ZABANA Y, Rodriguez L, Lobaton T, Gordillo J, et al
    Relevant infections in inflammatory bowel disease, their relationship with immunosuppressive therapy and their effects on disease mortality.
    J Crohns Colitis. 2019 Jan 18. pii: 5298189. doi: 10.1093.
    PubMed     Abstract available


  413. LOW END, Mokhtar NM, Wong Z, Raja Ali RA, et al
    Colonic Mucosal Transcriptomic Changes in Patients with Long-Duration Ulcerative Colitis Revealed Colitis-Associated Cancer Pathways.
    J Crohns Colitis. 2019 Jan 11. pii: 5430265. doi: 10.1093.
    PubMed     Abstract available


  414. TODO K, Osamura T, Imashuku S
    Mesalazine-induced acute bacterial focal nephritis-like features in two pediatric patients with ulcerative colitis.
    J Crohns Colitis. 2019 Jan 8. pii: 5280854. doi: 10.1093.
    PubMed    


  415. MOENS A, van Hoeve K, Humblet E, Rahier JF, et al
    Outcome of Pregnancies in Female Patients With Inflammatory Bowel Diseases Treated With Vedolizumab.
    J Crohns Colitis. 2019;13:12-18.
    PubMed     Abstract available


  416. CANTO E, Zamora C, Garcia-Planella E, Gordillo J, et al
    Bacteria-related Events and the Immunological Response of Onset and Relapse Adult Crohn's Disease Patients.
    J Crohns Colitis. 2019;13:92-99.
    PubMed     Abstract available


  417. ZHENG XB, Liu HS, Zhang LJ, Liu XH, et al
    Engulfment and Cell Motility Protein 1 Protects Against DSS-induced Colonic Injury in Mice via Rac1 Activation.
    J Crohns Colitis. 2019;13:100-114.
    PubMed     Abstract available


  418. WIERINGA JW, van der Woude CJ
    Editorial: The Effect of Thiopurines on Offspring.
    J Crohns Colitis. 2019;13:1-2.
    PubMed    


  419. SZVARCA D, Greenfest A, Borum M
    WebIBD: How Much Can We Trust Medical Information Online?
    J Crohns Colitis. 2019;13:138.
    PubMed    


    December 2018
  420. IMPERATORE N, Castiglione F, Testa A, De Palma GD, et al
    Augmented Endoscopy for Surveillance of Colonic Inflammatory Bowel Disease: Systematic Review with Network Meta-Analysis.
    J Crohns Colitis. 2018 Dec 28. pii: 5266692. doi: 10.1093.
    PubMed     Abstract available


  421. SAMAAN MA, Forsyth K, Segal JP, de Jong D, et al
    Current Practices in Ileal Pouch Surveillance for Patients with Ulcerative Colitis: A Multinational, Retrospective Cohort Study.
    J Crohns Colitis. 2018 Dec 24. pii: 5259264. doi: 10.1093.
    PubMed     Abstract available


  422. GATT K, Schembri J, Katsanos KH, Christodoulou D, et al
    Inflammatory Bowel Disease and Physical activity: a study on the impact of diagnosis on the level of exercise amongst patients with IBD.
    J Crohns Colitis. 2018 Dec 18. pii: 5250917. doi: 10.1093.
    PubMed     Abstract available


  423. CONRAD MA, Carreon CK, Dawany N, Russo P, et al
    Distinct histopathological features at diagnosis of very early onset inflammatory bowel disease.
    J Crohns Colitis. 2018 Dec 14. pii: 5247350. doi: 10.1093.
    PubMed     Abstract available


  424. THOMAS T, Chandan JS, Harvey PR, Bhala N, et al
    The risk of inflammatory bowel disease in subjects presenting with perianal abscess: findings from the THIN database.
    J Crohns Colitis. 2018 Dec 13. pii: 5244181. doi: 10.1093.
    PubMed     Abstract available


  425. LUNDER AK, Bakstad LT, Jahnsen J, Borthne A, et al
    Assessment of Bowel Inflammation and Strictures by Magnetic Resonance Enterography in Long-term Crohn s Disease.
    J Crohns Colitis. 2018 Dec 12. pii: 5240680. doi: 10.1093.
    PubMed     Abstract available


  426. YANAI H, Dotan I
    Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study.
    J Crohns Colitis. 2018 Dec 11. pii: 5238056. doi: 10.1093.
    PubMed    


  427. NUNES G, Patita M, Fernandes V
    Refractory pyoderma gangrenosum in a patient with Crohn s Disease: complete response to Ustekinumab.
    J Crohns Colitis. 2018 Dec 7. pii: 5232612. doi: 10.1093.
    PubMed    


  428. LOVISA S, Genovese G, Danese S
    Role of epithelial-to-mesenchymal transition in inflammatory bowel disease.
    J Crohns Colitis. 2018 Dec 6. pii: 5231866. doi: 10.1093.
    PubMed     Abstract available


  429. VEGNI E, Gilardi D, Bonovas S, Corro BE, et al
    Illness Perception in Inflammatory Bowel Disease Patients is Different Between Patients With Active Disease or in Remission: A Prospective Cohort Study.
    J Crohns Colitis. 2018 Dec 4. pii: 5230943. doi: 10.1093.
    PubMed     Abstract available


    November 2018
  430. GROSEN A, Bungum M, Christensen LA, Cordelli E, et al
    Semen Quality and Sperm DNA Integrity in Patients With Severe Active Inflammatory Bowel Disease and Effects of Tumour Necrosis Factor-alpha Inhibitors.
    J Crohns Colitis. 2018 Nov 30. pii: 5219032. doi: 10.1093.
    PubMed     Abstract available


  431. FORKEL M, van Tol S, Hoog C, Michaelsson J, et al
    Distinct Alterations in the Composition of Mucosal Innate Lymphoid Cells in Newly Diagnosed and Established Crohn's Disease and Ulcerative Colitis.
    J Crohns Colitis. 2018 Nov 29. pii: 5215151. doi: 10.1093.
    PubMed     Abstract available


  432. KUCHARZIK T, Maaser C, Maconi G
    Do We Need Activity Scores or Simply Clear Criteria for Intestinal Ultrasound in Ulcerative Colitis?
    J Crohns Colitis. 2018;12:1383-1384.
    PubMed    


  433. PAUWEN NY, Louis E, Siegel C, Colombel JF, et al
    Integrated Care for Crohn's Disease: A Plea for the Development of Clinical Decision Support Systems.
    J Crohns Colitis. 2018;12:1499-1504.
    PubMed     Abstract available


  434. THIBERGE C, Charpentier C, Gillibert A, Modzelewski R, et al
    Lower Subcutaneous or Visceral Adiposity Assessed by Abdominal Computed Tomography Could Predict Adverse Outcome in Patients With Crohn's Disease.
    J Crohns Colitis. 2018;12:1429-1437.
    PubMed     Abstract available


  435. SHIM HH, Cai SCS, Chan W, Low JGH, et al
    Mycobacterium abscessus Infection During Ustekinumab Treatment in Crohn's Disease: A Case Report and Review of the Literature.
    J Crohns Colitis. 2018;12:1505-1507.
    PubMed     Abstract available


  436. BEN-HORIN S, Van Assche G, Chowers Y, Fudim E, et al
    Pharmacokinetics and Immune Reconstitution Following Discontinuation of Thiopurine Analogues: Implications for Drug Withdrawal Strategies.
    J Crohns Colitis. 2018;12:1410-1417.
    PubMed     Abstract available


  437. GREUTER T, Piller A, Fournier N, Safroneeva E, et al
    Upper Gastrointestinal Tract Involvement in Crohn's Disease: Frequency, Risk Factors, and Disease Course.
    J Crohns Colitis. 2018;12:1399-1409.
    PubMed     Abstract available


  438. EVERHOV AH, Khalili H, Askling J, Myrelid P, et al
    Sick Leave and Disability Pension in Prevalent Patients With Crohn's Disease.
    J Crohns Colitis. 2018;12:1418-1428.
    PubMed     Abstract available


  439. MAK WY, Mak OS, Lee CK, Tang W, et al
    Significant Medical and Surgical Morbidity in Perianal Crohn's Disease: Results from a Territory-Wide Study.
    J Crohns Colitis. 2018;12:1392-1398.
    PubMed     Abstract available


  440. COLLINS CB, Puthoor PR, Nguyen TT, Strassheim D, et al
    C/EBPbeta Deletion Promotes Expansion of Poorly Functional Intestinal Regulatory T Cells.
    J Crohns Colitis. 2018;12:1475-1485.
    PubMed     Abstract available


  441. DE JONG MJ, Roosen D, Degens JHRJ, van den Heuvel TRA, et al
    Development and validation of a patient-reported score to screen for mucosal inflammation in inflammatory bowel disease.
    J Crohns Colitis. 2018 Nov 24. pii: 5205616. doi: 10.1093.
    PubMed     Abstract available


  442. WALSH A, Kormilitzin A, Hinds C, Sexton V, et al
    Defining faecal calprotectin thresholds as a surrogate for endoscopic and histological disease activity in ulcerative colitis - a prospective analysis.
    J Crohns Colitis. 2018 Nov 16. pii: 5184629. doi: 10.1093.
    PubMed     Abstract available


  443. ZAKRZEWSKI M, Simms LA, Brown A, Appleyard M, et al
    IL23R-protective coding variant promotes beneficial bacteria and diversity in the ileal microbiome in healthy individuals without inflammatory bowel disease.
    J Crohns Colitis. 2018 Nov 16. pii: 5184638. doi: 10.1093.
    PubMed     Abstract available


  444. BENOIT L, Mir O, Berveiller P
    Treating ulcerative colitis during pregnancy: evidence of materno-fetal transfer of golimumab.
    J Crohns Colitis. 2018 Nov 15. pii: 5183381. doi: 10.1093.
    PubMed    


  445. LEARY A, Mason I, Punshon G
    Modelling the Inflammatory Bowel Disease Specialist Nurse Workforce Standards by Determination of Optimum Caseloads in the UK.
    J Crohns Colitis. 2018;12:1295-1301.
    PubMed     Abstract available


  446. DENG F, He S, Cui S, Shi Y, et al
    A Molecular Targeted Immunotherapeutic Strategy for Ulcerative Colitis via Dual-Targeting Nanoparticles Delivering miR-146b to Intestinal Macrophages.
    J Crohns Colitis. 2018 Nov 15. pii: 5184562. doi: 10.1093.
    PubMed     Abstract available


  447. DI NARZO AF, Brodmerkel C, Telesco SE, Argmann C, et al
    High Throughput Identification of Plasma Proteomic Signature of Inflammatory Bowel Disease.
    J Crohns Colitis. 2018 Nov 15. pii: 5183355. doi: 10.1093.
    PubMed     Abstract available


  448. HUTTER S, van Haaften WT, Hunerwadel A, Baebler K, et al
    Intestinal Activation of pH-Sensing Receptor OGR1 [GPR68] Contributes to Fibrogenesis.
    J Crohns Colitis. 2018;12:1348-1358.
    PubMed     Abstract available


  449. ALLOCCA M, Fiorino G, Bonifacio C, Furfaro F, et al
    Comparative Accuracy of Bowel Ultrasound Versus Magnetic Resonance Enterography in Combination With Colonoscopy in Assessing Crohn's Disease and Guiding Clinical Decision-making.
    J Crohns Colitis. 2018;12:1280-1287.
    PubMed     Abstract available


  450. WEN KW, Rabinovitch PS, Wang D, Huang D, et al
    Utility of DNA Flow Cytometric Analysis of Paraffin-Embedded Tissue in the Risk Stratification and Management of "Indefinite for Dysplasia" in Patients with Inflammatory Bowel Disease.
    J Crohns Colitis. 2018 Nov 13. pii: 5180116. doi: 10.1093.
    PubMed     Abstract available


  451. FIORINO G, Allocca M, Chaparro M, Coenen S, et al
    'Quality of Care' Standards in Inflammatory Bowel Disease: A Systematic Review.
    J Crohns Colitis. 2018 Nov 13. pii: 5181323. doi: 10.1093.
    PubMed     Abstract available


  452. AMBROSE T, Simmons A
    Cannabis, cannabinoids and the endocannabinoid system - is there therapeutic potential for inflammatory bowel disease?
    J Crohns Colitis. 2018 Nov 12. pii: 5173479. doi: 10.1093.
    PubMed     Abstract available


  453. VISVANATHAN S, Baum P, Salas A, Vinisko R, et al
    Selective IL-23 Inhibition by Risankizumab Modulates the Molecular Profile in the Colon and Ileum of Patients With Active Crohn's Disease: Results From a Randomised Phase II Biopsy Sub-study.
    J Crohns Colitis. 2018;12:1170-1179.
    PubMed     Abstract available


  454. THIERRY ML, Rousseau H, Pouillon L, Girard-Gavanier M, et al
    Accuracy of Diffusion-weighted Magnetic Resonance Imaging in Detecting Mucosal Healing and Treatment Response, and in Predicting Surgery, in Crohn's Disease.
    J Crohns Colitis. 2018;12:1180-1190.
    PubMed     Abstract available


  455. BOSSUYT P, Louis E, Mary JY, Vermeire S, et al
    Defining Endoscopic Remission in Ileocolonic Crohn's Disease: Let's Start from Scratch.
    J Crohns Colitis. 2018;12:1245-1248.
    PubMed     Abstract available


  456. SHEN W, Li Y, Cao L, Cai X, et al
    Decreased Expression of Prox1 Is Associated With Postoperative Recurrence in Crohn's Disease.
    J Crohns Colitis. 2018;12:1210-1218.
    PubMed     Abstract available


  457. RUEMMELE FM, Rosh J, Faubion WA, Dubinsky MC, et al
    Efficacy of Adalimumab for Treatment of Perianal Fistula in Children with Moderately to Severely Active Crohn's Disease: Results from IMAgINE 1 and IMAgINE 2.
    J Crohns Colitis. 2018;12:1249-1254.
    PubMed     Abstract available


  458. ICHIKAWA R, Lamb CA, Eastham-Anderson J, Scherl A, et al
    AlphaE Integrin Expression Is Increased in the Ileum Relative to the Colon and Unaffected by Inflammation.
    J Crohns Colitis. 2018;12:1191-1199.
    PubMed     Abstract available


  459. KEITA AV, Lindqvist CM, Ost A, Magana CDL, et al
    Gut Barrier Dysfunction-A Primary Defect in Twins with Crohn's Disease Predominantly Caused by Genetic Predisposition.
    J Crohns Colitis. 2018;12:1200-1209.
    PubMed     Abstract available


  460. COFFEY CJ, Kiernan MG, Sahebally SM, Jarrar A, et al
    Inclusion of the Mesentery in Ileocolic Resection for Crohn's Disease is Associated With Reduced Surgical Recurrence.
    J Crohns Colitis. 2018;12:1139-1150.
    PubMed     Abstract available


  461. PANES J, Vermeire S, Lindsay JO, Sands BE, et al
    Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies.
    J Crohns Colitis. 2018 Nov 8. pii: 5167345. doi: 10.1093.
    PubMed    


  462. DAI C, Jiang M, Huang YH
    Appendectomy for Therapy-Refractory Ulcerative Colitis Results in Pathological Improvement of Colonic Inflammation.
    J Crohns Colitis. 2018 Nov 5. pii: 5161247. doi: 10.1093.
    PubMed    


  463. NYHOLM I, Hukkinen M, Koivusalo A, Merras-Salmio L, et al
    Long-term single center outcomes after proctocolectomy with ileoanal anastomosis for paediatric ulcerative colitis.
    J Crohns Colitis. 2018 Nov 3. pii: 5160018. doi: 10.1093.
    PubMed     Abstract available


  464. LOUIS E
    Do we still need predictors of disease severity when applying a treat-to-target approach in Inflammatory Bowel Disease?
    J Crohns Colitis. 2018 Nov 2. pii: 5156178. doi: 10.1093.
    PubMed    


    October 2018
  465. WINTJENS DSJ, de Jong MJ, van der Meulen-de Jong AE, Romberg-Camps MJ, et al
    Novel perceived stress and life events precede flares of inflammatory bowel disease: a prospective 12-month follow-up study.
    J Crohns Colitis. 2018 Oct 29. pii: 5146297. doi: 10.1093.
    PubMed     Abstract available


  466. BALRAM B, Battat R, Al-Khoury A, D'Aoust J, et al
    Reply to Letter on: "Risk factors associated with Clostridium difficile infection in inflammatory bowel disease: a systematic review and meta-analysis".
    J Crohns Colitis. 2018 Oct 29. pii: 5146063. doi: 10.1093.
    PubMed    


  467. ALFARO-CRUZ L, Schady D, Kellermayer R
    Giant cell (granulomatous) gastritis in left sided pediatric ulcerative colitis.
    J Crohns Colitis. 2018 Oct 23. pii: 5142539. doi: 10.1093.
    PubMed    


  468. CLOS-PARALS A, Rodriguez-Martinez P, Canete F, Manosa M, et al
    Prognostic value of the burden of cytomegalovirus colonic reactivation evaluated by immunohistochemical staining in patients with active ulcerative colitis.
    J Crohns Colitis. 2018 Oct 20. pii: 5139670. doi: 10.1093.
    PubMed     Abstract available


  469. LAMPINEN M, Vessby J, Fredricsson A, Wanders A, et al
    High serum sCD40 and a distinct colonic T-cell profile in ulcerative colitis associated with primary sclerosing cholangitis.
    J Crohns Colitis. 2018 Oct 20. pii: 5139660. doi: 10.1093.
    PubMed     Abstract available


  470. STELLINGWERF ME, de Koning MA, Pinkney T, Bemelman WA, et al
    The risk of colectomy and colorectal cancer after appendectomy in patients with ulcerative colitis: a systematic review and meta-analysis.
    J Crohns Colitis. 2018 Oct 18. pii: 5136376. doi: 10.1093.
    PubMed     Abstract available


  471. MAGRO F, Dias CC, Portela F, Miranda M, et al
    Development and validation of risk matrices concerning ulcerative colitis outcomes - Bayesian network analysis.
    J Crohns Colitis. 2018 Oct 17. pii: 5133622. doi: 10.1093.
    PubMed     Abstract available


  472. LOREN V, Garcia-Jaraquemada A, Naves JE, Carmona X, et al
    ANP32E, a protein involved in steroid-refractoriness in ulcerative colitis, identified by a systems biology approach.
    J Crohns Colitis. 2018 Oct 17. pii: 5134087. doi: 10.1093.
    PubMed     Abstract available


  473. AARESTRUP J, Jess T, Kobylecki CJ, Nordestgaard BG, et al
    Cardiovascular risk profile among patients with inflammatory bowel disease: a population-based study of >100,000 individuals.
    J Crohns Colitis. 2018 Oct 13. pii: 5128952. doi: 10.1093.
    PubMed     Abstract available


  474. NGUYEN GC, Bouchard S, Diong C
    Access to Specialists and Emergency Department Visits in Inflammatory Bowel Disease: A Population-Based Study.
    J Crohns Colitis. 2018 Oct 12. pii: 5127082. doi: 10.1093.
    PubMed     Abstract available


  475. DAI C, Jiang M, Huang YH
    Risk factors associated with Clostridium difficile infection in inflammatory bowel disease.
    J Crohns Colitis. 2018 Oct 12. pii: 5127329. doi: 10.1093.
    PubMed    


  476. MEGE D, Colombo F, Stellingwerf ME, Germain A, et al
    Risk factors for small bowel obstruction after laparoscopic ileal pouch-anal anastomosis for inflammatory bowel disease. A multivariate analysis in 4 expert centres in Europe.
    J Crohns Colitis. 2018 Oct 11. pii: 5127081. doi: 10.1093.
    PubMed     Abstract available


  477. GISBERT JP, Chaparro M
    Clinical usefulness of proteomics in inflammatory bowel disease: A comprehensive review.
    J Crohns Colitis. 2018 Oct 10. pii: 5126442. doi: 10.1093.
    PubMed     Abstract available


  478. TCYMBAREVICH I, Richards SM, Russo G, Kuhn-Georgijevic J, et al
    Lack of the pH-sensing Receptor TDAG8 [GPR65] in Macrophages Plays a Detrimental Role in Murine Models of Inflammatory Bowel Disease.
    J Crohns Colitis. 2018 Oct 9. pii: 5237755. doi: 10.1093.
    PubMed     Abstract available


  479. MACALUSO FS, Fries W, Privitera AC, Cappello M, et al
    A propensity score-matched comparison of infliximab and adalimumab in TNF-alpha inhibitors naive and non-naive patients with Crohn's disease: real-life data from the Sicilian Network for Inflammatory Bowel Disease (SN-IBD).
    J Crohns Colitis. 2018 Oct 6. pii: 5122861. doi: 10.1093.
    PubMed     Abstract available


  480. BURISCH J, Katsanos KH, Christodoulou DK, Barros L, et al
    Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort-An Epi-IBD Study.
    J Crohns Colitis. 2018 Oct 5. pii: 5115808. doi: 10.1093.
    PubMed     Abstract available


  481. ARMUZZI A, Avedano L, Greveson K, Kang T, et al
    Nurses are critical in aiding patients transitioning to biosimilars in inflammatory bowel disease: education and communication strategies.
    J Crohns Colitis. 2018 Oct 4. pii: 5114647. doi: 10.1093.
    PubMed     Abstract available


  482. SANDBORN WJ, Colombel JF, Panaccione R, Dulai PS, et al
    Deep remission with vedolizumab in patients with moderately to severely active ulcerative colitis: a GEMINI 1 post hoc analysis.
    J Crohns Colitis. 2018 Oct 4. pii: 5114646. doi: 10.1093.
    PubMed     Abstract available


  483. FELICE C, Armuzzi A
    Therapeutic role of appendectomy in ulcerative colitis: a tangible perspective?
    J Crohns Colitis. 2018 Oct 3. pii: 5114385. doi: 10.1093.
    PubMed    


  484. SAHAMI S, Wildenberg ME, Koens L, Doherty G, et al
    Appendectomy for Therapy-Refractory Ulcerative Colitis Results in Pathological Improvement of Colonic Inflammation: Short-Term Results of the PASSION Study.
    J Crohns Colitis. 2018 Oct 3. pii: 5114636. doi: 10.1093.
    PubMed     Abstract available


  485. DUNSMORE G, Koleva P, Ghobakhloo N, Sutton RT, et al
    Lower Abundance and Impaired Function of CD71+ Erythroid Cells in Inflammatory Bowel Disease Patients During Pregnancy.
    J Crohns Colitis. 2018 Oct 1. pii: 5113167. doi: 10.1093.
    PubMed     Abstract available


  486. KREDEL LI, Jodicke LJ, Scheffold A, Grone J, et al
    T-cell composition in ileal and colonic creeping fat - separating ileal from colonic Crohn s disease.
    J Crohns Colitis. 2018 Oct 1. pii: 5113232. doi: 10.1093.
    PubMed     Abstract available


    September 2018
  487. TRIVEDI PJ, Adams DH
    Chemokines and Chemokine Receptors as Therapeutic Targets in Inflammatory Bowel Disease; Pitfalls and Promise.
    J Crohns Colitis. 2018 Sep 29. pii: 5111299. doi: 10.1093.
    PubMed    


  488. WONG JJ, Sceats L, Dehghan M, Wren AA, et al
    Depression and Healthcare Utilization in Patients with Inflammatory Bowel Disease.
    J Crohns Colitis. 2018 Sep 25. pii: 5106946. doi: 10.1093.
    PubMed     Abstract available


  489. BALRAM B, Battat R, Al-Khoury A, D'Aoust J, et al
    Risk factors associated with Clostridium difficile infection in inflammatory bowel disease: a systematic review and meta-analysis.
    J Crohns Colitis. 2018 Sep 21. pii: 5104729. doi: 10.1093.
    PubMed     Abstract available


  490. PEREIRA MS, Maia L, Azevedo LF, Campos S, et al
    A (glyco)biomarker that predicts failure to standard therapy in Ulcerative Colitis patients.
    J Crohns Colitis. 2018 Sep 20. pii: 5104327. doi: 10.1093.
    PubMed     Abstract available


  491. VAN HOEVE K, Dreesen E, Hoffman I, Van Assche G, et al
    Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel Disease.
    J Crohns Colitis. 2018 Sep 19. pii: 5103494. doi: 10.1093.
    PubMed     Abstract available


  492. KIERNAN MG, Coffey JC, McDermott K, Cotter PD, et al
    The human mesenteric lymph node microbiome differentiates between Crohn's disease and ulcerative colitis.
    J Crohns Colitis. 2018 Sep 15. pii: 5098279. doi: 10.1093.
    PubMed     Abstract available


  493. CHAN W, Shim HH, Ng SC, Liu J, et al
    A Global Survey of Gastroenterologists' Travel Advice to Patients with Inflammatory Bowel Disease on Immunosuppressive Agents and Management of Those Visiting Tuberculosis-Endemic Areas.
    J Crohns Colitis. 2018 Sep 11. pii: 5095284. doi: 10.1093.
    PubMed     Abstract available


  494. SVRCEK M, Borralho Nunes PM, Villanacci V, Beaugerie L, et al
    Clinicopathological and molecular specificities of inflammatory bowel disease-related colorectal neoplastic lesions: the role of inflammation.
    J Crohns Colitis. 2018 Sep 10. pii: 5094505. doi: 10.1093.
    PubMed     Abstract available


  495. VLEUGELS JLA, Rutter MD, Ragunath K, Rees CJ, et al
    Diagnostic accuracy of Endoscopic Trimodal Imaging and Chromoendoscopy for lesion characterisation in ulcerative colitis surveillance: ETMI or chromoendoscopy for lesion characterisation in colitis.
    J Crohns Colitis. 2018 Sep 8. pii: 5092911. doi: 10.1093.
    PubMed     Abstract available


  496. FEAGAN BG, Sandborn WJ, Colombel JF, O'Byrne S, et al
    Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials.
    J Crohns Colitis. 2018 Sep 3. pii: 5089953. doi: 10.1093.
    PubMed     Abstract available


    August 2018
  497. ARTOM M, Czuber-Dochan W, Sturt J, Norton C, et al
    Corrigendum: Targets for Health Interventions for Inflammatory Bowel Disease-fatigue.
    J Crohns Colitis. 2018 Aug 28. pii: 5085555. doi: 10.1093.
    PubMed    


  498. STURM A, Maaser C, Calabrese E, Annese V, et al
    ECCO-ESGAR Guideline for Diagnostic Assessment in Inflammatory Bowel Disease.
    J Crohns Colitis. 2018 Aug 23. pii: 5078200. doi: 10.1093.
    PubMed    


  499. MAASER C, Sturm A, Vavricka SR, Kucharzik T, et al
    ECCO-ESGAR Guideline for Diagnostic Assessment in Inflammatory Bowel Disease.
    J Crohns Colitis. 2018 Aug 23. pii: 5078195. doi: 10.1093.
    PubMed    


  500. PANES J, Salas A
    Past, Present and Future of Therapeutic Interventions Targeting Leukocyte Trafficking in Inflammatory Bowel Disease.
    J Crohns Colitis. 2018;12.
    PubMed     Abstract available


  501. RIVERA-NIEVES J
    Targeting leukocyte traffic: A new era for the treatment of Inflammatory bowel disease.
    J Crohns Colitis. 2018;12.
    PubMed    


  502. TRIVEDI PJ, Adams DH
    Chemokines and Chemokine Receptors as Therapeutic Targets in Inflammatory Bowel Disease; Pitfalls and Promise.
    J Crohns Colitis. 2018;12.
    PubMed     Abstract available


  503. TAMAN H, Fenton CG, Hensel IV, Anderssen E, et al
    Genome-Wide DNA Methylation in Treatment-Naive Ulcerative Colitis.
    J Crohns Colitis. 2018 Aug 22. pii: 5077493. doi: 10.1093.
    PubMed     Abstract available


  504. REINISCH W, Hung K, Hassan-Zahraee M, Cataldi F, et al
    Targeting Endothelial Ligands: ICAM-1/alicaforsen, MAdCAM-1.
    J Crohns Colitis. 2018;12.
    PubMed     Abstract available


  505. GUI X, Li J, Ueno A, Iacucci M, et al
    Histopathologic Features of Inflammatory Bowel Disease are Associated with Different CD4+ T Cell Subsets in Colonic Mucosal Lamina Propria.
    J Crohns Colitis. 2018 Aug 20. pii: 5076882. doi: 10.1093.
    PubMed     Abstract available


  506. RICCIUTO A, Dhaliwal J, Walters TD, Griffiths AM, et al
    Clinical outcomes with therapeutic drug monitoring in inflammatory bowel disease: A systematic review with meta-analysis.
    J Crohns Colitis. 2018 Aug 10. pii: 5068814. doi: 10.1093.
    PubMed     Abstract available


  507. ALLOCCA M, Fiorino G, Bonovas S, Furfaro F, et al
    Accuracy of Humanitas Ultrasound Criteria in assessing disease activity and severity in ulcerative colitis: a prospective study.
    J Crohns Colitis. 2018 Aug 4. pii: 5066493. doi: 10.1093.
    PubMed     Abstract available


    July 2018
  508. YU M, Luo Y, Cong Z, Mu Y, et al
    MicroRNA-590-5p Inhibits Intestinal Inflammation by Targeting YAP.
    J Crohns Colitis. 2018;12:993-1004.
    PubMed     Abstract available


  509. KANIS SL, de Lima-Karagiannis A, van der Ent C, Rizopoulos D, et al
    Anti-TNF Levels in Cord Blood at Birth are Associated with Anti-TNF Type.
    J Crohns Colitis. 2018;12:939-947.
    PubMed     Abstract available


  510. DE LIMA A, Kanis SL, Escher JC, van der Woude CJ, et al
    Hepatitis B Vaccination Effective in Children Exposed to Anti-Tumour Necrosis Factor Alpha in Utero.
    J Crohns Colitis. 2018;12:948-953.
    PubMed     Abstract available


  511. SANDS BE, Han C, Gasink C, Jacobstein D, et al
    The Effects of Ustekinumab on Health-related Quality of Life in Patients With Moderate to Severe Crohn's Disease.
    J Crohns Colitis. 2018;12:883-895.
    PubMed     Abstract available


  512. PANACCIONE R, Sandborn WJ, D'Haens G, Wolf DC, et al
    Clinical Benefit of Long-Term Adalimumab Treatment in Patients With Crohn's Disease Following Loss of Response or Intolerance to Infliximab: 96-Week Efficacy Data From GAIN/ADHERE Trials.
    J Crohns Colitis. 2018;12:930-938.
    PubMed     Abstract available


  513. NIZZOLI G, Burrello C, Cribiu FM, Lovati G, et al
    Pathogenicity of In Vivo Generated Intestinal Th17 Lymphocytes is IFNgamma Dependent.
    J Crohns Colitis. 2018;12:981-992.
    PubMed     Abstract available


  514. BOTS S, Nylund K, Lowenberg M, Gecse K, et al
    Ultrasound for Assessing Disease Activity in IBD Patients: A Systematic Review of Activity Scores.
    J Crohns Colitis. 2018;12:920-929.
    PubMed     Abstract available


  515. BEMELMAN WA
    Evolving Role of IBD Surgery.
    J Crohns Colitis. 2018;12:1005-1007.
    PubMed    


  516. TAXONERA C, Ponferrada A, Riestra S, Bermejo F, et al
    Serial Tuberculin Skin Tests Improves the Detection of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease.
    J Crohns Colitis. 2018 Jul 21. pii: 5056955. doi: 10.1093.
    PubMed     Abstract available


  517. PROBERT F, Walsh A, Jagielowicz M, Yeo T, et al
    Plasma Nuclear Magnetic Resonance metabolomics discriminates between high and low endoscopic activity and predicts progression in a prospective cohort of patients with ulcerative colitis.
    J Crohns Colitis. 2018 Jul 17. pii: 5054826. doi: 10.1093.
    PubMed     Abstract available


  518. ESTEVINHO MM, Afonso J, Rosa I, Lago P, et al
    Placebo effect on the health-related quality of life of inflammatory bowel disease patients: a systematic review with meta-analysis.
    J Crohns Colitis. 2018 Jul 14. pii: 5053906. doi: 10.1093.
    PubMed     Abstract available


    June 2018
  519. VAN DER HAVE M, Oldenburg B, Kaptein AA, Jansen JM, et al
    Corrigendum: Non-adherence to Anti-TNF Therapy is Associated with Illness Perceptions and Clinical Outcomes in Outpatients with Inflammatory Bowel Disease: Results from a Prospective Multicentre Study.
    J Crohns Colitis. 2018 Jun 30. pii: 5047411. doi: 10.1093.
    PubMed    


  520. STEIN J, Aksan A, Klemm W, Nip K, et al
    Safety and Efficacy of Ferric Carboxymaltose in the Treatment of Iron Deficiency Anaemia in Patients with Inflammatory Bowel Disease, in Routine Daily Practice.
    J Crohns Colitis. 2018;12:826-834.
    PubMed     Abstract available


  521. DE BRUYN JR, van den Brink GR, Steenkamer J, Buskens CJ, et al
    Fibrostenotic Phenotype of Myofibroblasts in Crohn's Disease is Dependent on Tissue Stiffness and Reversed by LOX Inhibition.
    J Crohns Colitis. 2018;12:849-859.
    PubMed     Abstract available


  522. WARDLE RA, Thapaliya G, Nowak A, Radford S, et al
    An Examination of Appetite and Disordered Eating in Active Crohn's Disease.
    J Crohns Colitis. 2018;12:819-825.
    PubMed     Abstract available


  523. RISPO A, Imperatore N, Testa A, Bucci L, et al
    Combined Endoscopic/Sonographic-based Risk Matrix Model for Predicting One-year Risk of Surgery: A Prospective Observational Study of a Tertiary Centre Severe/Refractory Crohn's Disease Cohort.
    J Crohns Colitis. 2018;12:784-793.
    PubMed     Abstract available


  524. BONOVAS S, Peyrin-Biroulet L, Danese S
    Meta-analysis of the Association between anti-TNF use and Lymphoma Risk in Patients with Inflammatory bowel Disease: Methodological Considerations.
    J Crohns Colitis. 2018 Jun 27. pii: 5045852. doi: 10.1093.
    PubMed    


  525. OZAKI R, Kobayashi T, Okabayashi S, Nakano M, et al
    Histological Risk Factors to Predict Clinical Relapse in Ulcerative Colitis with Endoscopically Normal Mucosa.
    J Crohns Colitis. 2018 Jun 25. pii: 5043543. doi: 10.1093.
    PubMed     Abstract available


  526. CUSHING KC, Kordbacheh H, Gee MS, Kambadakone A, et al
    Reply to "Comment on Sarcopenia is a Novel Predictor of the Need for Rescue Therapy in Hospitalized Ulcerative Colitis Patients".
    J Crohns Colitis. 2018 Jun 23. pii: 5043266. doi: 10.1093.
    PubMed    


  527. COSTA JM, Carvalho SD, Soares JB
    Mesalazine-induced Bronchiolitis Obliterans with Organizing Pneumonia in a young patient with Ulcerative Colitis.
    J Crohns Colitis. 2018 Jun 20. pii: 5040612. doi: 10.1093.
    PubMed    


  528. REINISCH W, Gibson PR, Sandborn WJ, Feagan BG, et al
    Long-term Benefit of Golimumab for Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension.
    J Crohns Colitis. 2018 Jun 18. pii: 5039659. doi: 10.1093.
    PubMed     Abstract available


  529. GROSEN A, Nersting J, Bungum M, Christensen LA, et al
    Sperm DNA Integrity is Unaffected by Thiopurine Treatment in Men with Inflammatory Bowel Disease.
    J Crohns Colitis. 2018 Jun 16. pii: 5039596. doi: 10.1093.
    PubMed     Abstract available


  530. IHARA S, Hirata Y, Hikiba Y, Yamashita A, et al
    Adhesive interactions between Mononuclear Phagocytes and Intestinal Epithelium Perturb Normal Epithelial Differentiation and Serve as a Therapeutic Target in Inflammatory Bowel Disease.
    J Crohns Colitis. 2018 Jun 16. pii: 5039593. doi: 10.1093.
    PubMed     Abstract available


  531. SANDS BE, Sandborn WJ, Feagan BG, Lichtenstein GR, et al
    Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2 Study.
    J Crohns Colitis. 2018 Jun 15. pii: 5038906. doi: 10.1093.
    PubMed     Abstract available


  532. LEE HS, Yang SK, Hong M, Jung S, et al
    An intergenic variant rs9268877 between HLA-DRA and HLA-DRB contributes to the clinical course and long-term outcome of ulcerative colitis.
    J Crohns Colitis. 2018 Jun 13. pii: 5037295. doi: 10.1093.
    PubMed     Abstract available


  533. IRANI NR, Wang LM, Collins GS, Keshav S, et al
    Correlation between Endoscopic and Histological Activity in Ulcerative Colitis using Validated Indices.
    J Crohns Colitis. 2018 Jun 11. pii: 5035459. doi: 10.1093.
    PubMed     Abstract available


  534. BINAY SAFER V, Safer U
    Comment on "Sarcopenia is a Novel Predictor of the Need for Rescue Therapy in Hospitalized Ulcerative Colitis Patients".
    J Crohns Colitis. 2018 Jun 9. pii: 5035236. doi: 10.1093.
    PubMed    


    May 2018
  535. GUIDI L, Pugliese D, Panici Tonucci T, Berrino A, et al
    Therapeutic drug monitoring is more cost-effective than a clinically-based approach in the management of loss of response to infliximab in inflammatory bowel disease: an observational multi-centre study.
    J Crohns Colitis. 2018 May 31. pii: 5026188. doi: 10.1093.
    PubMed     Abstract available


  536. PAUL S, Williet N, Di Bernado T, Berger AE, et al
    Soluble Mucosal Addressin Cell Adhesion Molecule 1 and Retinoic Acid are Potential Tools for Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Treated with Vedolizumab: A Proof of Concept Study.
    J Crohns Colitis. 2018 May 31. pii: 5026191. doi: 10.1093.
    PubMed     Abstract available


  537. KANG B, Choi SY, Choi YO, Kim MJ, et al
    Subtherapeutic Infliximab Trough Levels and Complete Mucosal Healing Are Associated With Sustained Clinical Remission After Infliximab Cessation in Paediatric-onset Crohn's Disease Patients Treated With Combined Immunosuppressive Therapy.
    J Crohns Colitis. 2018;12:644-652.
    PubMed     Abstract available


  538. REUKEN PA, Kruis W, Maaser C, Teich N, et al
    Microbial Spectrum of Intra-Abdominal Abscesses in Perforating Crohn's Disease: Results from a Prospective German Registry.
    J Crohns Colitis. 2018;12:695-701.
    PubMed     Abstract available


  539. WRIGHT EK, Kamm MA, De Cruz P, Hamilton AL, et al
    Anti-TNF Therapeutic Drug Monitoring in Postoperative Crohn's Disease.
    J Crohns Colitis. 2018;12:653-661.
    PubMed     Abstract available


  540. SINGH S, George J, Boland BS, Vande Casteele N, et al
    Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis.
    J Crohns Colitis. 2018;12:635-643.
    PubMed     Abstract available


  541. WAGNER M, Ko HM, Chatterji M, Besa C, et al
    Magnetic Resonance Imaging Predicts Histopathological Composition of Ileal Crohn's Disease.
    J Crohns Colitis. 2018;12:718-729.
    PubMed     Abstract available


  542. BELVIS JIMENEZ M, Maldonado Perez B, Arguelles-Arias F
    Using Vedolizumab to treat Severe Sweet's Syndrome in a Patient with Ulcerative Colitis.
    J Crohns Colitis. 2018 May 19. pii: 4999769. doi: 10.1093.
    PubMed    


  543. FEAGAN BG, Bhayat F, Khalid M, Blake A, et al
    Respiratory Tract Infections in Patients With Inflammatory Bowel Disease: Safety Analyses From Vedolizumab Clinical Trials.
    J Crohns Colitis. 2018 May 17. pii: 4997031. doi: 10.1093.
    PubMed     Abstract available


  544. LAMB CA, O'Byrne S, Keir ME, Butcher EC, et al
    Gut-selective integrin-targeted therapies for inflammatory bowel disease.
    J Crohns Colitis. 2018 May 15. pii: 4996111. doi: 10.1093.
    PubMed     Abstract available


  545. SANDBORN WJ, Bhandari BR, Randall C, Younes ZH, et al
    Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease.
    J Crohns Colitis. 2018 May 14. pii: 4996034. doi: 10.1093.
    PubMed     Abstract available


  546. CUSHING KC, Kordbacheh H, Gee MS, Kambadakone A, et al
    Sarcopenia is a Novel Predictor of the Need for Rescue Therapy in Hospitalized Ulcerative Colitis Patients.
    J Crohns Colitis. 2018 May 12. pii: 4995527. doi: 10.1093.
    PubMed     Abstract available


  547. YANG C, Huang J, Huang X, Huang S, et al
    Risk of Lymphoma in Patients With Inflammatory Bowel Disease Treated With Anti-Tumor Necrosis Factor Alpha Agents: A Systematic Review and Meta-analysis.
    J Crohns Colitis. 2018 May 12. pii: 4995526. doi: 10.1093.
    PubMed     Abstract available


  548. LEE CK, Wong SH, Lui G, Tang W, et al
    A prospective study to monitor for tuberculosis during anti-tumour necrosis factor therapy in patients with inflammatory bowel disease and immune mediated inflammatory diseases.
    J Crohns Colitis. 2018 May 11. pii: 4994967. doi: 10.1093.
    PubMed     Abstract available


  549. FOBELO LOZANO MJ, Serrano Gimenez R, Castro Fernandez M
    Emergence of Inflammatory Bowel Disease During Treatment with Secukinumab.
    J Crohns Colitis. 2018 May 9. pii: 4994228. doi: 10.1093.
    PubMed     Abstract available


  550. COHEN-MEKELBURG S, Rosenblatt R, Gold S, Burakoff R, et al
    The Impact of Opioid Epidemic Trends on Hospitalized Inflammatory Bowel Disease Patients.
    J Crohns Colitis. 2018 May 7. pii: 4993358. doi: 10.1093.
    PubMed     Abstract available


  551. TSE CS, Deepak P, De La Fuente J, Bledsoe AC, et al
    Phenotype and Clinical Course of Inflammatory Bowel Disease with Co-Existent Celiac Disease.
    J Crohns Colitis. 2018 May 7. pii: 4993346. doi: 10.1093.
    PubMed     Abstract available


  552. GARG M, Hendy P, Ding JN, Shaw S, et al
    The effect of vitamin D on intestinal inflammation and faecal microbiota in patients with ulcerative colitis.
    J Crohns Colitis. 2018 May 3. pii: 4991883. doi: 10.1093.
    PubMed     Abstract available


    April 2018
  553. LAW CCY, Narula A, Lightner AL, McKenna NP, et al
    Systematic Review and Meta-Analysis: Preoperative Vedolizumab Treatment and Postoperative Complications in Patients with Inflammatory Bowel Disease.
    J Crohns Colitis. 2018;12:538-545.
    PubMed     Abstract available


  554. YARLAS A, Rubin DT, Panes J, Lindsay JO, et al
    Burden of Ulcerative Colitis on Functioning and Well-being: A Systematic Literature Review of the SF-36(R) Health Survey.
    J Crohns Colitis. 2018;12:600-609.
    PubMed     Abstract available


  555. FEAGAN BG, Schwartz D, Danese S, Rubin DT, et al
    Efficacy of Vedolizumab in Fistulising Crohn's Disease: Exploratory Analyses of Data from GEMINI 2.
    J Crohns Colitis. 2018;12:621-626.
    PubMed     Abstract available


  556. HOEKMAN DR, Stibbe JA, Baert FJ, Caenepeel P, et al
    Long-term Outcome of Early Combined Immunosuppression Versus Conventional Management in Newly Diagnosed Crohn's Disease.
    J Crohns Colitis. 2018;12:517-524.
    PubMed     Abstract available


  557. VISSCHEDIJK MC, Spekhorst LM, Cheng SC, van Loo ES, et al
    Genomic and Expression Analyses Identify a Disease-Modifying Variant for Fibrostenotic Crohn's Disease.
    J Crohns Colitis. 2018;12:582-588.
    PubMed     Abstract available


  558. BORREN NZ, Conway G, Garber JJ, Khalili H, et al
    Differences in Clinical Course, Genetics, and the Microbiome Between Familial and Sporadic Inflammatory Bowel Diseases.
    J Crohns Colitis. 2018;12:525-531.
    PubMed     Abstract available


  559. BOYAPATI RK, Ho GT, Satsangi J
    Top-down in the Long Term in Crohn's Disease.
    J Crohns Colitis. 2018;12:513-514.
    PubMed    


  560. WINTJENS DSJ, Bogie RMM, van den Heuvel TRA, le Clercq CMC, et al
    Incidence and classification of postcolonoscopy colorectal cancers in inflammatory bowel disease: A Dutch population-based cohort study.
    J Crohns Colitis. 2018 Apr 10. pii: 4965889. doi: 10.1093.
    PubMed     Abstract available


  561. WANG Z, Zhang W, Luo C, Zhu M, et al
    Primary Intestinal Epstein-Barr Virus-associated Natural killer/T-Cell Lymphoproliferative Disorder: A Disease Mimicking Inflammatory Bowel Disease.
    J Crohns Colitis. 2018 Apr 7. pii: 4964706. doi: 10.1093.
    PubMed     Abstract available


  562. KEVANS D, Murthy S, Mould DR, Silverberg MS, et al
    Accelerated Clearance of Infliximab is Associated With Treatment Failure in Patients With Corticosteroid-Refractory Acute Ulcerative Colitis.
    J Crohns Colitis. 2018 Apr 6. pii: 4963864. doi: 10.1093.
    PubMed     Abstract available


    March 2018
  563. PARRAGI L, Fournier N, Zeitz J, Scharl M, et al
    Colectomy Rates in Ulcerative Colitis Are Low and Decreasing: 10-year-follow-up Data from the Swiss IBD Cohort Study.
    J Crohns Colitis. 2018 Mar 31. pii: 4957044. doi: 10.1093.
    PubMed     Abstract available


  564. KOELINK PJ, Wildenberg ME, Stitt LW, Feagan BG, et al
    Development of Reliable, Valid and Responsive Scoring Systems for Endoscopy and Histology in Animal Models for Inflammatory Bowel Disease.
    J Crohns Colitis. 2018 Mar 28. pii: 4955731. doi: 10.1093.
    PubMed     Abstract available


  565. SNOWDEN JA, Panes J, Alexander T, Allez M, et al
    Autologous Haematopoietic Stem Cell Transplantation (AHSCT) in Severe Crohn's Disease: A Review on Behalf of ECCO and EBMT.
    J Crohns Colitis. 2018;12:476-488.
    PubMed     Abstract available


  566. GREENER T, Boland K, Steinhart AH, Silverberg MS, et al
    The Unfinished Symphony: Golimumab Therapy for Anti-Tumour Necrosis Factor Refractory Crohn's Disease.
    J Crohns Colitis. 2018;12:458-464.
    PubMed     Abstract available


  567. LIGHTNER AL, McKenna NP, Tse CS, Hyman N, et al
    Postoperative Outcomes in Ustekinumab-Treated Patients Undergoing Abdominal Operations for Crohn's Disease.
    J Crohns Colitis. 2018;12:402-407.
    PubMed     Abstract available


  568. HIRAI F, Andoh A, Ueno F, Watanabe K, et al
    Efficacy of Endoscopic Balloon Dilation for Small Bowel Strictures in Patients With Crohn's Disease: A Nationwide, Multi-centre, Open-label, Prospective Cohort Study.
    J Crohns Colitis. 2018;12:394-401.
    PubMed     Abstract available


  569. PAPAMICHAEL K, Vajravelu RK, Vaughn BP, Osterman MT, et al
    Proactive infliximab monitoring following reactive testing is associated with better clinical outcomes than reactive testing alone in patients with inflammatory bowel disease.
    J Crohns Colitis. 2018 Mar 24. pii: 4953445. doi: 10.1093.
    PubMed     Abstract available


  570. HONG M, Ye BD, Yang SK, Jung S, et al
    Immunochip meta-analysis of inflammatory bowel disease identifies three novel loci and four novel associations in previously reported loci.
    J Crohns Colitis. 2018 Mar 23. pii: 4951970. doi: 10.1093.
    PubMed     Abstract available


  571. LEDDER O, Assa A, Levine A, Escher JC, et al
    Corrigendum: Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN.
    J Crohns Colitis. 2018 Mar 17. pii: 4942346. doi: 10.1093.
    PubMed    


  572. KANG JE, Kim HD, Park SY, Pan JG, et al
    Dietary Supplementation with a Bacillus Superoxide Dismutase Protects Against gamma-Radiation-induced Oxidative Stress and Ameliorates Dextran Sulfate Sodium-induced Ulcerative Colitis in Mice.
    J Crohns Colitis. 2018 Mar 14. pii: 4935132. doi: 10.1093.
    PubMed     Abstract available


  573. LEE S, Metcalfe A, Raman M, Leung Y, et al
    Pregnant Women with Inflammatory Bowel Disease are at Increased Risk of Vitamin D Insufficiency: A Cross-Sectional Study.
    J Crohns Colitis. 2018 Mar 13. pii: 4931216. doi: 10.1093.
    PubMed     Abstract available


  574. CHEN T, Zhou Q, Zhang D, Jiang F, et al
    Effect of Faecal Microbiota Transplantation for Treatment of Clostridium difficile Infection in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Cohort Studies.
    J Crohns Colitis. 2018 Mar 8. pii: 4924729. doi: 10.1093.
    PubMed     Abstract available


  575. OTTAVIANO G, Salvatore S, Salvatoni A, Martelossi S, et al
    Ocular Manifestations of Pediatric Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
    J Crohns Colitis. 2018 Mar 6. pii: 4922546. doi: 10.1093.
    PubMed     Abstract available


  576. KEMP K, Dibley L, Chauhan U, Greveson K, et al
    2nd N-ECCO Consensus Statements on the European Nursing Roles in Caring for Patients with Crohn's Disease or Ulcerative Colitis.
    J Crohns Colitis. 2018 Mar 2. pii: 4917790. doi: 10.1093.
    PubMed    


    February 2018
  577. LO B, Vester-Andersen MK, Vind I, Prosberg M, et al
    Changes in Disease Behaviour and Location in Patients With Crohn's Disease After Seven Years of Follow-Up: A Danish Population-based Inception Cohort.
    J Crohns Colitis. 2018;12:265-272.
    PubMed     Abstract available


  578. ROTTOLI M, Vallicelli C, Bigonzi E, Gionchetti P, et al
    Prepouch Ileitis After Ileal Pouch-anal Anastomosis: Patterns of Presentation and Risk Factors for Failure of Treatment.
    J Crohns Colitis. 2018;12:273-279.
    PubMed     Abstract available


  579. WANG Y, Gao X, Ghozlane A, Hu H, et al
    Characteristics of Faecal Microbiota in Paediatric Crohn's Disease and Their Dynamic Changes During Infliximab Therapy.
    J Crohns Colitis. 2018;12:337-346.
    PubMed     Abstract available


  580. KLANG E, Amitai MM, Lahat A, Yablecovitch D, et al
    Capsule Endoscopy Validation of the Magnetic Enterography Global Score in Patients with Established Crohn's Disease.
    J Crohns Colitis. 2018;12:313-320.
    PubMed     Abstract available


  581. COHEN-DOLEV N, Sladek M, Hussey S, Turner D, et al
    Differences in Outcomes Over Time With Exclusive Enteral Nutrition Compared With Steroids in Children With Mild to Moderate Crohn's Disease: Results From the GROWTH CD Study.
    J Crohns Colitis. 2018;12:306-312.
    PubMed     Abstract available


  582. BESWICK L, Rosella O, Rosella G, Headon B, et al
    Exploration of Predictive Biomarkers of Early Infliximab Response in Acute Severe Colitis: A Prospective Pilot Study.
    J Crohns Colitis. 2018;12:289-297.
    PubMed     Abstract available


  583. SRINIVASAN A, Vasudevan A, McFarlane A, Sparrow MP, et al
    Anti-TNF Re-induction Is as Effective, Simpler, and Cheaper Compared With Dose Interval Shortening for Secondary Loss of Response in Crohn's Disease.
    J Crohns Colitis. 2018;12:280-288.
    PubMed     Abstract available


  584. ROWAN CR, Cullen G, Mulcahy HE, Keegan D, et al
    Ustekinumab Drug Levels in Maternal and Cord Blood in a Woman With Crohn's Disease Treated Until 33 Weeks of Gestation.
    J Crohns Colitis. 2018;12:376-378.
    PubMed     Abstract available


  585. LAMBDIN J, Rowe A, Borum M
    Physical Activity and Inflammatory Bowel Disease.
    J Crohns Colitis. 2018 Feb 27. pii: 4911522. doi: 10.1093.
    PubMed    


  586. DOMENECH E, Panes J, Hinojosa J, Annese V, et al
    "Addition of granulocyte/monocyte apheresis to oral prednisone for steroid-dependent ulcerative colitis: A randomized, multicentre, clinical trial".
    J Crohns Colitis. 2018 Feb 27. pii: 4911562. doi: 10.1093.
    PubMed     Abstract available


  587. NIELSEN OH, Rejnmark L, Moss AC
    Role of Vitamin D in the Natural History of Inflammatory Bowel Disease.
    J Crohns Colitis. 2018 Feb 24. pii: 4908651. doi: 10.1093.
    PubMed     Abstract available



  588. Corrigendum: Training Programs on Endoscopic Scoring Systems for Inflammatory Bowel Disease Lead to a Significant Increase in Interobserver Agreement Among Community Gastroenterologists.
    J Crohns Colitis. 2018 Feb 21. pii: 4883181. doi: 10.1093.
    PubMed    


  589. MORENO MARQUEZ C, Maldonado Perez B, Castro Laria L
    Infliximab as rescue treatment in a Sweet's Syndrome related to corticodependent ulcerative colitis.
    J Crohns Colitis. 2018 Feb 21. pii: 4883175. doi: 10.1093.
    PubMed    


  590. MOHAMMADI A, Kelly OB, Filice M, Kabakchiev B, et al
    Differential expression of microRNAs in peripheral blood mononuclear cells identifies autophagy and TGF-beta related signatures aberrantly expressed in inflammatory bowel disease.
    J Crohns Colitis. 2018 Feb 6. pii: 4840562. doi: 10.1093.
    PubMed     Abstract available


  591. BURISCH J, Gisbert JP, Siegmund B, Bettenworth D, et al
    Validation of the "United Registries for Clinical Assessment and Research" (UR-CARE), a European online registry for clinical care and research in Inflammatory Bowel Disease.
    J Crohns Colitis. 2018 Feb 3. pii: 4836265. doi: 10.1093.
    PubMed     Abstract available


    January 2018
  592. ROSARIO M, French JL, Dirks NL, Sankoh S, et al
    Corrigendum: Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.
    J Crohns Colitis. 2018 Jan 29. pii: 4828071. doi: 10.1093.
    PubMed    


  593. RAKNES G, Simonsen P, Smabrekke L
    The effect of Low Dose Naltrexone on Medication in Inflammatory Bowel Disease: A Quasi Experimental before-and-after Prescription Database Study.
    J Crohns Colitis. 2018 Jan 27. pii: 4827597. doi: 10.1093.
    PubMed     Abstract available


  594. LAHIFF C, Wang LM, Travis SPL, East JE, et al
    Diagnostic Yield of Dysplasia in Polyp-Adjacent Biopsies for Patients with Inflammatory Bowel Disease: A Cross-Sectional Study.
    J Crohns Colitis. 2018 Jan 27. pii: 4827063. doi: 10.1093.
    PubMed     Abstract available


  595. LASERNA-MENDIETA EJ, Clooney AG, Carretero-Gomez JF, Moran C, et al
    Determinants of Reduced Genetic Capacity for Butyrate Synthesis by the Gut Microbiome in Crohn's Disease and Ulcerative Colitis.
    J Crohns Colitis. 2018;12:204-216.
    PubMed     Abstract available


  596. ANDERSEN V, Chan S, Luben R, Khaw KT, et al
    Fibre intake and the development of inflammatory bowel disease: A European prospective multi-centre cohort study (EPIC-IBD).
    J Crohns Colitis. 2018;12:129-136.
    PubMed     Abstract available


  597. ENGEL T, Ungar B, Yung DE, Ben-Horin S, et al
    Vedolizumab in IBD-Lessons From Real-world Experience; A Systematic Review and Pooled Analysis.
    J Crohns Colitis. 2018;12:245-257.
    PubMed     Abstract available


  598. GUIZZETTI L, Zou G, Khanna R, Dulai PS, et al
    Development of Clinical Prediction Models for Surgery and Complications in Crohn's Disease.
    J Crohns Colitis. 2018;12:167-177.
    PubMed     Abstract available


  599. D'HAENS G, Vermeire S, Vogelsang H, Allez M, et al
    Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating beta7+ T Cells in Crohn's Disease: Report of the TOSCA Study.
    J Crohns Colitis. 2018;12:188-196.
    PubMed     Abstract available


  600. THOMAS C, Monteil-Ganiere C, Mirallie S, Hemont C, et al
    A Severe Neonatal Lymphopenia Associated With Administration of Azathioprine to the Mother in a Context of Crohn's Disease.
    J Crohns Colitis. 2018;12:258-261.
    PubMed     Abstract available


  601. ZHU Z, Mei Z, Guo Y, Wang G, et al
    Reduced Risk of Inflammatory Bowel Disease-associated Colorectal Neoplasia with Use of Thiopurines: a Systematic Review and Meta-analysis.
    J Crohns Colitis. 2018 Jan 23. pii: 4822002. doi: 10.1093.
    PubMed     Abstract available


  602. BOSSUYT P, Debeuckelaere C, Ferrante M, de Buck van Overstraeten A, et al
    Risk Stratification for Surgery in Stricturing Ileal Crohn's Disease: The BACARDI Risk Model.
    J Crohns Colitis. 2018;12:32-38.
    PubMed     Abstract available


  603. ORLANDO S, Fraquelli M, Coletta M, Branchi F, et al
    Ultrasound Elasticity Imaging Predicts Therapeutic Outcomes of Patients With Crohn's Disease Treated With Anti-Tumour Necrosis Factor Antibodies.
    J Crohns Colitis. 2018;12:63-70.
    PubMed     Abstract available


  604. HASSAN-ZAHRAEE M, Banerjee A, Cheng JB, Zhang W, et al
    Anti-MAdCAM Antibody Increases ss7+ T Cells and CCR9 Gene Expression in the Peripheral Blood of Patients With Crohn's Disease.
    J Crohns Colitis. 2018;12:77-86.
    PubMed     Abstract available


  605. BEMELMAN WA, Warusavitarne J, Sampietro GM, Serclova Z, et al
    ECCO-ESCP Consensus on Surgery for Crohn's Disease.
    J Crohns Colitis. 2018;12:1-16.
    PubMed    


  606. SALVADOR P, Macias-Ceja DC, Gisbert-Ferrandiz L, Hernandez C, et al
    CD16+ Macrophages Mediate Fibrosis in Inflammatory Bowel Disease.
    J Crohns Colitis. 2018 Jan 3. pii: 4783136. doi: 10.1093.
    PubMed     Abstract available


    December 2017
  607. VIDE J, Osorio F, Costa-Silva M, Lopes S, et al
    Cutaneous morbidity among inflammatory bowel disease patients: a cohort study.
    J Crohns Colitis. 2017 Dec 28. pii: 4781052. doi: 10.1093.
    PubMed     Abstract available


  608. DE BOER NKH, Peyrin-Biroulet L, Jharap B, Sanderson JD, et al
    Thiopurines in Inflammatory Bowel Disease: new findings and perspectives.
    J Crohns Colitis. 2017 Dec 25. pii: 4774531. doi: 10.1093.
    PubMed     Abstract available


  609. DAI C, Jiang M, Cao Q
    Steroid and the risk of venous thromboembolic events in inflammatory bowel disease.
    J Crohns Colitis. 2017 Dec 23. pii: 4774286. doi: 10.1093.
    PubMed    


  610. MCDERMOTT E, Healy G, Mullen G, Keegan D, et al
    Patient education in inflammatory bowel disease; a patient-centred, mixed methodology study.
    J Crohns Colitis. 2017 Dec 23. pii: 4773946. doi: 10.1093.
    PubMed     Abstract available


  611. POUILLON L, Peyrin-Biroulet L
    It is time to revise the STRIDE guidelines determining therapeutic goals for treat-to-target in inflammatory bowel disease.
    J Crohns Colitis. 2017 Dec 23. pii: 4773849. doi: 10.1093.
    PubMed    


  612. BRAGA NETO MB, Gregory M, Piovezani Ramos G, Loftus EV Jr, et al
    De-novo Inflammatory bowel disease after bariatric surgery: a large case series.
    J Crohns Colitis. 2017 Dec 20. pii: 4767779. doi: 10.1093.
    PubMed     Abstract available


  613. KONO M, Komeda Y, Sakurai T, Okamoto A, et al
    Induction of complete remission by azacitidine in a patient with myelodysplastic syndrome-associated inflammatory bowel disease.
    J Crohns Colitis. 2017 Dec 14. pii: 4743180. doi: 10.1093.
    PubMed     Abstract available


  614. ROMKENS TEH, Kranenburg P, van Tilburg A, Bronkhorst C, et al
    Assessment of histological remission in ulcerative colitis: discrepancies between daily practice and expert opinion.
    J Crohns Colitis. 2017 Dec 12. pii: 4733426. doi: 10.1093.
    PubMed     Abstract available


  615. HEIDA A, Dijkstra A, Muller Kobold A, Rossen J, et al
    The efficacy of home telemonitoring versus conventional follow-up: a randomised controlled trial among teenagers with inflammatory bowel disease.
    J Crohns Colitis. 2017 Dec 8. pii: 4710333. doi: 10.1093.
    PubMed     Abstract available


  616. LOPEZ RN, Gupta N, Lemberg DA
    Vedolizumab-associated pancreatitis in paediatric ulcerative colitis - functional selectivity of the alpha4beta7integrin and MAdCAM-1 pathway?
    J Crohns Colitis. 2017 Dec 8. pii: 4712095. doi: 10.1093.
    PubMed    


  617. ALAMEEL T, Mosli MH
    Combination therapy with adalimumab and thiopurines in inflammatory bowel disease. Is it a case of nepotism in pharmacology?
    J Crohns Colitis. 2017 Dec 6. pii: 4694420. doi: 10.1093.
    PubMed    


  618. SARLOS P, Szemes K, Hegyi P, Garami A, et al
    Steroid but not biological therapy elevates the risk of venous thromboembolic events in inflammatory bowel disease. A meta-analysis.
    J Crohns Colitis. 2017 Dec 6. pii: 4694102. doi: 10.1093.
    PubMed     Abstract available


  619. KIM AH, Roberts C, Feagan BG, Banerjee R, et al
    Developing a Standard Set of Patient-Centred Outcomes for Inflammatory Bowel Disease - an International, Cross-disciplinary Consensus.
    J Crohns Colitis. 2017 Dec 5. pii: 4694039. doi: 10.1093.
    PubMed     Abstract available


  620. SMIDS C, Horjus Talabur Horje CS, Drylewicz J, Roosenboom B, et al
    Intestinal T cell profiling in Inflammatory Bowel Disease; linking T cell subsets to disease activity and disease course.
    J Crohns Colitis. 2017 Dec 4. pii: 4689802. doi: 10.1093.
    PubMed     Abstract available


  621. ONOUFRIADIS A, Stone K, Katsiamides A, Amar A, et al
    Exome sequencing and genotyping identify a rare variant in NLRP7 gene associated with ulcerative colitis.
    J Crohns Colitis. 2017 Dec 4. pii: 4689794. doi: 10.1093.
    PubMed     Abstract available


    November 2017
  622. HENRIKSEN M, Hoivik ML, Jelsness-Jorgensen LP, Moum B, et al
    Irritable bowel-like symptoms in ulcerative colitis are as common in patients in deep remission as with inflammation; results from a population-based study (the IBSEN study).
    J Crohns Colitis. 2017 Nov 27. pii: 4668347. doi: 10.1093.
    PubMed     Abstract available


  623. VAVRICKA SR, Galvan JA, Dawson H, Soltermann A, et al
    Expression Patterns of TNFalpha, MAdCAM1 and STAT3 in Intestinal and Skin Manifestations of Inflammatory Bowel Disease.
    J Crohns Colitis. 2017 Nov 22. pii: 4647660. doi: 10.1093.
    PubMed     Abstract available


  624. MOGENSEN DV, Brynskov J, Ainsworth MA, Nersting J, et al
    A role for thiopurine metabolites in the synergism between thiopurines and infliximab in inflammatory bowel disease.
    J Crohns Colitis. 2017 Nov 14. doi: 10.1093.
    PubMed     Abstract available


  625. PAGNINI C, Mariani BM, Lorenzetti R
    Ulcerative Colitis Endoscopic Index of Severity is feasible and useful for endoscopic activity evaluation in ulcerative colitis patients in real-life setting.
    J Crohns Colitis. 2017 Nov 14. doi: 10.1093.
    PubMed    


    October 2017
  626. HARBORD M, Eliakim R, Bettenworth D, Karmiris K, et al
    Corrigendum: Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management.
    J Crohns Colitis. 2017 Oct 21. doi: 10.1093.
    PubMed    


  627. TAMAN H, Fenton CG, Hensel IV, Anderssen E, et al
    Transcriptomic Landscape of Treatment - Naive Ulcerative Colitis.
    J Crohns Colitis. 2017 Oct 10. doi: 10.1093.
    PubMed     Abstract available


    September 2017
  628. ANIWAN S, Tremaine WJ, Raffals LE, Kane SV, et al
    Antibiotic use and new-onset inflammatory bowel disease in Olmsted County, Minnesota: a population-based case-control study.
    J Crohns Colitis. 2017 Sep 28. doi: 10.1093.
    PubMed     Abstract available


  629. NORDENVALL C, Rosvall O, Bottai M, Everhov AH, et al
    Surgical treatment in childhood-onset inflammatory bowel disease -A nationwide register-based study of 4,695 incident patients in Sweden 2002-2014.
    J Crohns Colitis. 2017 Sep 27. doi: 10.1093.
    PubMed     Abstract available


  630. DEDERICHS F, Iesalnieks I, Sladek M, Tzivinikos C, et al
    Genital granulomatosis in male and female patients with Crohn`s disease: clinical presentation and treatment outcomes.
    J Crohns Colitis. 2017 Sep 27. doi: 10.1093.
    PubMed     Abstract available


  631. PANES J, Vermeire S, Lindsay JO, Sands BE, et al
    Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomized Controlled Induction and Maintenance Studies.
    J Crohns Colitis. 2017 Sep 27. doi: 10.1093.
    PubMed     Abstract available


  632. VANHOVE W, Nys K, Arijs I, Cleynen I, et al
    Biopsy-derived intestinal epithelial cell cultures for pathway based stratification of patients with inflammatory bowel disease.
    J Crohns Colitis. 2017 Sep 23. doi: 10.1093.
    PubMed     Abstract available


  633. OSSUM AM, Palm O, Lunder AK, Cvancarova M, et al
    Ankylosing spondylitis and axial spondyloarthritis in patients with long-term inflammatory bowel disease: Results from 20 years of follow-up in the IBSEN study.
    J Crohns Colitis. 2017 Sep 13. doi: 10.1093.
    PubMed     Abstract available


  634. ASSA A, Rinawi F, Shamir R
    The long-term predictive properties of the Paris classification in pediatric inflammatory bowel disease patients.
    J Crohns Colitis. 2017 Sep 7. doi: 10.1093.
    PubMed     Abstract available


  635. HOSOMI S, Yamagami H, Itani S, Yukawa T, et al
    Sepsis markers soluble IL-2 receptor and soluble CD14 subtype as potential biomarkers for complete mucosal healing in patients with inflammatory bowel disease.
    J Crohns Colitis. 2017 Sep 7. doi: 10.1093.
    PubMed     Abstract available


  636. SHI HY, Chan FKL, Chan AWH, Higashimori A, et al
    Accuracy of Faecal Immunochemical Test to Predict Endoscopic and Histological Healing in Ulcerative Colitis: A Prospective Study Based on Validated Histological Scores.
    J Crohns Colitis. 2017;11:1071-1077.
    PubMed     Abstract available


  637. SINGH A, Agrawal N, Kurada S, Lopez R, et al
    Efficacy, Safety, and Long-term Outcome of Serial Endoscopic Balloon Dilation for Upper Gastrointestinal Crohn's Disease-associated Strictures-A Cohort Study.
    J Crohns Colitis. 2017;11:1044-1051.
    PubMed     Abstract available


  638. CONNORS J, Basseri S, Grant A, Giffin N, et al
    Exclusive Enteral Nutrition Therapy in Paediatric Crohn's Disease Results in Long-term Avoidance of Corticosteroids: Results of a Propensity-score Matched Cohort Analysis.
    J Crohns Colitis. 2017;11:1063-1070.
    PubMed     Abstract available


  639. WESTEROUEN VAN MEETEREN MJ, Hayee B, Inderson A, van der Meulen AE, et al
    Safety of Anti-TNF Treatment in Liver Transplant Recipients: A Systematic Review and Meta-analysis.
    J Crohns Colitis. 2017;11:1146-1151.
    PubMed     Abstract available


  640. FELDBRUGGE L, Moss AC, Yee EU, Csizmadia E, et al
    Expression of Ecto-nucleoside Triphosphate Diphosphohydrolases-2 and -3 in the Enteric Nervous System Affects Inflammation in Experimental Colitis and Crohn's Disease.
    J Crohns Colitis. 2017;11:1113-1123.
    PubMed     Abstract available


  641. BIRIMBERG-SCHWARTZ L, Zucker DM, Akriv A, Cucchiara S, et al
    Development and Validation of Diagnostic Criteria for IBD Subtypes Including IBD-unclassified in Children: a Multicentre Study From the Pediatric IBD Porto Group of ESPGHAN.
    J Crohns Colitis. 2017;11:1078-1084.
    PubMed     Abstract available


  642. SMIDS C, Horjus Talabur Horje CS, Nierkens S, Drylewicz J, et al
    Candidate Serum Markers in Early Crohn's Disease: Predictors of Disease Course.
    J Crohns Colitis. 2017;11:1090-1100.
    PubMed     Abstract available


  643. CATALAN-SERRA I, Sandvik AK, Bruland T, Andreu-Ballester JC, et al
    Gammadelta T Cells in Crohn's Disease: A New Player in the Disease Pathogenesis?
    J Crohns Colitis. 2017;11:1135-1145.
    PubMed     Abstract available


    August 2017
  644. NAKARAI A, Hiraoka S, Takahashi S, Inaba T, et al
    Simultaneous measurements of fecal calprotectin and the fecal immunochemical test in quiescent ulcerative colitis patients can stratify risk of relapse.
    J Crohns Colitis. 2017 Aug 31. doi: 10.1093.
    PubMed     Abstract available


  645. LAHAT A, Shitrit AB, Naftali T, Milgrom Y, et al
    Vedolizumab levels in breast milk of nursing mothers with inflammatory bowel disease.
    J Crohns Colitis. 2017 Aug 31. doi: 10.1093.
    PubMed     Abstract available


  646. HINDRYCKX P, Vande Casteele N, Novak G, Khanna R, et al
    The expanding therapeutic armamentarium for inflammatory bowel disease: how to choose the right drug(s) for our patients?
    J Crohns Colitis. 2017 Aug 25. doi: 10.1093.
    PubMed     Abstract available



  647. Corrigendum: Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease.
    J Crohns Colitis. 2017 Aug 23. doi: 10.1093.
    PubMed    


  648. ZHANG M, Xu C, Liu D, Han MK, et al
    Oral delivery of nanoparticles loaded with ginger active compound, 6-shogaol, attenuates ulcerative colitis and promotes wound healing in a murine model of ulcerative colitis.
    J Crohns Colitis. 2017 Aug 18. doi: 10.1093.
    PubMed     Abstract available


  649. SIGALL-BONEH R, Levine A, Lomer M, Wierdsma N, et al
    Research Gaps in Diet and Nutrition in Inflammatory Bowel Disease. A Topical Review by D-ECCO Working Group (Dietitians of ECCO).
    J Crohns Colitis. 2017 Aug 10. doi: 10.1093.
    PubMed     Abstract available


  650. MARK-CHRISTENSEN A, Erichsen R, Brandsborg S, Rosenberg J, et al
    Long-term Risk of Cancer Following Ileal Pouch-anal Anastomosis for Ulcerative Colitis.
    J Crohns Colitis. 2017 Aug 3. doi: 10.1093.
    PubMed     Abstract available


  651. WILKENS R, Hagemann-Madsen RH, Peters DA, Nielsen AH, et al
    Validity of Contrast Enhanced Ultrasonography and Dynamic Contrast Enhanced MR Enterography in the Assessment of Transmural Activity and Fibrosis in Crohn s Disease.
    J Crohns Colitis. 2017 Aug 3. doi: 10.1093.
    PubMed     Abstract available


  652. DOHERTY G, Katsanos KH, Burisch J, Allez M, et al
    European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal ('Exit Strategies') in Inflammatory Bowel Disease.
    J Crohns Colitis. 2017 Aug 2. doi: 10.1093.
    PubMed     Abstract available


  653. TURNER D, Carle A, Steiner SJ, Margolis PA, et al
    Quality Items Required for Running a Paediatric Inflammatory Bowel Disease Centre: An ECCO Paper.
    J Crohns Colitis. 2017;11:981-987.
    PubMed     Abstract available


    July 2017
  654. DANESE S, Furfaro F, Vetrano S
    Targeting S1P in Inflammatory bowel disease: new avenues for modulating intestinal leukocyte migration.
    J Crohns Colitis. 2017 Jul 28. doi: 10.1093.
    PubMed     Abstract available


  655. LEUNG CM, Tang W, Moe K, Niamul G, et al
    Endoscopic and Histologic Mucosal Healing in Ulcerative Colitis in the First Year of Diagnosis: Results from a Population-based Inception Cohort from Six Countries in Asia.
    J Crohns Colitis. 2017 Jul 26. doi: 10.1093.
    PubMed     Abstract available


  656. CASANOVA MJ, Chaparro M, Molina B, Merino O, et al
    Prevalence of Malnutrition and Nutritional Characteristics of Patients With Inflammatory Bowel Disease.
    J Crohns Colitis. 2017 Jul 24. doi: 10.1093.
    PubMed     Abstract available


  657. RIVIERE P, Zallot C, Desobry P, Sabate JM, et al
    Frequency of and Factors Associated With Sexual Dysfunction in Patients With Inflammatory Bowel Disease.
    J Crohns Colitis. 2017 Jul 22. doi: 10.1093.
    PubMed     Abstract available


  658. SPEKHORST LM, Severs M, de Boer NKH, Festen EAM, et al
    The Impact of Ethnicity and Country of Birth on Inflammatory Bowel Disease Phenotype: a Prospective Cohort Study.
    J Crohns Colitis. 2017 Jul 22. doi: 10.1093.
    PubMed     Abstract available


  659. MORAR PS, Hollingshead J, Bemelman W, Sevdalis N, et al
    Establishing Key Performance Indicators [KPIs] and Their Importance for the Surgical Management of Inflammatory Bowel Disease-Results From a Pan-European, Delphi Consensus Study.
    J Crohns Colitis. 2017 Jul 20. doi: 10.1093.
    PubMed     Abstract available


  660. TRAVIS S, Feagan BG, Peyrin-Biroulet L, Panaccione R, et al
    Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADA.
    J Crohns Colitis. 2017 Jul 17. doi: 10.1093.
    PubMed     Abstract available


  661. LAMB CA, Kirby JA, Keir ME, Mansfield JC, et al
    T Lymphocytes Expressing AlphaE Beta7 Integrin in Ulcerative Colitis: Associations With Cellular Lineage and Phenotype.
    J Crohns Colitis. 2017 Jul 17. doi: 10.1093.
    PubMed    


  662. FERRANTE M, de Buck van Overstraeten A, Schils N, Moens A, et al
    Perioperative Use of Vedolizumab is not Associated with Postoperative Infectious Complications in Patients with Ulcerative Colitis Undergoing Colectomy.
    J Crohns Colitis. 2017 Jul 12. doi: 10.1093.
    PubMed     Abstract available


  663. HIBI T, Panaccione R, Katafuchi M, Yokoyama K, et al
    The 5C Concept and 5S Principles in Inflammatory Bowel Disease Management.
    J Crohns Colitis. 2017 Jul 12. doi: 10.1093.
    PubMed     Abstract available


  664. PLANELL N, Masamunt MC, Leal RF, Rodriguez L, et al
    Usefulness of Transcriptional Blood Biomarkers as a Non-invasive Surrogate Marker of Mucosal Healing and Endoscopic Response in Ulcerative Colitis.
    J Crohns Colitis. 2017 Jul 10. doi: 10.1093.
    PubMed     Abstract available


  665. DURICOVA D, Leroyer A, Savoye G, Sarter H, et al
    Extra-intestinal Manifestations at Diagnosis in Paediatric- and Elderly-onset Ulcerative Colitis are Associated With a More Severe Disease Outcome: A Population-based Study.
    J Crohns Colitis. 2017 Jul 7. doi: 10.1093.
    PubMed     Abstract available


    June 2017
  666. ESTEVINHO MM, Afonso J, Rosa I, Lago P, et al
    A Systematic Review and Meta-Analysis of 6-Thioguanine Nucleotide Levels and Clinical Remission in Inflammatory Bowel Disease.
    J Crohns Colitis. 2017 Jun 30. doi: 10.1093.
    PubMed     Abstract available


  667. ABREU C, Afonso J, Dias CC, Ruas R, et al
    Serial Tuberculosis screening in inflammatory bowel disease patients under anti-TNFalpha therapy.
    J Crohns Colitis. 2017 Jun 9. doi: 10.1093.
    PubMed     Abstract available


  668. LEDDER O, Assa A, Levine A, Escher JC, et al
    Vedolizumab in pediatric inflammatory bowel disease: a retrospective multi-center experience from the Paediatric IBD Porto group of ESPGHAN.
    J Crohns Colitis. 2017 Jun 9. doi: 10.1093.
    PubMed     Abstract available


    May 2017
  669. BURISCH J, Vegh Z, Katsanos KH, Christodoulou DK, et al
    Occurrence of anaemia in the first year of inflammatory bowel disease in a European population-based inception cohort - An ECCO-EpiCom study.
    J Crohns Colitis. 2017 May 31. doi: 10.1093.
    PubMed     Abstract available


  670. ANIWAN S, Loftus EV Jr
    Bringing the Mucosa to Heal with Vedolizumab in Patients with Inflammatory Bowel Disease.
    J Crohns Colitis. 2017 May 27. doi: 10.1093.
    PubMed    


  671. STREMMEL W, Staffer S, Schneider MJ, Gan-Schreier H, et al
    Genetic mouse models with intestinal-specific tight junction deletion resemble an ulcerative colitis phenotype.
    J Crohns Colitis. 2017 May 27. doi: 10.1093.
    PubMed     Abstract available


  672. GASPAR R, Liberal R, Macedo G
    Mucosal healing in ulcerative colitis patients treated with vedolizumab: patient-, dose- or duration-dependant?
    J Crohns Colitis. 2017 May 22. doi: 10.1093.
    PubMed    


  673. CARBONNEL F, Boutron MC
    Incidence, phenotype and mortality of inflammatory bowel disease twenty years after.
    J Crohns Colitis. 2017 May 19. doi: 10.1093.
    PubMed    


  674. COX SR, Prince AC, Myers CE, Irving PM, et al
    Fermentable carbohydrates (FODMAPs) exacerbate functional gastrointestinal symptoms in patients with inflammatory bowel disease: a randomised, double-blind, placebo-controlled, cross-over, re-challenge trial.
    J Crohns Colitis. 2017 May 19. doi: 10.1093.
    PubMed     Abstract available


  675. KAROLEWSKA-BOCHENEK K, Dziekiewicz M, Banaszkiewicz A
    Budesonide MMX in pediatric patients with ulcerative colitis.
    J Crohns Colitis. 2017 May 15. doi: 10.1093.
    PubMed    


  676. PARAMSOTHY S, Paramsothy R, Rubin DT, Kamm MA, et al
    Faecal Microbiota Transplantation for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
    J Crohns Colitis. 2017 May 9. doi: 10.1093.
    PubMed     Abstract available


  677. NIKOLAUS S, Schreiber S, Siegmund B, Bokemeyer B, et al
    Patient education in a 14 month randomized trial fails to improve adherence in ulcerative colitis: Influence of demographic and clinical parameters on non-adherence.
    J Crohns Colitis. 2017 May 9. doi: 10.1093.
    PubMed     Abstract available


  678. BURISCH J, Ungaro R, Vind I, Prosberg MV, et al
    Proximal disease extension in patients with limited ulcerative colitis: a Danish population-based inception cohort.
    J Crohns Colitis. 2017 May 9. doi: 10.1093.
    PubMed     Abstract available


  679. HORJUS TALABUR HORJE CS
    AlfaEbeta7 integrin expression on T cells in Ulcerative Colitis.
    J Crohns Colitis. 2017 May 9. doi: 10.1093.
    PubMed    


  680. MACMANUS CF, Collins CB, Nguyen TT, Alfano RW, et al
    VEN-120, a recombinant human lactoferrin, promotes a regulatory T cell (Treg) phenotype and drives resolution of inflammation in distinct murine models of inflammatory bowel disease.
    J Crohns Colitis. 2017 May 2. doi: 10.1093.
    PubMed     Abstract available


  681. KOTZE PG, Yamamoto T
    Preoperative Vedolizumab and Postoperative Outcomes in Inflammatory Bowel Disease: Does Smoke Always Mean Fire?
    J Crohns Colitis. 2017;11:643.
    PubMed    


  682. LAMB CA, Mansfield JC, Tew GW, Gibbons D, et al
    alphaEbeta7 Integrin Identifies Subsets of Pro-Inflammatory Colonic CD4+ T Lymphocytes in Ulcerative Colitis.
    J Crohns Colitis. 2017;11:610-620.
    PubMed     Abstract available


  683. CHU TPC, Moran GW, Card TR
    The Pattern of Underlying Cause of Death in Patients with Inflammatory Bowel Disease in England: A Record Linkage Study.
    J Crohns Colitis. 2017;11:578-585.
    PubMed     Abstract available


  684. LIM KJ, Lee SJ, Kim S, Lee SY, et al
    Comparable Immune Function Inhibition by the Infliximab Biosimilar CT-P13: Implications for Treatment of Inflammatory Bowel Disease.
    J Crohns Colitis. 2017;11:593-602.
    PubMed     Abstract available


  685. LIGHTNER AL, Loftus EV
    Response to 'Preoperative Vedolizumab and Postoperative Outcomes in Inflammatory Bowel Disease: Does Smoke Always Mean Fire?'
    J Crohns Colitis. 2017;11:644-645.
    PubMed    


  686. MELESSE DY, Lix LM, Nugent Z, Targownik LE, et al
    Estimates of Disease Course in Inflammatory Bowel Disease Using Administrative Data: A Population-level Study.
    J Crohns Colitis. 2017;11:562-570.
    PubMed     Abstract available


  687. KARREMAN MC, Luime JJ, Hazes JMW, Weel AEAM, et al
    The Prevalence and Incidence of Axial and Peripheral Spondyloarthritis in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
    J Crohns Colitis. 2017;11:631-642.
    PubMed     Abstract available


  688. EBERHARDSON M, Karlen P, Linton L, Jones P, et al
    Randomised, Double-blind, Placebo-controlled Trial of CCR9-targeted Leukapheresis Treatment of Ulcerative Colitis Patients.
    J Crohns Colitis. 2017;11:534-542.
    PubMed     Abstract available


  689. DAPERNO M, Comberlato M, Bossa F, Armuzzi A, et al
    Training Programs on Endoscopic Scoring Systems for Inflammatory Bowel Disease Lead to a Significant Increase in Interobserver Agreement Among Community Gastroenterologists.
    J Crohns Colitis. 2017;11:556-561.
    PubMed     Abstract available


  690. BEQUET E, Sarter H, Fumery M, Vasseur F, et al
    Incidence and Phenotype at Diagnosis of Very-early-onset Compared with Later-onset Paediatric Inflammatory Bowel Disease: A Population-based Study [1988-2011].
    J Crohns Colitis. 2017;11:519-526.
    PubMed     Abstract available


  691. HOVDE O, Hoivik ML, Henriksen M, Solberg IC, et al
    Malignancies in Patients with Inflammatory Bowel Disease: Results from 20 Years of Follow-up in the IBSEN Study.
    J Crohns Colitis. 2017;11:571-577.
    PubMed     Abstract available


  692. TURNER D, Yerushalmi B, Kori M, Broide E, et al
    Once- Versus Twice-daily Mesalazine to Induce Remission in Paediatric Ulcerative Colitis: A Randomised Controlled Trial.
    J Crohns Colitis. 2017;11:527-533.
    PubMed     Abstract available


  693. MARAFINI I, Monteleone I, Dinallo V, Di Fusco D, et al
    CCL20 Is Negatively Regulated by TGF-beta1 in Intestinal Epithelial Cells and Reduced in Crohn's Disease Patients With a Successful Response to Mongersen, a Smad7 Antisense Oligonucleotide.
    J Crohns Colitis. 2017;11:603-609.
    PubMed     Abstract available


  694. ZITTAN E, Kabakchiev B, Kelly OB, Milgrom R, et al
    Development of the Harvey-Bradshaw Index-pro (HBI-PRO) Score to Assess Endoscopic Disease Activity in Crohn's Disease.
    J Crohns Colitis. 2017;11:543-548.
    PubMed     Abstract available


  695. DAVIDOV Y, Ungar B, Bar-Yoseph H, Carter D, et al
    Association of Induction Infliximab Levels With Clinical Response in Perianal Crohn's Disease.
    J Crohns Colitis. 2017;11:549-555.
    PubMed     Abstract available


  696. EL MOUZAN M, Wang F, Al Mofarreh M, Menon R, et al
    Fungal Microbiota Profile in Newly Diagnosed Treatment-naive Children with Crohn's Disease.
    J Crohns Colitis. 2017;11:586-592.
    PubMed     Abstract available


    April 2017
  697. HARKIN G, Keogh A, Slattery E
    The Effect of Biosimilars (Inflectra(R),) in the management of Acute Severe Ulcerative Colitis.
    J Crohns Colitis. 2017 Apr 24. doi: 10.1093.
    PubMed    


  698. GWELA A, Siddhanathi P, Chapman RW, Travis S, et al
    Th1 and Innate Lymphoid Cells accumulate in Primary Sclerosing Cholangitis-associated Inflammatory Bowel Disease.
    J Crohns Colitis. 2017 Apr 5. doi: 10.1093.
    PubMed     Abstract available


  699. GUIRGIS M, Wendt E, Wang LM, Walsh A, et al
    Beyond Histological Remission: Intramucosal Calprotectin as a Potential Predictor of Outcomes in Ulcerative Colitis.
    J Crohns Colitis. 2017;11:460-467.
    PubMed     Abstract available


  700. REINISCH W, Colombel JF, D'Haens G, Sandborn WJ, et al
    Characterisation of Mucosal Healing with Adalimumab Treatment in Patients with Moderately to Severely Active Crohn's Disease: Results from the EXTEND Trial.
    J Crohns Colitis. 2017;11:425-434.
    PubMed     Abstract available


  701. DIAS CC, Rodrigues PP, Coelho R, Santos PM, et al
    Development and Validation of Risk Matrices for Crohn's Disease Outcomes in Patients Who Underwent Early Therapeutic Interventions.
    J Crohns Colitis. 2017;11:445-453.
    PubMed     Abstract available


  702. SCHOLMERICH J, Fellermann K, Seibold FW, Rogler G, et al
    A Randomised, Double-blind, Placebo-controlled Trial of Trichuris suis ova in Active Crohn's Disease.
    J Crohns Colitis. 2017;11:390-399.
    PubMed     Abstract available


  703. ARSONIADIS EG, Ho YY, Melton GB, Madoff RD, et al
    African Americans and Short-Term Outcomes after Surgery for Crohn's Disease: An ACS-NSQIP Analysis.
    J Crohns Colitis. 2017;11:468-473.
    PubMed     Abstract available


  704. ALEXAKIS C, Gordon K, Mellor R, Chong H, et al
    Ano-genital Granulomatosis and Crohn's Disease: A Case Series of Males Presenting with Genital Lymphoedema.
    J Crohns Colitis. 2017;11:454-459.
    PubMed     Abstract available


  705. MAGRO F, Lopes S, Coelho R, Cotter J, et al
    Accuracy of Faecal Calprotectin and Neutrophil Gelatinase B-associated Lipocalin in Evaluating Subclinical Inflammation in UlceRaTIVE Colitis-the ACERTIVE study.
    J Crohns Colitis. 2017;11:435-444.
    PubMed     Abstract available


  706. MIKOCKA-WALUS A, Hughes PA, Bampton P, Gordon A, et al
    Fluoxetine for Maintenance of Remission and to Improve Quality of Life in Patients with Crohn's Disease: a Pilot Randomized Placebo-Controlled Trial.
    J Crohns Colitis. 2017;11:509-514.
    PubMed     Abstract available


  707. DING YP, Ladeiro Y, Morilla I, Bouhnik Y, et al
    Integrative Network-based Analysis of Colonic Detoxification Gene Expression in Ulcerative Colitis According to Smoking Status.
    J Crohns Colitis. 2017;11:474-484.
    PubMed     Abstract available


  708. LOFTUS EV JR, Colombel JF, Feagan BG, Vermeire S, et al
    Long-term Efficacy of Vedolizumab for Ulcerative Colitis.
    J Crohns Colitis. 2017;11:400-411.
    PubMed     Abstract available


  709. VERMEIRE S, Loftus EV Jr, Colombel JF, Feagan BG, et al
    Long-term Efficacy of Vedolizumab for Crohn's Disease.
    J Crohns Colitis. 2017;11:412-424.
    PubMed     Abstract available


  710. SMIDS C, Horjus Talabur Horje CS, van Wijk F, van Lochem EG, et al
    The Complexity of alpha E beta 7 Blockade in Inflammatory Bowel Diseases.
    J Crohns Colitis. 2017;11:500-508.
    PubMed     Abstract available


    March 2017
  711. WISNIEWSKI A, Flejou JF, Siproudhis L, Abramowitz L, et al
    Anal Neoplasia in Inflammatory Bowel Disease: Classification Proposal, Epidemiology, Carcinogenesis, and Risk Management Perspectives.
    J Crohns Colitis. 2017 Mar 30. doi: 10.1093.
    PubMed     Abstract available


  712. NOMAN M, Ferrante M, Bisschops R, De Hertogh G, et al
    Vedolizumab induces long term mucosal healing in patients with Crohn's disease and ulcerative colitis.
    J Crohns Colitis. 2017 Mar 24. doi: 10.1093.
    PubMed     Abstract available


  713. LEVINE A, Yerushalmi B, Kori M, Broide E, et al
    Mesalamine enemas for induction of remission in oral mesalamine refractory pediatric ulcerative colitis: a prospective cohort study.
    J Crohns Colitis. 2017 Mar 23. doi: 10.1093.
    PubMed     Abstract available


  714. COTON C, Maggiori L, Mege D, Naudot C, et al
    Ileal pouch-anal anastomosis for dysplasia or cancer complicating inflammatory bowel disease: Is total mesorectal excision always mandatory? an analysis of 36 consecutive patients.
    J Crohns Colitis. 2017 Mar 22. doi: 10.1093.
    PubMed     Abstract available


  715. REBOREDO MM, Pinheiro BV, Chebli JM
    Physical exercise programs in patients with inflammatory bowel disease.
    J Crohns Colitis. 2017 Mar 22. doi: 10.1093.
    PubMed    


  716. CANTORO L, Di Sabatino A, Papi C, Margagnoni G, et al
    The time course of diagnostic delay in inflammatory bowel disease over the last sixty years: an Italian multicentre study.
    J Crohns Colitis. 2017 Mar 17. doi: 10.1093.
    PubMed     Abstract available


  717. JUNG YS, Han M, Kim WH, Park S, et al
    Cancer risk in the Early Stages of Inflammatory Bowel Disease in Korean patients: A Nationwide Population-based Study.
    J Crohns Colitis. 2017 Mar 16. doi: 10.1093.
    PubMed     Abstract available


  718. MOHAMMED K, Shaik NA, Al-Abbasi FA
    Novel de novo mutations of the interleukin-10 receptor gene lead to infantile onset inflammatory bowel disease: A Correction.
    J Crohns Colitis. 2017 Mar 15. doi: 10.1093.
    PubMed    


  719. WISNIEWSKI A, Flejou JF, Siproudhis L, Abramowitz L, et al
    Anal neoplasia in Inflammatory Bowel Disease: Classification proposal, epidemiology, carcinogenesis and risk management perspectives.
    J Crohns Colitis. 2017 Mar 10. doi: 10.1093.
    PubMed     Abstract available



  720. Corrigendum: The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease.
    J Crohns Colitis. 2017 Mar 9. doi: 10.1093.
    PubMed    



  721. Erratum: Use of digital technology to boost patient recruitment in inflammatory bowel disease clinical trials.
    J Crohns Colitis. 2017 Mar 9. doi: 10.1093.
    PubMed    


  722. RUBIN DT, Cohen RD, Sandborn WJ, Lichtenstein GR, et al
    Budesonide Multi-Matrix Is Efficacious for Mesalamine-Refractory, Mild to Moderate Ulcerative Colitis: A Randomized, Placebo-Controlled Trial.
    J Crohns Colitis. 2017 Mar 4. doi: 10.1093.
    PubMed     Abstract available


  723. BOJIC D, Bodger K, Travis S
    Patient Reported Outcome Measures (PROMs) in Inflammatory Bowel Disease: New Data.
    J Crohns Colitis. 2017;11.
    PubMed     Abstract available


  724. VILLANACCI V, Baert F, Cornillie F, De Hertogh G, et al
    Challenges Faced by Cross-sectional Imaging and Histological Endpoints in Clinical Trials.
    J Crohns Colitis. 2017;11.
    PubMed     Abstract available


  725. FIORINO G, Morin M, Bonovas S, Bonifacio C, et al
    Prevalence of Bowel Damage Assessed by Cross-Sectional Imaging in Early Crohn's Disease and its Impact on Disease Outcome.
    J Crohns Colitis. 2017;11:274-280.
    PubMed     Abstract available


  726. BUER LC, Moum BA, Cvancarova M, Warren DJ, et al
    Switching from Remicade(R) to Remsima(R) is well Tolerated and Feasible: A Prospective, Open-label Study.
    J Crohns Colitis. 2017;11:297-304.
    PubMed     Abstract available


  727. MOURAD FH, Barada KA, Saade NE
    Impairment of Small Intestinal Function in Ulcerative Colitis: Role of Enteric Innervation.
    J Crohns Colitis. 2017;11:369-377.
    PubMed     Abstract available


  728. DIBLEY L, Bager P, Czuber-Dochan W, Farrell D, et al
    Identification of Research Priorities for Inflammatory Bowel Disease Nursing in Europe: a Nurses-European Crohn's and Colitis Organisation Delphi Survey.
    J Crohns Colitis. 2017;11:353-359.
    PubMed     Abstract available


  729. SEVERS M, Mangen MJ, van der Valk ME, Fidder HH, et al
    Smoking is Associated with Higher Disease-related Costs and Lower Health-related Quality of Life in Inflammatory Bowel Disease.
    J Crohns Colitis. 2017;11:342-352.
    PubMed     Abstract available


  730. CESARINI M, Collins GS, Ronnblom A, Santos A, et al
    Predicting the Individual Risk of Acute Severe Colitis at Diagnosis.
    J Crohns Colitis. 2017;11:335-341.
    PubMed     Abstract available


  731. KOLHO KL, Pessia A, Jaakkola T, de Vos WM, et al
    Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease.
    J Crohns Colitis. 2017;11:321-334.
    PubMed     Abstract available


  732. DECOCK A, Van Assche G, Vermeire S, Wuyts W, et al
    Sarcoidosis-Like Lesions: Another Paradoxical Reaction to Anti-TNF Therapy?
    J Crohns Colitis. 2017;11:378-383.
    PubMed     Abstract available


  733. COLLINS M, Sarter H, Gower-Rousseau C, Koriche D, et al
    Previous Exposure to Multiple Anti-TNF Is Associated with Decreased Efficiency in Preventing Postoperative Crohn's Disease Recurrence.
    J Crohns Colitis. 2017;11:281-288.
    PubMed     Abstract available


  734. SEVERS M, Oldenburg B, van Bodegraven AA, Siersema PD, et al
    The Economic Impact of the Introduction of Biosimilars in Inflammatory Bowel Disease.
    J Crohns Colitis. 2017;11:289-296.
    PubMed     Abstract available


  735. JAUREGUI-AMEZAGA A, Geerits A, Das Y, Lemmens B, et al
    A Simplified Geboes Score for Ulcerative Colitis.
    J Crohns Colitis. 2017;11:305-313.
    PubMed     Abstract available


  736. KEANE TJ, Dziki J, Sobieski E, Smoulder A, et al
    Restoring Mucosal Barrier Function and Modifying Macrophage Phenotype with an Extracellular Matrix Hydrogel: Potential Therapy for Ulcerative Colitis.
    J Crohns Colitis. 2017;11:360-368.
    PubMed     Abstract available


    February 2017
  737. LEE HS, Oh H, Baek J, Jung S, et al
    X chromosome-wide association study identifies a susceptibility locus for inflammatory bowel disease in Koreans.
    J Crohns Colitis. 2017 Feb 22. doi: 10.1093.
    PubMed     Abstract available


  738. UCHIYAMA K, Takagi T, Kashiwagi S, Toyokawa Y, et al
    Assessment of endoscopic mucosal healing of ulcerative colitis using linked colour imaging, a novel endoscopic enhancement system.
    J Crohns Colitis. 2017 Feb 22. doi: 10.1093.
    PubMed     Abstract available


  739. DANESE S, Bonovas S, Peyrin-Biroulet L
    Budesonide MMX Add-on to 5-Aminosalicylic Acid Therapy in Mild-to-Moderate Ulcerative Colitis: A Favourable Risk-Benefit Profile.
    J Crohns Colitis. 2017 Feb 21. doi: 10.1093.
    PubMed    


  740. UZZAN M, Kirchgesner J, Oubaya N, Amiot A, et al
    Risk of rectal neoplasia after colectomy and ileorectal anastomosis for ulcerative colitis.
    J Crohns Colitis. 2017 Feb 21. doi: 10.1093.
    PubMed     Abstract available


  741. ROSARIO M, French JL, Dirks NL, Sankoh S, et al
    Exposure-Efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.
    J Crohns Colitis. 2017 Feb 17. doi: 10.1093.
    PubMed     Abstract available


  742. RUIZ DE MORALES JG, Munoz F, Hernando M
    Successful treatment of Common Variable Immunodeficiency-associated inflammatory bowel disease with Ustekinumab.
    J Crohns Colitis. 2017 Feb 17. doi: 10.1093.
    PubMed    


  743. TAXONERA C, Ponferrada A, Bermejo F, Riestra S, et al
    Early Tuberculin Skin Test for the Diagnosis of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease.
    J Crohns Colitis. 2017 Feb 17. doi: 10.1093.
    PubMed     Abstract available


  744. LYKOURAS D, Karkoulias K, Triantos C
    Physical Exercise in Patients With Inflammatory Bowel Disease.
    J Crohns Colitis. 2017 Feb 10. doi: 10.1093.
    PubMed    


  745. MAGRO F, Gionchetti P, Eliakim R, Ardizzone S, et al
    Third European Evidence-Based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders.
    J Crohns Colitis. 2017 Feb 2. doi: 10.1093.
    PubMed    


  746. VAN RHEENEN PF, Aloi M, Biron IA, Carlsen K, et al
    European Crohn's and Colitis Organisation Topical Review on Transitional Care in Inflammatory Bowel Disease.
    J Crohns Colitis. 2017 Feb 2. doi: 10.1093.
    PubMed    


  747. DE VRIES L, Wildenberg M, de Jonge W, D'Haens G, et al
    The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease.
    J Crohns Colitis. 2017 Feb 2. doi: 10.1093.
    PubMed    


  748. ONIDI FM, Mocci G, Cabras F
    N814 Improvement in the treatment and management of patients affected by inflammatory bowel disease: hepatitis B and vaccination status.
    J Crohns Colitis. 2017;11.
    PubMed    


  749. SHAH SC, Khalili H, Gower-Rousseau C, Olen O, et al
    P734 The sex ratio of inflammatory bowel disease varies according to age at onset: results from a worldwide survey.
    J Crohns Colitis. 2017;11.
    PubMed    


  750. SILVA RP, Bissoli GC, Farinelli E, Sibia CF, et al
    N811 Infliximab versus adalimumab: clinical and endoscopy response in ulcerative colitis patients. A prospective study.
    J Crohns Colitis. 2017;11.
    PubMed    


  751. MANCENIDO MARCOS N, Pajares Villarroya R, Salinas Moreno S, Arribas Lomicronpez MR, et al
    P697 Association of inflammatory bowel disease and celiac disease. Experience in a hospital of the autonomous community of Madrid (Spain).
    J Crohns Colitis. 2017;11.
    PubMed    


  752. HIRANO A, Umeno J, Shibata H, Kitazono T, et al
    P784 A comparison study of the mucosa-associated microbiota between inflamed and non-inflamed sites in ulcerative colitis patients.
    J Crohns Colitis. 2017;11.
    PubMed    


  753. PONCE-ALONSO M, Garcia-Fernandez S, Aguilera L, Rodriguez-de-Santiago E, et al
    P782 A new compatibility test for donor selection for faecal microbiota transplantation in ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed    


  754. BASTON I, Sueiro R, Uribarri L, Ferreiro R, et al
    P785 Association of Bacteroidetes with endoscopic activity in patients with inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed    


  755. RICANEK P, Rahul K, Ber Y, Vatn S, et al
    P788 Microbiota related disease activity and distribution in subgroups of inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed    


  756. RIVERA SEQUEIROS A, Gil Garcia E, Chillomicronn Martinez R
    N800 Statistical comparison of predictors of quality of life in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed    


  757. SLADEK M, Vultaggio A, Ghione S, Nencini F, et al
    P661 Comparable clinical efficacy, safety and immunogenicity of infliximab biosimilar (CT-P13) after transition from reference infliximab (Remicade(R)) in children with established inflammatory bowel disease: a multi-centre prospective observational s
    J Crohns Colitis. 2017;11.
    PubMed    


  758. HELLSTROM PM, Stalhammar J, Beydogan H, Huetson P, et al
    P735 Indirect burden of patients with moderate inflammatory bowel disease in Uppsala County Council, Sweden: a retrospective study using real-world data.
    J Crohns Colitis. 2017;11.
    PubMed    


  759. ISHIKAWA D, Takahashi M, Haga K, Shibuya T, et al
    P766 Combination therapy of fresh fecal microbial transplantation and antibiotics for ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed    


  760. DING NS, Yazdanian B, Bettenworth D, Cleynen I, et al
    P738 Assessing aCCess to investigations in IBD (ACCID) - results from an international inflammatory bowel disease survey.
    J Crohns Colitis. 2017;11.
    PubMed    


  761. FONSECA CAMARILLO G, Iturriaga Goyon E, Yamamoto Furusho JK
    P765 Transcriptome of intestinal epithelial barrier genes in the colonic mucosa from patients with ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed    


  762. BORREN N, Tan W, Andrews E, Khalili H, et al
    P704 The impact of travel distance on disease outcomes in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed    


  763. SIBIA CF, Silva RP, Ariede JR, Severino FE, et al
    P760 microRNA expression profiling of inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed    


  764. JELAKOVIC M, Brinar M, Turk N, Prijic R, et al
    P747 Extracolonic and colonic cancer risk in patients with ulcerative colitis and primary sclerosing cholangitis.
    J Crohns Colitis. 2017;11.
    PubMed    


  765. FRAGAKI M, Bachlitzanaki M, Karmiris K, Theodoropoulou A, et al
    P709 inflammatory bowel disease and colorectal cancer: analysis of a single center retrospective chart review.
    J Crohns Colitis. 2017;11.
    PubMed    


  766. CROWLEY E, Elkadri A, Warner N, Zhang S, et al
    P754 X-linked inhibitor of apoptosis protein genetic variants in paediatric-onset inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed    


  767. FONSECA CAMARILLO G, Iturriaga Goyon E, Yamamoto Furusho JK
    P762 Gene expression profiling of immune adaptive response in the colonic mucosa from patients with ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed    


  768. DIBLEY L, Williams E, Young P, Ironside P, et al
    N798 Kinship stigma in community-dwelling people with inflammatory bowel disease: family acknowledgement matters.
    J Crohns Colitis. 2017;11.
    PubMed    


  769. RASMUSSEN M, Brynskov J, Ainsworth MA, Buhl S, et al
    P584 A role for therapeutic drug-monitoring during infliximab induction treatment in inflammatory bowel disease?
    J Crohns Colitis. 2017;11.
    PubMed    


  770. GOMPERTZ M, Alfaro I, Ricart E, Lomicronpez A, et al
    P679 Infliximab biosimilar CT-P13 in inflammatory bowel disease patients that require intensification treatment.
    J Crohns Colitis. 2017;11.
    PubMed    


  771. FIORINO G, Ruiz-Aguello MB, Maguregui A, Nagore D, et al
    P633 Antibodies to infliximab in patients treated with either the reference biologic or the biosimilar CT-P13 show identical reactivity towards biosimilars CT-P13 and SB2 in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed    


  772. GARCIA ORTIZ JM, Saenz Gallo M, Trigo Salado C, De La Cruz Ramirez MD, et al
    P634 Long term risk of relapse after anti-TNF discontinuation based on mucosal healing in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed    


  773. SANDBORN W, Sakuraba A, Wang A, Macaulay D, et al
    P676 Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States.
    J Crohns Colitis. 2017;11.
    PubMed    


  774. MOLNAR T, Farkas K, Rutka M, Ferenci T, et al
    P675 Infliximab biosimilar CT-P13 therapy is effective in maintaining clinical remission in Crohn's disease and ulcerative colitis - 54 week data.
    J Crohns Colitis. 2017;11.
    PubMed    


  775. CHAO CY, Lemieux C, Afif W, Bitton A, et al
    P677 Impact of patient reported outcomes, coping strategies and psychosocial factors on medication adherence in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed    


  776. RODRIGUEZ GLEZ GE, Diaz Hernandez L, Morales Barrios JA, Vela Gonzalez M, et al
    P629 Efficacy, safety and economic impact of the switch to biosimilar of infliximab in inflammatory bowel disease patients in clinical practice: results of one year.
    J Crohns Colitis. 2017;11.
    PubMed    


  777. DE VILLE DE GOYET L, Moreels T, Denis MA, De Vroey B, et al
    P732 Clinical characteristics of inflammatory bowel disease in Belgian immigrants from Moroccan and Caucasian origin.
    J Crohns Colitis. 2017;11.
    PubMed    


  778. ROSEIRA J, Tavares de Sousa H, Marreiros A, Estevens D, et al
    P723 SexIDI study - sexual satisfaction in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed    


  779. MYRELID P, Landerholm K, Nordenvall C, Pinkney TD, et al
    P724 Appendectomy is not a treatment option for ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed    


  780. DERWA Y, Gracie DJ, Williams CJ, Sood R, et al
    P655 A study to determine factors affecting clinical decision making in outpatients with inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed    


  781. RIVIERE P, Laharie D, Zerbib F, Poullenot F, et al
    P680 Quality of sex life in patients with inflammatory bowel disease: the gastroenterologists' perspective.
    J Crohns Colitis. 2017;11.
    PubMed    


  782. MCGOWAN M, Kokkorou M, Rebull M, Koh Y, et al
    P587 Fermentation capacity of gut microbiota in patients with inflammatory bowel disease compared to healthy controls.
    J Crohns Colitis. 2017;11.
    PubMed    


  783. AKSAN A, Isik H, Radeke HH, Dignass A, et al
    P620 Network meta-analysis of efficacy and safety of different intravenous iron compounds for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed    


  784. HUGUET M, Pereira B, Goutte M, Goutorbe F, et al
    P628 Anti-TNF therapy in refractory pouchitis and Crohn's disease-like complications of the pouch after ileal pouch-anal anastomosis following colectomy for ulcerative colitis: a systematic review and meta-analysis.
    J Crohns Colitis. 2017;11.
    PubMed    


  785. PENA-SANCHEZ JN, Lix LM, Teare GF, Li W, et al
    P725 The impact of an integrated model of care for patients with inflammatory bowel disease in Canada.
    J Crohns Colitis. 2017;11.
    PubMed    


  786. EL-MATARY W, Deora V
    P651 Barriers to clinical research in children with inflammatory bowel disease: the patients' perspective.
    J Crohns Colitis. 2017;11.
    PubMed    


  787. SUTTON R, Wierstra K, Ambrosio L, Dieleman L, et al
    P552 An online educational portal improves concerns of inflammatory bowel disease patients regarding pregnancy and medication.
    J Crohns Colitis. 2017;11.
    PubMed    


  788. SCHREIBER S, Dignass A, Peyrin-Biroulet L, Hather G, et al
    P466 Real world effectiveness of vedolizumab over one year in inflammatory bowel disease: a meta-analysis.
    J Crohns Colitis. 2017;11.
    PubMed    


  789. KIM KO, Jang BI, Koo EJ, Kang MK, et al
    P657 The predictors and clinical outcomes of follow up loss of clinics in patients with inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed    


  790. KOO JS, Kim DJ, Lee DW, Jeen YJ, et al
    P604 Usefulness of stool hemoglobin and fecal calprotectin for detecting of mild to moderate ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed    


  791. FIORINO G, Ametzazurra A, Nagore D, Hernandez AM, et al
    P605 Rapid detection of anti-infliximab antibodies in inflammatory bowel disease patients treated with the reference biologic or the biosimilar CT-P13: performance comparison with ELISA.
    J Crohns Colitis. 2017;11.
    PubMed    


  792. TANAKA T, Goishi H, Kajihara T, Akagi M, et al
    P518 Remission induction in corticosteroid naive children and adolescents with ulcerative colitis by adsorptive leucocytapheresis as monotherapy or in combination with low dose prednisolone after failure of first-line medications.
    J Crohns Colitis. 2017;11.
    PubMed    


  793. YLISAUKKO-OJA T, Eberl A, Aaltonen J, Nuutinen H, et al
    P515 Evaluation of treatment persistence of vedolizumab among Finnish inflammatory bowel disease patients in real-life clinical practice (FINVEDO).
    J Crohns Colitis. 2017;11.
    PubMed    


  794. RASMUSSEN M, Brynskov J, Ainsworth MA, Buhl S, et al
    P643 Therapeutic thresholds for infliximab trough levels during maintenance treatment in patients with inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed    


  795. YAMAMOTO T, Tanaka T, Yokoyama T, Shimoyama T, et al
    P540 Efficacy of granulocyte and monocyte apheresis for antibiotic-refractory pouchitis after proctocolectomy for ulcerative colitis: an open-label, prospective, multicentre study.
    J Crohns Colitis. 2017;11.
    PubMed    


  796. KANG B, Lee K, Choe YH
    P542 Long-term outcomes after switching from originator infliximab to biosimilar in paediatric-onset inflammatory bowel disease patients: a single centre prospective observational study.
    J Crohns Colitis. 2017;11.
    PubMed    


  797. LITTLE R, Taylor K, Friedman A, Headon B, et al
    P609 A treat-to-target approach via a virtual clinic amongst inflammatory bowel disease patients with secondary loss of response to anti-TNF therapy improves clinical outcomes.
    J Crohns Colitis. 2017;11.
    PubMed    


  798. NORTON C, Czuber-Dochan W, Artom M, Sweeney L, et al
    P555 Systematic review of interventions for chronic abdominal pain management in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed    


  799. SAIBENI S, Bezzio C, Armuzzi A, Bossa F, et al
    P652 Unmet needs of physicians managing inflammatory bowel disease. A Survey of the Italian Group for Inflammatory Bowel Disease (IG-IBD).
    J Crohns Colitis. 2017;11.
    PubMed    


  800. GREWAL CS, Sood A, Mehta V, Kaur D, et al
    P596 FMT in patients with steroid dependant ulcerative colitis a single centre observational study.
    J Crohns Colitis. 2017;11.
    PubMed    


  801. NARULA N, Borges L, Steinhart AH, Colombel JF, et al
    P415 Trends in narcotic and corticosteroid prescriptions in patients with inflammatory bowel disease in the United States ambulatory care setting from 2003 to 2011.
    J Crohns Colitis. 2017;11.
    PubMed    


  802. YOKOYAMA K, Kawagishi K, Kobayashi K, Koizumi W, et al
    P570 Current status of the effectiveness of infliximab in patients with ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed    


  803. MANOSA M, Corrales G, Olivares D, Vicuna M, et al
    P480 Characteristics of drug-induced lupus 2 degrees to anti-TNF agents in inflammatory bowel disease patients and evolution after switch to a second anti-TNF.
    J Crohns Colitis. 2017;11.
    PubMed    


  804. GULATI S, Emmanuel A, Burt M, Hayee B, et al
    P535 Outcomes of endoscopic resections of large non-polypoid lesions inflammatory bowel disease: a single United Kingdom centre experience.
    J Crohns Colitis. 2017;11.
    PubMed    


  805. WALJEE A, Liu B, Sauder K, Zhu J, et al
    P361 Machine learning models at week 6 of vedolizumab therapy for ulcerative colitis can predict week 52 corticosteroid free endoscopic remission.
    J Crohns Colitis. 2017;11.
    PubMed    


  806. PROTIC M, Seibold F, Manser C, Frei P, et al
    P569 Sequential rescue treatments in steroid refractory ulcerative colitis: two-year follow-up.
    J Crohns Colitis. 2017;11.
    PubMed    


  807. KOLAR M, Duricova D, Bortlik M, Hruba V, et al
    P532 Biosimilar infliximab in anti-TNF naive inflammatory bowel disease patients - one-year clinical follow-up.
    J Crohns Colitis. 2017;11.
    PubMed    


  808. SPIZZO P
    P556 Female Crohn's disease patients and ulcerative colitis patients on biologic therapy are most disabled.
    J Crohns Colitis. 2017;11.
    PubMed    


  809. BRYANT R, Costello S, Schoeman S, Sathananthan D, et al
    P577 "Treat to target" recommendations in ulcerative colitis in practice: clinician perceptions and potential barriers.
    J Crohns Colitis. 2017;11.
    PubMed    


  810. YE L, Liu J, Lin Z, Cao Q, et al
    P568 Does infliximab therapy increase incidence of tuberculosis in patients with inflammatory bowel disease in an endemic area: a nationwide study from China.
    J Crohns Colitis. 2017;11.
    PubMed    


  811. LOBATON T, Canete F, Teniente A, Cabre E, et al
    P562 Real-life infliximab trough levels among inflammatory bowel disease patients on maintenance therapy: should we redefine therapeutic range based on inflammatory load?
    J Crohns Colitis. 2017;11.
    PubMed    


  812. AMETZAZURRA A, Rivera N, Hernandez AM, Arreba MP, et al
    P503 Rapid point-of-care monitoring of anti-infliximab antibodies in patients with inflammatory bowel disease treated with the reference infliximab or CT-P13 in routine clinical practice.
    J Crohns Colitis. 2017;11.
    PubMed    


  813. YADAV A, Forry M, O'Toole A, Patchett S, et al
    P520 Perspective and self-efficacy of adolescents with inflammatory bowel disease post transition to adult care.
    J Crohns Colitis. 2017;11.
    PubMed    


  814. BERNARDO S, Fernandes S, Goncalves AR, Baldaia C, et al
    P453 Efficacy of therapeutic drug monitoring of anti-TNF therapy in the control of patients with inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed    


  815. ESTEVEZ-GIL M, De Castro ML, Hernandez V, Pineda JR, et al
    P455 Clinical features of tuberculosis infection in inflammatory bowel disease patients on anti-TNF therapy.
    J Crohns Colitis. 2017;11.
    PubMed    


  816. CARMAN N, Huynh H, Walsh CM, Ricciuto A, et al
    P450 Reliability assessment of endoscopic scoring tools using central video review of colonoscopies in paediatric patients with ulcerative colitis: data from the Canadian Children IBD Network.
    J Crohns Colitis. 2017;11.
    PubMed    


  817. PITUCH-ZDANOWSKA A, Stawicka A, Jarocka-Cyrta E, Banaszkiewicz A, et al
    P346 Dietary practices and beliefs among parents of children with inflammatory bowel disease: preliminary results.
    J Crohns Colitis. 2017;11.
    PubMed    


  818. HAZEL K, Forry M, Patchett S, O'Toole A, et al
    P371 Healthcare maintenance in inflammatory bowel disease patients: need for a top down approach.
    J Crohns Colitis. 2017;11.
    PubMed    


  819. SAIBENI S, Bezzio C, Armuzzi A, Bossa F, et al
    P574 Limitations and difficulties in using anti-TNF-alpha agents in inflammatory bowel disease. A survey of the Italian Group for Inflammatory Bowel Disease (IG-IBD).
    J Crohns Colitis. 2017;11.
    PubMed    


  820. HEIDA A, Knol M, Muller Kobold A, Dijkstra G, et al
    P374 Home or hospital-based analysis of stool calprotectin: assessing two methods for monitoring inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed    


  821. SOUSA P, Martins D, Pinho J, Cancela E, et al
    P284 Ulcerative colitis - presentation during pregnancy or puerperium.
    J Crohns Colitis. 2017;11.
    PubMed    


  822. AL KHOURY A, Chao CY, Aruljothy A, Wyse J, et al
    P495 Intensified infliximab rescue therapy for acute severe ulcerative colitis does not improve long term colectomy-free survival.
    J Crohns Colitis. 2017;11.
    PubMed    


  823. BALABAN DV, Popp A, Robu G, Bucurica S, et al
    P323 Fatty liver assessment in inflammatory bowel disease patients using controlled attenuation parameter.
    J Crohns Colitis. 2017;11.
    PubMed    


  824. MELLOTTE G, McShane C, O'Connell J, Mc Kiernan S, et al
    P491 Comparison of the durability of response to subcutaneous anti-TNF therapy between ulcerative colitis and Crohn's disease.
    J Crohns Colitis. 2017;11.
    PubMed    


  825. FUH F, Tew W, Keir M, Looney C, et al
    P431 Colonic Treg levels are reduced in patients with ulcerative colitis achieving clinical remission, but are not differentially affected by etrolizumab dose.
    J Crohns Colitis. 2017;11.
    PubMed    


  826. PUGLIESE D, Armuzzi A, Panici Tonucci T, Tolusso B, et al
    P440 Therapeutic drug monitoring of infliximab for the management of loss of response in inflammatory bowel disease: an observational multicenter study.
    J Crohns Colitis. 2017;11.
    PubMed    


  827. SIECZKOWSKA-GOLUB J, Jarzebicka D, Borys-Iwanicka A, Korlatowicz-Bilar A, et al
    P504 Differences between paediatric and adult inflammatory bowel disease presentation - analysis based on the data from multicenter, prospective cohort observational study assessing safety of anti-TNF therapy - Satimos study.
    J Crohns Colitis. 2017;11.
    PubMed    


  828. TRAVIS S, Feagan B, Peyrin-Biroulet L, Panaccione R, et al
    P329 Effect of adalimumab dose escalation on clinical, health-related quality of life, treatment satisfaction and work productivity outcomes among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA.
    J Crohns Colitis. 2017;11.
    PubMed    


  829. ORLANDINI B, Dragoni G, Bagnoli S, Deiana S, et al
    P407 Prospective evaluation of clinical efficacy and safety of golimumab in biologic experienced and naive patients with moderate to severe ulcerative colitis: experience from a tertiary referral centre.
    J Crohns Colitis. 2017;11.
    PubMed    


  830. GHOSH S, Peyrin-Biroulet L, Sensky T, Casellas F, et al
    P359 Correlation between physician and patient disease assessments in ulcerative colitis: baseline data from the ICONIC study of 1816 patients in 33 countries.
    J Crohns Colitis. 2017;11.
    PubMed    


  831. MARSHALL JK, Marrache AM, Ewara E
    P383 Increasing treatment time on REMICADE(R) (infliximab) predicts subsequent long-term retention in stable infliximab inflammatory bowel disease patients in Canada.
    J Crohns Colitis. 2017;11.
    PubMed    


  832. PEREZ-PAMPIN E, Ferreiro R, Lorenzo A, Mera A, et al
    P285 Usefulness of a multidisciplinary approach combining both rheumatology and gastroenterology for the assessment and treatment of inflammatory bowel disease patients.
    J Crohns Colitis. 2017;11.
    PubMed    


  833. MULCAHY H, Wynne B, McHugh L, Rowan C, et al
    P370 A randomised controlled trial of acceptance and commitment therapy for the treatment of stress in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed    


  834. ZAMBORSKY T, Berakova K, Kadleckova B, Podmanicky D, et al
    P339 MadCAM1 expression in intestinal lamina propria endothelium varies among inflammatory bowel disease patients.
    J Crohns Colitis. 2017;11.
    PubMed    


  835. PARRA RS, Feitosa MR, Feres O, Rocha JJ, et al
    P424 Association between infliximab trough levels, clinical remission, mucosal healing and quality of life in patients with inflammatory bowel disease on maintenance therapy.
    J Crohns Colitis. 2017;11.
    PubMed    


  836. MANTAKA A, Renieri V, Koutroubakis I
    P340 Prevalence and long-term effect of antiplatelet use in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed    


  837. KEETARUT K, Bloom S, Qu X, Grimble G, et al
    P376 Assessment of nutritional status and food related experience of adult inflammatory bowel disease inpatients.
    J Crohns Colitis. 2017;11.
    PubMed    


  838. OGASHIWA T, Nishio M, Otake H, Inoue E, et al
    P337 Efficacy of intravenous cyclosporine in fulminant steroid-refractory ulcerative colitis with massive bleeding: a retrospective, observational study.
    J Crohns Colitis. 2017;11.
    PubMed    


  839. MORTIER K, Arnott I, Russell RK
    P333 Changing patterns of biological therapy use with the introduction of biosimilars in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed    


  840. GUBATAN JM, Mitsuhashi S, Longhi MS, Zenlea T, et al
    P344 Vitamin D-Induced alterations in Cytokine levels lower the risk of clinical relapse in ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed    


  841. YANG HR, Cho JM
    P237 Hair mineral and trace element contents as reliable markers of nutritional status compared to serum levels in children with inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed    


  842. KIM M
    P399 Adverse events associated with azathioprine treatment in Korean pediatric inflammatory bowel disease patients.
    J Crohns Colitis. 2017;11.
    PubMed    


  843. LEVINE A, Yerushalmi B, Kori M, Broide E, et al
    P409 Mesalamine enemas for induction of remission in pediatric ulcerative colitis refractory to oral mesalamine: a prospective cohort study.
    J Crohns Colitis. 2017;11.
    PubMed    


  844. COHEN S, Martinez-Vinson C, Aloi M, Turner D, et al
    P302 Cytomegalovirus infection in pediatric acute severe ulcerative colitis - a multicenter case-controlled study from the Pediatric IBD Porto group of ESPGHAN.
    J Crohns Colitis. 2017;11.
    PubMed    


  845. COHEN I, Benyamini Y, Tulchinsky H, Dotan I, et al
    P300 Illness perceptions and coping with health-related quality of life in patients with inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed    


  846. MEGLICKA M, Szczepanski M, Bierla J, Dadalski M, et al
    P265 Comparison of two faecal calprotectin assays in monitoring children with inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed    


  847. PITTET V, Maillard MH, Rogler G, Michetti P, et al
    P298 Comparison between clinical and patient-reported symptoms among Crohn's disease and ulcerative colitis patients.
    J Crohns Colitis. 2017;11.
    PubMed    


  848. WILLIET N, Nancey S, Boureille A, Altwegg R, et al
    P310 Development of a new clinico-biological score associated with disease activity in patients with inflammatory bowel disease treated with thiopurine.
    J Crohns Colitis. 2017;11.
    PubMed    


  849. GONZALEZ-LOPEZ J, Giraldez-Montero JM, Ferreiro R, Lorenzo A, et al
    P280 Therapeutic drug monitoring of infliximab and adalimumab for detection of patients at risk of loss of response in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed    


  850. MAJOROVA E, Susterova I, Kolarcik P, Fandakova I, et al
    P247 Fungal infections in children with inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed    


  851. LIMSRIVILAI J, Stidham RW, Govani S, Waljee A, et al
    P303 Gastrointestinal infectious agents detected by Biofire FilmArray GI PCR panel stool testing in active inflammatory bowel disease are common and associated with a more benign course of IBD.
    J Crohns Colitis. 2017;11.
    PubMed    


  852. FERREIRA J, Thomas S, Tomer G
    P334 Medication adherence in diverse inner city pediatric patients with inflammatory bowel disease and comparison to physician perception of adherence.
    J Crohns Colitis. 2017;11.
    PubMed    


  853. YI F
    P286 Evaluation of fecal S100A12 in patients with inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed    


  854. BUDZYNSKA A, Nowakowska-Dulawa E, Gawron-Kiszka M, Spiewak J, et al
    P189 Serum neutrophil gelatinase-associated lipocalin correlates with Mayo Clinic score in ulcerative colitis but fails to predict activity in Crohn's disease.
    J Crohns Colitis. 2017;11.
    PubMed    


  855. LORES T, Goess C, Hrycek C, Grafton R, et al
    P238 Mental health issues and healthcare utilisation in outpatients with inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed    


  856. ADMYRE C, Zargari A, Atreya R, Knittel T, et al
    P080 IL-10 induction properties of the TLR-9 agonist cobitolimod - a candidate for treatment of active ulcerative colitis in late stage of clinical development.
    J Crohns Colitis. 2017;11.
    PubMed    


  857. LEE SH, Seo H, Chang K, Song EM, et al
    P148 Fecal calprotectin as a noninvasive indicator for ulcerative colitis disease activity in the Korean cohort.
    J Crohns Colitis. 2017;11.
    PubMed    


  858. SMIDS C, Horjus Talabur Horje C, Groenen M, van Koolwijk E, et al
    P313 Glycan antibodies and pANCA in newly diagnosed inflammatory bowel disease patients at presentation and during follow-up.
    J Crohns Colitis. 2017;11.
    PubMed    


  859. PAUL S, Duru G, De Vries A, Marini JC, et al
    P226 Comparison of four different immunoassays for measuring golimumab and anti-golimumab antibody concentration in patients with ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed    


  860. HICKS L, Powles S, Swann J, Chong L, et al
    P182 Assessing the effect of ethnicity on urinary metabolic profiles in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed    


  861. CHAPARRO M, Barreiro-de Acosta M, Echarri A, Almendros R, et al
    P186 Association between anti-TNF serum levels and mucosal healing in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed    


  862. BOUTALEB A, Saoula H, Aissaoui M, Hamidouche D, et al
    P206 Celiac disease and inflammatory bowel disease, a rare association.
    J Crohns Colitis. 2017;11.
    PubMed    


  863. BITTL M, Petersen F, Maaser C, Rath S, et al
    P171 Reliable assessment of ultrasound parameters during transabdominal ultrasonography in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed    


  864. WEI SC, Shih IL, Lin BR, Yen RF, et al
    P199 PET/MR for evaluating subclinical inflammation of ulcerative colitis in remission.
    J Crohns Colitis. 2017;11.
    PubMed    


  865. ZHANG W, Teng G, Wang H, Tian Y, et al
    P166 Decreased expression of elafin in peripheral blood and intestinal mucosa in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed    


  866. ZAMBRANO PEREZ A, Shergill-Bonner R, Kiparissi F, Acton N, et al
    P219 Inflammatory bowel disease in children is a challenging diagnosis when overlaps with coeliac disease.
    J Crohns Colitis. 2017;11.
    PubMed    


  867. OHTA Y, Taida T, Nakagawa T, Hamanaka S, et al
    P231 Backgrounds and D-dimer on admission are useful factors for predicting venous thromboembolic complications in hospitalized patients with inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed    


  868. UDUPA V, Baird A, Winter D
    P109 Profiling of receptor for advanced glycation end products expression in cases of primary sclerosing cholangitis with ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed    


  869. FONSECA CAMARILLO G, Furuzawa Carballeda J, Iturriaga Goyon E, Yamamoto Furusho JK, et al
    P042 Expression of IL-38 and their antagonists in patients with inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed    


  870. LOMICRONPEZ-SERRANO A, Paredes JM, Polanco A, Garcia C, et al
    P224 Virtual chromoendoscopy with i-Scan as alternative to dye-spray chromoendoscopy for dysplasia detection in long-standing colonic inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed    


  871. TEIXEIRA C, Martins C, Ribeiro S, Trabulo D, et al
    P137 Ulcerative colitis in the elderly - Different disease course?
    J Crohns Colitis. 2017;11.
    PubMed    


  872. ZARGARI A, Admyre C, Knittel T
    P106 Binding properties of human TLR-9 receptor to cobitolimod - a candidate for treatment of active ulcerative colitis in late stage of clinical development.
    J Crohns Colitis. 2017;11.
    PubMed    


  873. CHAO K, Zhu X, Cao Q, Yang H, et al
    P096 Combined detection variants of NUDT15 could highly predict thiopurine-induced leukopenia in Chinese patients with inflammatory bowel disease: a multi-center analysis.
    J Crohns Colitis. 2017;11.
    PubMed    


  874. TAIDA T, Nakagawa T, Fujie M, Ohta Y, et al
    P159 Real-time endoscopic-guided measurement of rectal mucosal admittance: a novel and safety method for prediction of relapse in ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed    


  875. ROTTOLI M, Vallicelli C, Bigonzi E, Di Simone M, et al
    DOP041 Prepouch ileitis after ileal pouch anal anastomosis for ulcerative colitis: patterns of presentation and risk factors for failure of treatment.
    J Crohns Colitis. 2017;11.
    PubMed    


  876. CARMAN N, Huynh H, Mouzaki M, Crowley E, et al
    DOP072 Assessment of the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) using central video review of colonoscopies in paediatric patients with ulcerative colitis: data from the Canadian Children IBD Network.
    J Crohns Colitis. 2017;11.
    PubMed    


  877. ATREYA R, Kuhbacher T, Waldner MJ, Hirschmann S, et al
    DOP073 Submucosal injection of the oligonucleotide STNM01 is able to induce clinical remission, mucosal healing and histological response in left-sided ulcerative colitis patients with moderate-to-severe disease.
    J Crohns Colitis. 2017;11.
    PubMed    


  878. BORREN N, Goel G, Lassen K, Devaney K, et al
    P023 Fatigue in quiescent inflammatory bowel disease is associated with low GM-CSF levels and metabolomic alterations.
    J Crohns Colitis. 2017;11.
    PubMed    


  879. VANDE CASTEELE N, Jairath V, Levesque B, Feagan B, et al
    DOP033 Severely active ulcerative colitis is associated with high baseline infliximab clearance, reduced serum half-life and worse endoscopic outcomes.
    J Crohns Colitis. 2017;11.
    PubMed    


  880. GAGNIERE C, Bourrier A, Seksik P, Gornet JM, et al
    DOP011 Risk of opportunistic infection in healthcare personnel with inflammatory bowel disease: a case-control study of the GETAID.
    J Crohns Colitis. 2017;11.
    PubMed    


  881. COSTELLO S, Waters O, Bryant R, Katsikeros R, et al
    OP036 Short duration, low intensity pooled faecal microbiota transplantation induces remission in patients with mild-moderately active ulcerative colitis: a randomised controlled trial.
    J Crohns Colitis. 2017;11.
    PubMed    


  882. SPEKHORST L, Severs M, de Boer NK, Festen EA, et al
    DOP004 Ethnicity and country of birth are associated with phenotypic differences in patients with inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed    


  883. DULAI P, Buckey J, Raffals L, Swoger J, et al
    OP021 Hyperbaric oxygen therapy is safe and effective for hospitalized ulcerative colitis patients suffering from moderate-severe flares: a multi-center, randomized, double-blind, sham-controlled trial.
    J Crohns Colitis. 2017;11.
    PubMed    


  884. BURISCH J, Vind I, Prosberg M, Colombel JF, et al
    DOP003 Proximal disease extension in patients with limited ulcerative colitis: a Danish population-based inception cohort.
    J Crohns Colitis. 2017;11.
    PubMed    


  885. BOTS S, Hoekman D, Benninga M, Ponsioen C, et al
    DOP017 Patterns of anti-TNF use and associated treatment outcomes in inflammatory bowel disease patients: results from an analysis of Dutch health insurance claims data.
    J Crohns Colitis. 2017;11.
    PubMed    


  886. IQBAL T, Beggs A, Taniere P, Wallis Y, et al
    OP002 Epigenetic biomarkers to detect ulcerative colitis-associated neoplasia: results from phase I of the ENDCAP-C study.
    J Crohns Colitis. 2017;11.
    PubMed    


  887. SACLEUX SC, Charpentier C, Sarter H, Fumery M, et al
    DOP045 Post-operative complications in elderly-onset inflammatory bowel disease: a population-based study.
    J Crohns Colitis. 2017;11.
    PubMed    


  888. SANDBORN WJ, Cyrille M, Hansen MB, Feagan BG, et al
    OP034 Efficacy and safety of abrilumab in subjects with moderate to severe ulcerative colitis: results of a phase 2b, randomised, double-blind, multiple-dose, placebo-controlled study.
    J Crohns Colitis. 2017;11.
    PubMed    


  889. DE FRANCISCO R, Riestra S, Perez-Martinez I, Castano A, et al
    DOP012 Impact on clinical practice of Epstein-Barr virus infection in patients with inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed    


  890. SIGALL BONEH R, Levine A, Lomer M, Wierdsma N, et al
    DOP006 Research gaps in diet and nutrition in inflammatory bowel disease. A topical review by ECCO.
    J Crohns Colitis. 2017;11.
    PubMed    


  891. DE JONG M, van der Meulen-de Jong A, Romberg-Camps M, Becx M, et al
    OP017 Telemedicine enables a safe shift from examination room based care to personalised care for inflammatory bowel disease: a pragmatic randomised multicenter trial with myIBDcoach.
    J Crohns Colitis. 2017;11.
    PubMed    


  892. SANDBORN W, Feagan B, D'Haens G, Levesque B, et al
    OP014 Histological remission is predictive of improved clinical outcomes in patients with ulcerative colitis: results from the TOUCHSTONE open-label extension.
    J Crohns Colitis. 2017;11.
    PubMed    


  893. STALLMACH A, Bokemeyer B, Axler J, Curtis R, et al
    DOP026 Sustained remission with vedolizumab in patients with moderately to severely active ulcerative colitis: a GEMINI 1 post hoc analysis of week 14 remitters.
    J Crohns Colitis. 2017;11.
    PubMed    


  894. SELLGE G, Papoutsopoulou S, Verdier J, Trautwein C, et al
    DOP049 Inflammatory dyskinesis: defects of NF-kappaB dynamic behaviour as a new potential biomarker for personalized medicine in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed    


  895. MOUTSIANAS L, De Lange K, Luo Y, Lee J, et al
    OP001 Whole genome sequencing and imputation in inflammatory bowel disease identifies 26 novel loci and offers therapeutically-relevant mechanistic insights.
    J Crohns Colitis. 2017;11.
    PubMed    


  896. FARINELLI E, Pagnin AF, Silva RP, Sibia CF, et al
    N817 Epidemiological profile of Crohn's disease and ulcerative colitis in a Brazilian single centre.
    J Crohns Colitis. 2017;11.
    PubMed    


  897. VINAYAGA-PAVAN M, Frampton M, Pontikos N, Levine A, et al
    P758 Elevation in ribosomal and cell cycle gene transcription in macroscopically normal colonic tissue from Icelandic patients with ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed    


  898. OLBJORN C, Cvancarova Smastuen M, Casen C, Nakstad B, et al
    P778 Microbial characterization of paediatric inflammatory bowel disease and stratification into disease severity groups.
    J Crohns Colitis. 2017;11.
    PubMed    


  899. GORDILLO J, Torres P, Garcia-Garcia de Paredes A, Llaomicron J, et al
    P706 Caracterization of de novo inflammatory bowel disease (IBD) diagnosed in immigrants migrating from low to high prevalence areas of IBD: a case-control study.
    J Crohns Colitis. 2017;11.
    PubMed    


  900. BARROS J, Baima J, Renosto F, Sibia C, et al
    NO001 Clinical and psychological factors associated with Erectile Dysfunction in inflammatory bowel disease patients.
    J Crohns Colitis. 2017;11.
    PubMed    


  901. SANROMAN ALVAREZ L, Figueira Alvarez M, De Castro Parga ML, Hernandez Ramirez V, et al
    N801 Patient opinion assessment of a comprehensive clinical tool to improve health-care in inflammatory bowel disease. The Implica-2 project.
    J Crohns Colitis. 2017;11.
    PubMed    


  902. BRANCO JC, Cardoso M, Anapaz V, Lourenco L, et al
    P714 Vitamin D deficiency in inflammatory bowel disease: prevalence and relation to disease activity in a cohort of patients of a Mediterranean country.
    J Crohns Colitis. 2017;11.
    PubMed    


  903. JOHNS K
    N810 Audit of patient satisfaction with telephone reviews for inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed    


  904. SARID O, Slomin-Nevo V, Schwartz D, Friger M, et al
    P749 Impact of psycho-social variables on the activity of inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed    


  905. LIM WC, Lin H
    P660 Prevalence and clinical course of cytomegalovirus colitis in Asian patients with acute exacerbation of ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed    


  906. SILVA RP, Baima JP, Bissoli GC, Farinelli E, et al
    N816 Anti-TNF therapy improves the quality of life in patients with ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed    


  907. MORREALE GC, Calvaruso V, Sanfratello A, Cappello M, et al
    P658 The Inflammatory Bowel Disease Disability Index (IBD-DI) in ulcerative colitis is related to disease activity, need of immunosuppressive therapy and quality of life.
    J Crohns Colitis. 2017;11.
    PubMed    


  908. VAN DEN HEUVEL T, Bijnens E, Verhaegh B, Nawrot T, et al
    P690 Ambient air quality does not affect disease course in inflammatory bowel disease - a population based risk factor analysis using geographic information systems.
    J Crohns Colitis. 2017;11.
    PubMed    


  909. HUH G, Yoon H, Choi YJ, Park YS, et al
    P715 Trends in emergency department visits and hospitalization rates for inflammatory bowel disease: results from a single-center in 2004, 2009 and 2014.
    J Crohns Colitis. 2017;11.
    PubMed    


  910. JUZENAS S, Skieceviciene J, Salteniene V, Kupcinskas J, et al
    P759 MiRNA expression patterns in colon of active and inactive ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed    


  911. PERDIGOTO D, Portela F, Ferreira M, Mendes S, et al
    P600 Infliximab trough levels for remission induction and long term therapy management of inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed    


  912. WEISSHOF R, Aharoni Golan M, Masching A, Rubin DT, et al
    P619 Tofacitinib for the treatment of resistant ulcerative colitis: the University of Chicago experience.
    J Crohns Colitis. 2017;11.
    PubMed    


  913. VANCAMELBEKE M, Sabino J, Deroover L, Vandermeulen G, et al
    P774 Metagenomics and metabolomics of patients with inflammatory bowel disease and their unaffected relatives.
    J Crohns Colitis. 2017;11.
    PubMed    


  914. PASCHOS P, Katsoula A, Giouleme O, Tsapas A, et al
    P662 Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis.
    J Crohns Colitis. 2017;11.
    PubMed    


  915. BROLY F, Fumery M, Vasseur F, Savoye G, et al
    P756 Diagnosing rare inherited disorders using targeted next generation sequencing in patients with early-onset inflammatory bowel disease: a population-based study.
    J Crohns Colitis. 2017;11.
    PubMed    


  916. JUAN G, Alvarino A, Mora M, Oltra L, et al
    P557 Utility of "trough levels" adalimumab determination in patients with inflammatory bowel disease. Estimation of individual pharmacokinetic parameters through population pharmacokinetic model.
    J Crohns Colitis. 2017;11.
    PubMed    


  917. PEERANI F, Chang H, Ungaro R, Torres J, et al
    P705 Peripheral arterial disease is associated with an increased risk of elderly-onset inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed    


  918. OPSTELTEN J, Chan S, Hart A, van Schaik F, et al
    P722 Prediagnostic serum vitamin D levels and risk of inflammatory bowel disease: a pan-European, nested case-control study.
    J Crohns Colitis. 2017;11.
    PubMed    


  919. GOBBO MONTOYA M, Marin-Jimenez I, Panadero A, Modino Y, et al
    P736 Psychological impact of inflammatory bowel disease: differences by gender and age. The ENMENTE Project.
    J Crohns Colitis. 2017;11.
    PubMed    


  920. WILLEMZE R, Bakker T, Pippias M, Ponsioen C, et al
    P716 Beta-blocker use is associated with a higher relapse risk of inflammatory bowel disease - a Dutch retrospective cohort study.
    J Crohns Colitis. 2017;11.
    PubMed    


  921. BURISCH J, Halfvarson J, Kupcinskas L, Hernandez V, et al
    P695 The risk of proximal disease extension in patients with limited ulcerative colitis in a prospective European population-based inception cohort - the ECCO-EpiCom cohort.
    J Crohns Colitis. 2017;11.
    PubMed    


  922. WATTS G, Arasaradnam R, Travis S, Sharma A, et al
    P512 Real world use of adalimumab: effects on corticosteroid treatment and hospital resource utilisation in UK patients with moderate/severe ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed    


  923. KAMPERIDIS N, O'Connor M, Crook K, Arebi N, et al
    P490 A pilot study of the electronic patient portal "Patient Knows Best" for monitoring biologic therapy in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed    


  924. YAMAMOTO T, Shimoyama T, Umegae S
    P497 Impacts of mucosal healing on clinical outcomes in patients with refractory ulcerative colitis on tacrolimus or biologics.
    J Crohns Colitis. 2017;11.
    PubMed    


  925. RUBIN DT, Panes J, Lindsay JO, Vermeire S, et al
    P558 The SF-36(R) Health Survey distinguishes disease burden on functioning and well-being between patients with active vs inactive ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed    


  926. GUERRERO PUENTE LN, Iglesias Flores E, Benitez Cantero JM, Cardenas Aranzana MJ, et al
    P545 Clinical outcomes following a switch from Remicade(R) to the biosimilar CT-P13 in inflammatory bowel disease patients in clinical remission: preliminary results.
    J Crohns Colitis. 2017;11.
    PubMed    


  927. SMITS L, Grelack A, Drenth J, de Jong D, et al
    P663 Switching from Remicade(R) to biosimilar CT-P13 in inflammatory bowel disease patients: one year follow-up of a prospective observational cohort study.
    J Crohns Colitis. 2017;11.
    PubMed    


  928. HUOPONEN S, Eberl A, Rasanen P, Roine RP, et al
    P685 Switching from originator-infliximab to biosimilar-infliximab has no influence on health-related quality of life and clinical disease activity among patients with inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed    


  929. MAKARCHUK P, Belousova E, Volchkova E, Kudriavtseva E, et al
    P517 Features of cytomegalovirus infection in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed    


  930. SAMBUELLI A, Bellicoso M, Negreira S, Goncalves S, et al
    P585 Infliximab in moderate to severe ulcerative colitis: comparison between scheduled treatment strategy and bridge strategy.
    J Crohns Colitis. 2017;11.
    PubMed    


  931. BAKER D, Marshall J, Lee M, Jones G, et al
    P443 Systematic review of internet decision making resources for patients considering surgery for ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed    


  932. CHADOKUFA S, Sider S, Huggett B, Sawney T, et al
    P591 Therapeutic drug monitoring in Paediatric inflammatory bowel disease on maintenance infliximab and adalimumab treatment improves clinical remission with a proactive approach.
    J Crohns Colitis. 2017;11.
    PubMed    


  933. DE BRUYN M, Ringold R, Ferrante M, Van Assche G, et al
    P382 A panel of serum markers for early detection of endoscopic healing with infliximab in patients with ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed    


  934. BOSSA F, Valvano MR, Costantino G, Vinci E, et al
    P621 Efficacy and safety of golimumab in ulcerative colitis. Preliminary data from a multicenter Italian study.
    J Crohns Colitis. 2017;11.
    PubMed    


  935. CAGOL L, Frivolt K, Krahl A, Forster N, et al
    P486 Immunization status of children and adolescents with inflammatory bowel disease or autoimmune hepatitis in Germany.
    J Crohns Colitis. 2017;11.
    PubMed    


  936. LOPETUSO LR, Petito V, Graziani C, Scannone D, et al
    P498 Emerging role of the IL-33/ST2 axis in predicting mucosal response to anti-TNF therapy in ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed    


  937. SANDBORN WJ, Rutgeerts P, Zhang H, Adedokun OJ, et al
    P446 Characterization of ulcerative colitis patients in the Golimumab PURSUIT-Maintenance study: post-hoc analyses of patients who maintained and did not maintain clinical response through week 54.
    J Crohns Colitis. 2017;11.
    PubMed    


  938. KANG B, Choi JY, Lee K, Lee SY, et al
    P755 NUDT15 polymorphism is associated with thiopurine-related leukopenia independently of 6-thioguanine nucleotide levels in Korean paediatric inflammatory bowel disease patients.
    J Crohns Colitis. 2017;11.
    PubMed    


  939. PANES J, Rubin DT, Vermeire S, Lindsay JO, et al
    P467 Maintenance of quality of life improvement in a phase 3 study of tofacitinib for patients with moderately to severely active ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed    


  940. ORDAS I, Domenech E, Aguas M, Fernandez-Banares F, et al
    P607 Post-operative mortality and predictive factors in a cohort of severe refractory ulcerative colitis patients from the ENEIDA Registry (1989-2013): a multicenter nationwide study.
    J Crohns Colitis. 2017;11.
    PubMed    


  941. BEN-HORIN S, Andrews JM, Katsanos KH, Rieder F, et al
    P341 Combination of corticosteroids and 5-aminosalycilates or corticosteroids alone for patients with moderate-severe active ulcerative colitis: a global survey of physicians' practice.
    J Crohns Colitis. 2017;11.
    PubMed    


  942. PAUWELS RW, De Vries AC, Van der Woude CJ
    P447 Vedolizumab induces significantly higher endoscopic remission rates at week 16 in ulcerative colitis as compared to Crohn's disease.
    J Crohns Colitis. 2017;11.
    PubMed    


  943. BASTIDA G, Sargalt L, Garcia V, Mesonero F, et al
    P528 Long-term outcome of ulcerative colitis patients responders to cyclosporine in the biological era.
    J Crohns Colitis. 2017;11.
    PubMed    


  944. DANESE S, Gisbert JP, Lobo AJ, Dignass A, et al
    P328 Patient and physician perspectives on managing iron deficiency with or without anaemia in inflammatory bowel disease: findings from a European online survey.
    J Crohns Colitis. 2017;11.
    PubMed    


  945. THI AA, Bouri S, Wolfson P, Owen L, et al
    P439 Diagnosis and management of latent and active tuberculosis in the context of biologic therapy in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed    


  946. LEFEVRE C, Fotsing G, Wangermez M, Beau P, et al
    P396 Long-term efficacy of thiopurines as maintenance treatment in 130 patients with ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed    


  947. GIONCHETTI P, Dignass A, Danese S, Magro Dias FJ, et al
    3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 2: Surgical Management and Special Situations.
    J Crohns Colitis. 2017;11:135-149.
    PubMed     Abstract available


  948. KIM HJ, Oh SH, Kim DY, Lee HS, et al
    Clinical Characteristics and Long-Term Outcomes of Paediatric Crohn's Disease: A Single-Centre Experience.
    J Crohns Colitis. 2017;11:157-164.
    PubMed     Abstract available


  949. VIRTA LJ, Saarinen MM, Kolho KL
    Inflammatory Bowel Disease Incidence is on the Continuous Rise Among All Paediatric Patients Except for the Very Young: A Nationwide Registry-based Study on 28-Year Follow-up.
    J Crohns Colitis. 2017;11:150-156.
    PubMed     Abstract available


  950. LIGHTNER AL, Raffals LE, Mathis KL, Cima RR, et al
    Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Abdominal Operations for Inflammatory Bowel Disease.
    J Crohns Colitis. 2017;11:185-190.
    PubMed     Abstract available


  951. WILLIET N, Sarter H, Gower-Rousseau C, Adrianjafy C, et al
    Patient-reported Outcomes in a French Nationwide Survey of Inflammatory Bowel Disease Patients.
    J Crohns Colitis. 2017;11:165-174.
    PubMed     Abstract available


  952. HART AL, Lomer M, Verjee A, Kemp K, et al
    What Are the Top 10 Research Questions in the Treatment of Inflammatory Bowel Disease? A Priority Setting Partnership with the James Lind Alliance.
    J Crohns Colitis. 2017;11:204-211.
    PubMed     Abstract available


  953. JAIRATH V, Levesque BG, Vande Casteele N, Khanna R, et al
    Evolving Concepts in Phases I and II Drug Development for Crohn's Disease.
    J Crohns Colitis. 2017;11:246-255.
    PubMed     Abstract available


  954. SUZUKI K, Yokoyama J, Kawauchi Y, Honda Y, et al
    Phase 1 Clinical Study of siRNA Targeting Carbohydrate Sulphotransferase 15 in Crohn's Disease Patients with Active Mucosal Lesions.
    J Crohns Colitis. 2017;11:221-228.
    PubMed     Abstract available


  955. DEVRIESE S, Eeckhaut V, Geirnaert A, Van den Bossche L, et al
    Reduced Mucosa-associated Butyricicoccus Activity in Patients with Ulcerative Colitis Correlates with Aberrant Claudin-1 Expression.
    J Crohns Colitis. 2017;11:229-236.
    PubMed     Abstract available


  956. WRIGHT EK, Kamm MA, Wagner J, Teo SM, et al
    Microbial Factors Associated with Postoperative Crohn's Disease Recurrence.
    J Crohns Colitis. 2017;11:191-203.
    PubMed     Abstract available


  957. LEMMENS B, de Buck van Overstraeten A, Arijs I, Sagaert X, et al
    Submucosal Plexitis as a Predictive Factor for Postoperative Endoscopic Recurrence in Patients with Crohn's Disease Undergoing a Resection with Ileocolonic Anastomosis: Results from a Prospective Single-centre Study.
    J Crohns Colitis. 2017;11:212-220.
    PubMed     Abstract available


  958. KATSANOS KH, Domenech E, Rahier JF, Kopylov U, et al
    Making a Case for Case Reports: The ECCO-CONFER Viewpoint on Investigating Rare Events in a Medical World Reigned by Group-comparative Statistics.
    J Crohns Colitis. 2017;11:256-257.
    PubMed    


  959. WONG DR, Coenen MJ, Vermeulen SH, Derijks LJ, et al
    Early Assessment of Thiopurine Metabolites Identifies Patients at Risk of Thiopurine-induced Leukopenia in Inflammatory Bowel Disease.
    J Crohns Colitis. 2017;11:175-184.
    PubMed     Abstract available


    January 2017
  960. HARBORD M, Eliakim R, Bettenworth D, Karmiris K, et al
    Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management.
    J Crohns Colitis. 2017 Jan 28. doi: 10.1093.
    PubMed    


  961. RAZANSKAITE V, Bettey M, Downey L, Wright J, et al
    Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme.
    J Crohns Colitis. 2017 Jan 27. pii: jjw216. doi: 10.1093.
    PubMed     Abstract available


  962. DANESE S, Fiorino G, Raine T, Ferrante M, et al
    ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update.
    J Crohns Colitis. 2017;11:26-34.
    PubMed    


  963. SHINZAKI S, Matsuoka K, Iijima H, Mizuno S, et al
    Leucine-rich Alpha-2 Glycoprotein is a Serum Biomarker of Mucosal Healing in Ulcerative Colitis.
    J Crohns Colitis. 2017;11:84-91.
    PubMed     Abstract available


  964. GOMOLLON F, Dignass A, Annese V, Tilg H, et al
    3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management.
    J Crohns Colitis. 2017;11:3-25.
    PubMed     Abstract available


  965. DETREZ I, Gils A
    Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies.
    J Crohns Colitis. 2017;11:1-2.
    PubMed    


  966. PEYRIN-BIROULET L, Lonnfors S, Roblin X, Danese S, et al
    Patient Perspectives on Biosimilars: A Survey by the European Federation of Crohn's and Ulcerative Colitis Associations.
    J Crohns Colitis. 2017;11:128-133.
    PubMed     Abstract available


  967. ROBBINS L, Zaghiyan K, Melmed G, Vasiliauskas E, et al
    Outcomes with Anti-Tumour Necrosis Factor-Alpha Therapy and Serology in Patients with Denovo Crohn's Disease After Ileal Pouch Anal Anastomosis.
    J Crohns Colitis. 2017;11:77-83.
    PubMed     Abstract available


  968. ADEDOKUN OJ, Xu Z, Marano CW, Strauss R, et al
    Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies.
    J Crohns Colitis. 2017;11:35-46.
    PubMed     Abstract available


  969. SIMON M, Cosnes J, Gornet JM, Seksik P, et al
    Endoscopic Detection of Small Bowel Dysplasia and Adenocarcinoma in Crohn's Disease: A Prospective Cohort-Study in High-Risk Patients.
    J Crohns Colitis. 2017;11:47-52.
    PubMed     Abstract available


  970. PAPAMICHAEL K, Baert F, Tops S, Assche GV, et al
    Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis.
    J Crohns Colitis. 2017;11:53-59.
    PubMed     Abstract available


  971. HERNANZ N, Lopez-Sanroman A
    A Pitfall to Avoid: Hyperlipasemia, Azathioprine, and Autoimmune Pancreatitis.
    J Crohns Colitis. 2017;11:134.
    PubMed    


  972. HOOPER KM, Barlow PG, Stevens C, Henderson P, et al
    Inflammatory Bowel Disease Drugs: A Focus on Autophagy.
    J Crohns Colitis. 2017;11:118-127.
    PubMed     Abstract available


  973. CHEN W, Lu C, Hirota C, Iacucci M, et al
    Smooth Muscle Hyperplasia/Hypertrophy is the Most Prominent Histological Change in Crohn's Fibrostenosing Bowel Strictures: A Semiquantitative Analysis by Using a Novel Histological Grading Scheme.
    J Crohns Colitis. 2017;11:92-104.
    PubMed     Abstract available


  974. KAMMERMEIER J, Dziubak R, Pescarin M, Drury S, et al
    Phenotypic and Genotypic Characterisation of Inflammatory Bowel Disease Presenting Before the Age of 2 years.
    J Crohns Colitis. 2017;11:60-69.
    PubMed     Abstract available


  975. JOSHI NM, Marks IH, Crowson R, Ball D, et al
    Incidence and Outcome of Clostridium difficile Infection in Hospitalized Patients with Inflammatory Bowel Disease in the UK.
    J Crohns Colitis. 2017;11:70-76.
    PubMed     Abstract available


    November 2016
  976. EBERHARDSON M, Karlen P, Linton L, Jones P, et al
    Randomised, Double-blind, Placebo-controlled Trial of CCR9-targeted Leukapheresis Treatment of Ulcerative Colitis Patients.
    J Crohns Colitis. 2016 Nov 2. doi: 10.1093.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: